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ABSTRACT 
 
The aim of this thesis was to explore three factors that are easily available and 
contribute important information for women before commencing in-vitro fertilisation 
(IVF) treatment: ethnicity, body-mass index (BMI) and thyroid disease.  Results of the 
systematic review, cohort study and meta-analysis investigating ethnicity and IVF 
outcome showed South Asian and Black women have lower adjusted live-birth (LB) 
rates, after fresh cycle treatment, compared with White women.  The relationship 
between BMI and IVF outcome was explored in a prediction model estimating 
chances of LB following first cycle.  The model found BMI has reduced effect on IVF 
outcome when adjusting for other confounders such as age.  The prevalence of 
thyroid dysfunction and thyroid peroxidase antibodies (TPOAb) was examined across 
the UK in >7000 women of reproductive age, and a cohort study investigating the 
effect of subclinical hypothyroidism (SCH) on IVF outcome was also performed.  The 
prevalence of overt thyroid disease was 0.38% and subclinical disease 3.45%.  Using 
an upper limit cut off for thyroid-stimulating hormone of 2.5mU/L the prevalence of 
SCH was 19.64%.  The overall prevalence of TPOAb was 9.11%; this was 7.98% in 
euthyroid women.  Finally, there were no significant differences in LB between 
euthyroid women and women with SCH. 
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CHAPTER 1 
Thesis overview and objectives 
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Introduction to in-vitro fertilisation (IVF) 
Since the introduction of IVF treatment in 1978 the technology has improved greatly.  
Figures from the annual Human Fertilisation and Embryology Authority (HFEA) 
reports show a trend in success rates over the years due to technological 
advancements and changes in clinical practice1.  The popularity of assisted 
reproduction also continues to grow, the most recent HFEA report found that 49,636 
women underwent a total of 64,600 cycles of IVF or intra-cytoplasmic sperm injection 
(ICSI) in 2013, compared with 62,158 cycles in 2012, this is an increase in the 
number of treatment cycles of 3.9%1.  Despite the significantly increased success 
rates since the introduction of IVF, the average chance of a couple having a baby 
following IVF treatment (if the female is aged 35 and under) is still only around 33%1.  
Consequently there is constant pressure from patients and policy makers to improve 
fertility services and outcomes, therefore much research is conducted within the field 
of assisted reproductive technology (ART).   
 
There are many factors that can affect IVF outcome, which can be split into three 
main categories: pre-treatment factors (i.e. the age of the female, the ovarian 
reserve, the cause of infertility etc); embryo factors (e.g. poor embryo quality, having 
no embryos) and uterine factors (e.g. endometrial thickness, uterine receptivity).  The 
work of this thesis focuses solely on pre-treatment factors and the impact of certain 
important under-investigated factors on IVF outcome.   
 
While there is an exhaustive list of pre-treatment factors that have been identified as 
having an effect on IVF outcome, the work in this thesis focuses on three in particular 
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which are common, easily available and contribute important information for women 
before embarking on their IVF treatment; ethnicity, body-mass index and thyroid 
function.    
 
Ethnicity and IVF outcome 
Ethnicity is often explored as a prognostic marker in studies in medicine, but the link 
between ethnicity and assisted reproduction outcome remains unclear.  Large 
studies, using the Society for Assisted Reproductive Technologies (SART) database, 
in the United States (US) have attempted to explore the relationship between 
ethnicity and IVF outcome; however, many of these studies have been unable to 
account for the common confounders2–5.  The two largest studies, by Seifer et al in 
2008 and 2010 (n=44,585 cycles and n=158,693 cycles respectively) only looked at 
differences between Black women and White women4,5.  Furthermore, as US 
populations dominate the existing studies, this means inclusion of ethnic groups such 
as Hispanic, Pacific Islander and American Indian2, which makes the findings non-
transferrable to a UK population.  In addition to this, several large studies have 
inappropriately combined ethnic groups that do not necessarily behave the same i.e 
Indian and Chinese grouped into “Asian”2,3,6.  There is yet to be a large study in the 
UK to investigate whether ethnicity impacts on IVF outcome.  Furthermore there 
needs to be clear and appropriate definitions of different ethnic groups and finally the 
common confounders need to be accounted for; such as age, cause of infertility, 
duration of infertility and so forth.  While ethnicity is not a factor that women can 
change, it is important to determine whether it effects success rates following IVF 
treatment as it should be taken into consideration when counselling women pre-
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treatment.  Moreover, if there is an association between ethnicity and IVF outcome 
we need to work to explain why and find ways to improve IVF outcomes for all 
women of all ethnicities.  
 
BMI and IVF outcome 
The relationship between raised body mass index and poor obstetric outcomes is 
well known7,8.  However, the literature regarding the association between raised 
body-mass index and IVF outcome is conflicting.  Some recent studies have shown 
that raised BMI does not appear to reduce clinical pregnancy or live birth rates and 
that women with raised BMI do not require higher doses of gonadotrophins in their 
treatment compared with normal BMI women9,10.  Whereas other studies, including a 
large systematic review and meta-analysis by Rittenberg et al, have shown increased 
cancellation rates for women with raised BMI and lower clinical pregnancy and live 
birth rates11–13.  Despite this conflicting evidence linking raised BMI to poorer IVF 
outcome, because the relationship between raised BMI and adverse pregnancy 
outcomes is well established this has dictated the UK government funding criteria; 
with NHS funded treatment only provided for those with a body-mass index under 30.  
What remains unclear is exactly to what degree body mass index affects IVF 
outcome, and the interplay of this with other factors.  Often when counselling patients 
clinicians advise women to lose weight to improve their chances of success, however 
there is no tool or model available that allows for calculation of success rates based 
on body-mass index and it’s association with other important predictive factors, such 
as age.  In fact there is currently no model available for use that predicts the chances 
of IVF success for women before they undergo their first treatment.  Frequently in 
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clinical consultations with couples seeking IVF treatment, clinicians are asked what 
the couples chances of live birth are; crude age related success rates are provided 
based on national data.  To date there is no model to calculate a more personalised 
probability of live birth at the point before commencing treatment.  Creation of such a 
model would be important as it would facilitate decision making for couples at the 
most critical part of their journey and fill a gap in counselling in current clinical 
practice.  There is a need for a relevant prediction model, incorporating body mass 
index, to be used as an adjunct to counselling and decision-making for clinicians and 
patients before they embark on IVF treatment. 
 
Thyroid dysfunction and thyroid autoimmunity 
Finally, thyroid problems are one of the most prevalent of all medical conditions, 
especially in women of reproductive age.  The most prevalent form of thyroid disease 
is subclinical hypothyroidism (SCH).  SCH is more common in females and in 
particular those with fertility problems14.  In the infertility population the incidence of 
SCH has ranged between 1-43% with a mean of around 13%15.  Subclinical thyroid 
problems are often asymptomatic and therefore go undetected, however evidence 
has shown that subclinical disease can have negative effects on a pregnancy, 
including increased risk of miscarriage, perinatal loss, preterm birth, pre-eclampsia 
and low IQ in the offspring16,17.  Consequently, the Endocrine Society Clinical 
Practice Guideline (ESCPG) regarding “Management of Thyroid Dysfunction during 
Pregnancy and post-partum” recommends the use of hormone replacement therapy, 
in the form of Levothyroxine (LT4) treatment, for pregnant women with subclinical 
hypothyroidism as well as those with overt disease15. 
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One of the central challenges in defining SCH is agreeing on the upper limit of TSH.  
This has lead to significant debate over whether routine screening should be 
performed on all pre-conception women; with a view to treating prior to- and during 
pregnancy in order to optimise obstetric outcomes.  The most widely accepted 
reference range for a “normal” TSH is 0.4-4.5mU/l.  However, there is currently a shift 
in clinical practice, in certain parts of the world, towards routinely treating women with 
SCH who are trying for a pregnancy, particularly the infertility population, and aiming 
for a pre-conception target TSH of <2.5mU/l.  Despite this suggestion of aiming for a 
tighter pre-conception TSH threshold below 2.5mU/l, it is not currently recommended 
routine practice for universal thyroid function screening in women trying for a 
pregnancy, or even in women who are pregnant, by any of the major endocrine 
societies.  This is based on the limited conclusive evidence to suggest that treatment 
with Levothyroxine for women with TSH 2.5-4.5mU/l has any benefit on pregnancy 
outcomes, including fertility outcomes after assisted reproduction, compared with 
untreated women18.    
 
 
Following on from thyroid dysfunction there is also the issue of thyroid autoimmunity.  
The presence of thyroid auto-antibodies in women, specifically Thyroid Peroxidase 
antibodies (TPOAb), has been linked to increasing the chances of adverse effects on 
the pregnancy, including miscarriage and pre-term birth19.  Furthermore, it is thought 
that around 1 in 5 women are positive for TPOAb19 and that this figure is even higher 
in women with backgrounds of infertility or recurrent miscarriage19–21.  However as 
the antibodies alone (without thyroid dysfunction) are asymptomatic, the vast majority 
of women who have them will never know unless specifically investigated. 
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Despite the fairly common prevalence and known detrimental effects in pregnancy it 
is currently not routine practice to check thyroid function for women who are actively 
trying for a pregnancy, either via natural conception or fertility treatment.  
Furthermore, existing literature shows that women who carry these antibodies are 
also at higher risk of developing thyroid abnormalities during pregnancy and should 
therefore be offered routine thyroid monitoring throughout pregnancy22; however 
without routine screening of pre-conception women, the majority of TPOAb positive 
women will be missed.     
 
Existing research has yet to identify if there are specific higher risk women, based on 
demographic such as age, BMI or ethnicity, within the cohort of those of reproductive 
age who are trying for a pregnancy (including fertility patients), who may benefit from 
routine TFT and TPOAb screening and/or treatment prior to embarking on a 
pregnancy.  A large-scale prevalence study of thyroid dysfunction and thyroid 
autoimmunity is required to help identify the women who may benefit the most from 
thyroid screening.  A further important unanswered question is at what severity of 
subclinical thyroid disease (i.e. what threshold of TSH concentration) should 
treatment be commenced and will this improve pregnancy success.  
 
Undergoing assisted reproductive technologies can be a very costly and emotional 
burden for many couples.  It is therefore crucial that women are well informed about 
their chances of success and that they are appropriately stratified, investigated and 
managed before commencing their fertility treatment.  The work presented in this 
thesis has adopted a mixed methodological approach to explore certain key factors 
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that affect IVF outcome in order to aid effective counselling and clinical decision-
making for both patients and clinicians prior to commencing assisted reproduction 
treatment. 
 
Thesis objectives 
The aim of the work in this thesis is to address in detail the three key factors 
identified as having an effect on IVF and pregnancy outcome; ethnicity, BMI and 
thyroid function/autoimmunity.  Chapters 2 and 3 will explore ethnicity and IVF 
outcome; chapter 2 will be a systematic review and meta-analysis of all the existing 
literature and chapter 3 will be a cohort study and an updated meta-analysis 
combining the cohort study with the existing studies.  Chapter 4 will be the derivation 
and validation of a prediction model incorporating BMI.  Finally, chapters 5-7 will be 
the thyroid work; prevalence of thyroid dysfunction (chapter 5), prevalence of thyroid 
autoimmunity (chapter 6) and a cohort study investigating the effect of SCH on IVF 
outcome (chapter 7).   
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The summary of research studies and the methodology applied in this thesis, as per PICO format, is displayed in Table 1. 
 
Table 1.  Summary of research studies within the PhD thesis 
Chapter 
Number 
Population Intervention or 
factor of interest 
Comparison 
or reference 
standard 
Outcome Study Design 
  
Objective 1: To investigate the effect of ethnicity on IVF outcome 
 
 
2 
 
First non-donor cycle of IVF or ICSI 
treatment for all women.  Both fresh 
and frozen cycles.  No year or 
country restrictions. 
 
 
Ethnic group; Black, 
Asian, Hispanic 
 
White 
population 
 
Live birth rates 
and clinical 
pregnancy rates 
 
Systematic 
review and 
meta-analysis 
 
 
3 
 
 
 
 
 
 
 
Women undergoing first non-donor 
cycle of IVF or ICSI treatment at any 
CARE clinic across the UK between 
2008-2012.  Both fresh and frozen 
cycles. 
 
 
All studies included in systematic 
review plus cohort study. 
 
Ethnic group; Black, 
South Asian, 
Chinese, mixed, or 
other 
 
 
 
Ethnic group; Black, 
South Asian, 
Chinese, mixed, or 
other 
 
White 
population 
 
 
 
 
 
White 
population 
 
Live birth, 
clinical 
pregnancy and 
miscarriage. 
 
 
 
Live birth, 
clinical 
pregnancy and 
miscarriage. 
 
Observational 
cohort study 
 
 
 
 
Updated meta-
analysis 
including data 
from cohort 
study 
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Chapter 
Number 
Population Intervention or 
factor of interest 
Comparison 
or reference 
standard 
Outcome Study Design 
  
Objective 2: To investigate the effect of body mass index (BMI) and it’s interplay with other predictors on IVF 
outcome 
 
 
 
4 
 
 
Women undergoing their first fresh 
non-donor cycle of IVF or ICSI 
treatment at any CARE clinic across 
the UK between 2008-2012.   
 
 
Body mass index is the primary factor 
of interest for the prediction model as 
this is an important factor that has not 
previously been used in any 
prediction tool for IVF outcome. 
 
Other predictors built into the model: 
age, ethnicity, ovarian reserve, cause 
of infertility, duration of infertility 
history of previous live birth and 
history of previous miscarriage.  
 
 
 
 
Live birth rate 
 
 
Construction of 
prediction 
model. 
 
 
4 
 
 
 
 
 
 
 
Women undergoing their first fresh 
non-donor cycle of IVF or ICSI 
treatment at any CARE clinic across 
the UK between 2013-2014.   
 
 
As above 
 
 
Live birth rate 
 
 
External 
validation of 
prediction 
model. 
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Chapter 
Number 
Population Intervention or 
factor of interest 
Comparison 
or reference 
standard 
Outcome Study Design 
 
 
 
Objective 3: To investigate the prevalence of thyroid dysfunction and autoimmunity in women of reproductive age 
 
 
5 
 
All women who underwent screening 
blood test for thyroid function as part 
of the “Prevalence study” (sub-study 
to TABLET trial) across the UK. 
 
 
Women with 
abnormal thyroid 
function (overt or 
subclinical) 
 
Euthyroid 
women 
 
Demographic 
features: age, 
ethnicity, BMI, 
originating 
population 
 
Prospective 
national multi-
centre 
prevalence 
study 
 
6 
 
All women who underwent screening 
blood test for thyroid peroxidase 
antibodies (TPO) as part of the 
“Prevalence study” (sub-study to 
TABLET trial) across the UK.  
 
Women who are TPO 
antibody positive 
 
Women who 
are TPO 
antibody 
negative 
 
Demographic 
features: age, 
ethnicity, BMI, 
originating 
population 
 
Prospective 
national multi-
centre 
prevalence 
study 
  
Objective 4: To investigate the effect of subclinical hypothyroidism (SCH) on IVF outcome 
 
 
7 
 
All women screened as part of the 
TABLET trial at Birmingham 
Womens Hospital Assisted 
Conception unit between June 2012- 
December 2013. 
 
 
Women with SCH, 
TSH >3.63 and 
normal T4.  Women 
with TSH 3.63-5.9 
received no 
treatment, women 
with TSH 6.0≤ started 
on Levothyroxine. 
 
Euthyroid 
women 
 
Live birth, 
clinical 
pregnancy, 
miscarriage 
 
Prospective 
observational 
cohort study 
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CHAPTER 2 
Investigating the effect of ethnicity on IVF outcome: 
a systematic review and meta-analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work in this chapter was published in Reproductive Biomedicine Online; 
published online 03.06.15 
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Introduction 
 
Ethnicity is one of the most investigated prognostic factors in medicine.  However, 
studies investigating the relationship of ethnicity to IVF outcome are often limited in 
terms of sample sizes and have produced inconclusive findings.  Furthermore, the 
large majority of existing studies are American and so focus on ethnic groups that are 
specific to their population, such as Hispanic, African American and American Indian, 
making the findings non-transferable to a UK population.  
 
A study published in 2009 by Dayal et al23 compared IVF outcomes for 251 females; 
180 White and 71 African American.  They concluded that there were no differences 
in pregnancy outcomes following IVF, although they did find that African Americans 
produced fewer embryos than White women.  A larger study published in 2005 by 
Bendikson et al24 looked at 1135 women (1039 White, 43 African American, 35 Asian 
(combining South Asians and South-East Asians) and 18 Hispanic), also concluded 
that their data showed no significant difference in pregnancy outcomes with IVF 
among the ethnic groups. 
 
More recent larger studies4,5,25–29 have collectively provided stronger evidence on the 
existence of racial disparity in assisted reproductive technology (ART) outcomes.  In 
2008 and 2010 Seifer et al4,5, showed that Black race was an independent risk factor 
for not achieving live birth.  Fujimoto et al6 found a statistically significant decreased 
odds ratio of achieving live birth amongst Asians, Hispanics and Blacks compared 
with Whites. 
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A review by Wellons et al30 in 2012 found that there were significant racial disparities 
in IVF outcomes, however they restricted their findings to studies using Society for 
Assisted Reproductive Technologies (SART) data only and did not perform a meta-
analysis of the data.  A UK based study31 recently published data showing that 
ethnicity was an independent risk factor for IVF and ICSI outcome, although this was 
not statistically significant.  Furthermore, the numbers representing each ethnic group 
were small, meaning that they had to group all ethnicities into one group.   
 
There appears to be variation in success rates with assisted conception for women 
from different ethnic groups with several studies producing inconsistent findings.  
There is a need for accurate information regarding ethnicity and its effect on IVF 
outcome as this can lead us to investigate the potential biological plausibility.  
 
Aims and objectives 
1. To provide a robust synthesis of all available literature on the relationship 
between ethnicity and IVF outcome.  
2. To perform the first meta-analysis of all the published data regarding ethnicity 
and IVF outcome. 
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Methods 
 
Our systematic review followed a protocol developed using widely recommended and 
comprehensive methodology32–34.  
 
Data sources 
This review focused on studies where IVF was performed and the primary outcomes 
measured were clinical pregnancy or live birth.    
 
MEDLINE (from inception to Jan 2015) EMBASE (from inception to Jan 2015) and 
CINAHL (from inception to Jan 2015) databases were searched electronically and 
Web of Science was used to search for grey literature.  The search of MEDLINE and 
EMBASE and CINAHL captured citations containing the relevant MeSH keywords 
and word variants for “ethnicity” and “in-vitro fertilisation”; race, assisted reproductive 
technology.  Bibliographies of relevant articles were manually searched to identify 
papers not captured by the electronic searches.  Authors were contacted for 
completeness of the search.  There were no language restrictions in the search or 
selection of papers. 
 
Eligibility criteria for selecting studies 
Studies were selected in a two-stage process.  Initially, all abstracts or titles in the 
electronic searches were scrutinised by two reviewers (R.D. and R.M.) and full 
manuscripts of potentially eligible citations were obtained.  Differences were resolved 
by discussion with a third reviewer (H.H).  Studies were selected if the primary 
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outcomes measured were clinical pregnancy and or live birth and if IVF (including 
ICSI) was the method of assisted conception.  Studies had to report their success 
rates by ethnic group to allow data extraction for meta-analysis.  Only studies where 
first cycle was used were selected, this was to eliminate bias from previous cycles.  
Both fresh and frozen cycles were included with the outcome data analysed 
separately.  Data were analysed separately to reduce treatment type (i.e. fresh vs. 
frozen) acting as a confounder.  A summary of the selection process is displayed in 
Figure 1. 
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Figure 1.  Summary of PRISMA flow diagram – summary of selection process 
of included papers 
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Additional records identified 
through other sources 
(n = 11) 
Records after duplicates removed 
(n = 990) 
Records screened 
(n = 990) 
Records excluded  
(n = 955) 
Full-text articles 
assessed for eligibility  
(n = 35) 
Full-text articles excluded (n = 19) 
 
- Combined data for fresh and 
frozen cycles, unable to separate 
(Luke et al 2011) 
- Duplicate data overlapping other 
included papers – (Feinburg et al 
2006, Langen et al 2010, Moon et 
al 2011, Sunderam et al 2009,) 
- No original data/ “review” type 
article (Butts et al 2010, 
Huddleston et al 2010, Wellons et 
al 2012) 
- Donor oocytes only (Bodri et al 
2010, Bodri et al 2009, 
Huddleston, Rosen et al 2010, 
Gleicher et al 2007) 
- IUI rather than IVF/ICSI (Lamb et 
al 2009) 
- Unable to extract raw data (Baker 
et al 2010) 
- Insufficient study data (Anand 
Kumar et al 1988) 
- Abstract only, unable to retrieve 
full paper (Clark et al 2010, 
Fisher et al 2011, Bullough et al 
2011, Kukreja et al 2013) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
n = 16 
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Data extraction and synthesis 
Data were extracted by two reviewers (R.D. and R.M.) and verified by a 3rd reviewer 
(H.H.).  For each of the outcomes, data were extracted into tables.  Primary 
outcomes were live birth and clinical pregnancy (also recorded as clinical intrauterine 
gestation).  Data was collected regarding the ethnicities reported, study design, 
population size, outcomes measured and whether fresh or frozen cycles were 
included. 
 
Data were extracted from each paper for unadjusted live birth and clinical pregnancy 
rates per cycle.  Baker et al25 were contacted for the raw numbers, as this was not 
extractable from the paper, however no correspondence was received and so this 
paper was not included.  Several of the papers published by US authors used data 
from the same time period and from the SART database.  To avoid analysing 
duplicate data, those papers with the greater sample numbers were included for 
analysis and any overlapping datasets from the remaining papers were 
removed6,27,35.  Any papers where the outcome data for fresh and frozen data were 
combined, and we were not able to extract separately, were also removed36.   
 
The meta-analysis was performed using Review Manager (version 5.0 for Windows) 
to combine and analyse the data; using the generic inverse variance method.  For 
the purpose of the meta-analysis the ethnicities were grouped into four broad 
categories; White, Black, Asian and Hispanic.  For the Asian group this included both 
South Asians and South-East Asians.  Each ethnic group was compared with a White 
reference population for all outcomes.  The outcomes from fresh and frozen cycles 
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were analysed separately.  The adjusted odds ratios were pooled where possible to 
account for potential confounders.  Heterogeneity was assessed by examining the χ2 
statistics and a random-effects model was used where there was statistically 
significant heterogeneity.  Heterogeneity was presented statistically and graphically 
using forest plot estimates of rates and 95% confidence intervals. 
 
Quality assessment 
All articles meeting the selection criteria were assessed for quality using the 
Newcastle Ottawa Scale37,38 (Table 2), the exact criteria used to award points for 
quality are described following Table 2.  This tool was selected as it is designed to 
assess the quality of non-randomised studies; which is in-line with the study design 
of the included studies in this review.  The quality of reporting was assessed using 
the STROBE checklist39 (Figure 2).  
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Table 2.  Assessment for quality of a cohort study – Newcastle Ottawa Scale 
Study 1. 
Selection 
   2. 
Comparability  
(max 2 stars 
available) 
3. 
Outcome 
  Total 
no. of 
stars  
 
 (i) 
Represen-
tativeness 
of the 
interven-
tion cohort  
(ii) 
Selection 
of the non-
interven-
tion cohort 
(iii) 
Ascertain-
ment of 
interven-
tion 
(iv) 
Demonstration 
that outcome 
of interest was 
not present at 
start of study 
(i)  
Comparability 
of cohorts on 
the basis of 
the design/ 
analysis 
(i) 
Assess-
ment of 
outcome 
(ii)  
Was follow 
up long 
enough for 
outcomes 
to occur 
(iii) 
Adequacy 
of follow 
up of 
cohorts 
 
Bendikson 
et al 2005 
 
* * * * --- * * * 7 
Csokmay et 
al 2011 
  
* * * * --- * * * 7 
Dayal et al 
2009  
 
* * * * --- * * * 7 
Fujimoto et 
al 2010  
 
* * * * --- * * * 7 
Jayapraka-
san et al 
2014 
 
* * * * --- * * * 7 
Lashen et al 
1999 
 
* * * * * * * * 8 
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Mahmud et 
al 1995 
 
* * * * * * * * 8 
McCarthy-
Keith et al 
2010 
 
* * * * --- * * * 7 
Nichols et al 
2001 
 
* * * * --- * * * 7 
Purcell et al 
2007  
 
* * * * --- * * * 7 
Seifer et al 
2008  
 
* * * * --- * * * 7 
Seifer et al 
2010  
 
* * * * --- * * * 7 
Shahine et 
al 2009  
 
* * * * --- * * * 7 
Sharara and 
McClamrock 
2000  
 
* * * * --- * * * 7 
Sharara et 
al 2012 
 
* * * * --- * * * 7 
Shuler et al 
2011  
* * * * --- * * * 7 
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Key: Each * represents if individual criterion within the subsection was fulfilled (maximum 9 stars). 
 
  1. (i)  Studies received a * if the cohort of interest included all non-White women undergoing their first non-donor cycle of IVF  
      (ii) Studies received a * if the reference cohort included all White women undergoing their first non-donor cycle of IVF 
      (iii) Studies received a * if the ascertainment of intervention was in a secure record or via a structured interview 
      (iv) Studies received a * if the women were non-pregnant at the start of the study 
 
2. (i) Studies received a * if the women were matched by at least age and body mass index.  
          Studies received ** if they were matched for additional factors (e.g. socioeconomic status, education) 
 
3. (i) Studies received a * if there were independent blinded assessments 
      (ii) Studies received a * if the women were followed up to the end of their first IVF cycle of treatment 
     (iii) Studies received a * if all subjects were accounted for or if those lost to follow up were unlikely to introduce bias (i.e. number 
lost  <=20%, or description of those lost suggesting no different from those followed) 
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Figure 2.  STROBE assessment for the included 16 papers 
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Results 
 
Sixteen studies were included for the meta-analysis2–6,23,24,26,28,29,31,40–43.  Thirteen of 
the studies had data for fresh cycles only2,3,6,23,24,28,29,31,40–44 , 1 for frozen only26 and 
2 studies included both4,5.  All papers used data for non-donor cycles and first 
treatment cycles only were included.  A summary of each of the included study 
characteristics is shown in Table 3. 
 
The demographic breakdown for each paper is shown in Table 4.  Where possible, 
data has been extracted for age, BMI and fertility diagnosis.  Of the 8 papers which 
reported BMI only two found statistical significant differences; Dayal et al23 and 
Nichols et al41 both reported the White population as having a lower mean BMI 
compared with Black (African American).  
 
When comparing age; Seifer et al4 found a statistically significantly higher proportion 
of White women under the age of 35 years compared with Black women, and 
Fujimoto et al6 also showed the highest mean age amongst Black women compared 
with White, Asian and Hispanic.  Both Sharara et al42 and Shahine et al28 found Asian 
women to have a statistically significant mean younger age compared with White 
women, whereas Purcell et al3 found Asian women to be older than Caucasian from 
the SART dataset.   
 
Nine of the 16 papers2,4–6,23,24,26,41,43 found that Black women have a statistically 
significantly higher likelihood of tubal and/or uterine factor compared with White 
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women, whereas White women were found to have a higher likely diagnosis of 
endometriosis.  Polycystic ovarian syndrome (PCOS) was found to be more common 
amongst Asians than White women40,42. There was also a statistically significantly 
increased duration of fertility seen in Asian women compared with White women40,44. 
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Table 3.  Summary of study characteristics 
Reference, year and 
study design 
Sample population Outcomes measured Fresh/frozen 
cycles 
Patient numbers 
Bendikson et al 2005 
Retrospective Cohort study 
Women undergoing first 
IVF cycle between 
August 1994 and March 
1998 at Boston IVF, 
Brigham Womens 
Hospital and Boston 
Reproductive Science 
Centre (USA) 
Live birth, chemical and 
ectopic pregnancies, 
miscarriage 
First cycle, fresh 
non-donor 
transfer 
 
Total 1135 cycles 
White = 1039 
Black (African American) = 
43 
Asian = 35. 
Hispanic = 18 
 
 
Csokmay et al 2011  
Retrospective Cohort 
Study  
 
All patients who 
underwent frozen 
blastocyst transfer 
between 2003 and 2008 
in a University-based 
ART program. 
University of California. 
 
Clinical pregnancy and 
live birth  
 
Frozen embryo 
cycles with 
autologous 
oocytes 
 
Total 169 women  
White (Caucasian) = 119 
Black (African American) = 
50 
 
 
Dayal et al 2009  
Retrospective Cohort 
Study  
 
All African-American 
women and Caucasian 
women who underwent 
IVF cycles between 01-
Jan-2004 and 31-Dec-
2005 at George 
Washington Fertility & 
IVF Centre (USA) 
 
Biochemical and clinical 
pregnancy, live birth and 
implantation  
 
Initial fresh non-
donor IVF 
cycles/embryo 
transfer 
 
Total 251 women 
White (Caucasian) = 180 
Black (African American) = 
71 
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Fujimoto et al 2010  
Retrospective Cohort 
Study  
Cycles between 2004 
and 2006 in White, 
Asian, Black and 
Hispanic women, 
identified using the 
SART database (USA). 
Clinical pregnancy and 
live birth given as an 
adjusted odds ratio 
compared to the white 
women group. Also 
stillbirth rate and 
plurality of live-born 
pregnancies 
Fresh non-donor 
cycles 
Total 139,027 cycles.  
White = 107484  
Asian = 13671  
Black = 8903  
Hispanic = 8969  
 
Black data not used for 
analysis as duplicate data 
from Seifer et al 2010. 
White data used for 
reference purposes. 
 
Jayaprakasan et al 2014 
Retrospective cohort study 
 
All women undergoing 
first cycle of ART 
between 2006 and 2011 
at Nottingham University 
Research and 
Treatment Unit in 
Reproduction 
(NURTURE), UK. 
 
Biochemical pregnancy 
rate, clinical pregnancy 
rate and live birth rate 
 
First cycle, fresh, 
non-donor 
 
Total 1571 women 
White (Caucasian) = 1291 
South Asian = 182 
African-Caribbean = 30 
Middle Eastern = 14 
 
Lashen et al 1999 
Nested case-control study 
 
Patients undergoing IVF 
between 1994-1997 at 
Birmingham Womens 
Hospital, Assisted 
conception unit (UK). 
 
Implantation rate and 
clinical pregnancy 
 
First cycle, fresh, 
non-donor 
 
Total 324 women 
White (Caucasian) = 216 
Asian = 108 (58 Pakistani, 
34 Indian, 16 Bangladeshi) 
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Mahmud et al 1995 
Controlled comparative 
clinical study  
Patients selected 
prospectively from a 
Oxford (UK) IVF 
database from April 
1987- Dec 1993. 
“Indian” women 
(Pakistani, Bangladeshi 
and Indian).  Matched 
by age, BMI and year of 
treatment. 
Cumulative pregnancy 
rates over 3 cycles. 
Rates of abandoned 
cycles, egg retrievals, 
endometrial thickness, 
clinical pregnancies, 
miscarriages and live 
births from the first IVF 
cycle. 
First fresh IVF 
cycles 
Total 132 women.  
White = 88 
Asian (Indian) = 44 
 
 
McCarthy-Keith et al 2010  
Retrospective Cohort 
Study  
 
Women undergoing 
cycles from 2000 - 2005 
in federal assisted 
reproduction 
programmes (USA). 
Walter Reed Army 
Medical Center, Wilford 
Hall Medical Center and 
Tripler Army Medical 
Center. 
 
Assisted reproduction 
technique utilisation 
rate, clinical pregnancy 
and live birth 
 
First cycle fresh 
non-donor 
transfer 
Total 2050 women.  
White =1280 
Black (African American) = 
353 
Asian = 110 
Hispanic = 81 
American Indian = 8 
Pacific Islander = 12  
Multi-racial = 85 
Not stated = 121 
Data for LB only available 
for Whites, African-
American and Hispanics. 
 
Nichols et al 2001 
Retrospective cohort study 
 
Women undergoing IVF 
between Nov 1996 and 
June 2000 in a Hospital 
based IVF practice 
(Greenville Hospital, 
South Carolina, US). 
 
Implantation rate and 
clinical pregnancy 
 
Non-donor, 
multiple cycles. 
Only data for 1 
cycle per patient 
analysed 
 
Total cycles 297 
White = 273 
Black (African American) = 
24 
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Purcell et al 2007  
Retrospective Cohort 
Study 
Caucasian and self-
identified Asian women. 
Clinics reporting to 
SART for years 1999-
2000, and University 
based clinic – University 
of California (USA) for 
years Jan 2001 – 
December 2003. 
Clinical pregnancy and 
live birth  
First Fresh non-
donor cycles 
Two data sets:  
1) SART dataset;  
White (Caucasian) = 
25,843 cycles 
Asian = 1,429 cycles 
 
2) University database;  
Asian = 197 cycles. White 
(Caucasian) = 370 cycles 
 
Seifer et al 2008  
Retrospective Cohort 
Study  
 
Cycles performed 
between 1999 and 2000 
by Society of Assisted 
Reproductive 
Technology member 
clinics who perform >50 
cycles/ year and have 
race/ethnicity reported 
in >95% of cycles. 
 
Live birth per cycle 
started. 
 
Fresh and frozen 
embryos 
 
Total 44,585 IVF 1st cycles.  
(34,042 cycles not used for 
analysis as not 1st cycle) 
 
Fresh cycles: White = 
32049. Black = 1839  
 
Frozen cycles: White = 
10147.  Black = 550 
 
Seifer et al 2010  
Retrospective Cohort 
Study  
Non-donor IVF cycles 
between 2004 and 2006 
in White and Black 
women, identified using 
the SART database 
(USA). 
Live birth per cycle 
started 
Fresh and frozen 
non-donor IVF 
cycles 
Total 158,693 cycles.  
(50,143 cycles not used for 
analysis as not 1st cycle) 
 
Fresh cycles: White = 
120,994.  Black = 10,354  
 
Frozen cycles: White = 
25,412.  Black = 1,933  
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Shahine et al 2009  
Retrospective Cohort 
Study 
Indian and Caucasian 
Women undergoing 
blastocyst transfer 
between Jan ‘05 – July 
‘07 in Stanford 
University fertility centre, 
USA 
Live birth per cycle 
started 
Initial Fresh 
cycle, blastocyst 
transfer 
Total 225 women 
White (Caucasian) = 145 
Asian (Indian) = 80  
 
Sharara and McClamrock 
2000  
Retrospective Cohort 
Study  
 
Women undergoing IVF 
at an inner city, 
university-based IVF 
programme (University 
of Maryland, USA) 
between April 1997 and 
July 1999  <40years.  
 
Implantation rate, 
clinical pregnancy and 
ongoing/delivered 
pregnancy 
 
Fresh non-donor 
IVF cycles 
 
Total 168 cycles 
White = 121 cycles  
Black = 47 cycles 
 
Sharara et al 2012 
Retrospective Cohort 
Study 
 
All white and South 
Asian Women <40years 
undergoing blastocyst 
transfers at Virginia 
Centre for Reproductive 
Medicine, USA. 
 
Clinical pregnancy and 
live birth  
 
Non-donor, initial 
fresh cycle, 
blastocyst 
transfer 
 
Total = 292 
White = 238 cycles 
Asian (South Asian) = 54 
 
Shuler et al 2011  
Retrospective Cohort 
Study  
 
Patients who self 
identified as Hispanic or 
as non-Hispanic white 
undergoing IVF cycles 
at South Texas Fertility 
Centre (USA) between 
1998 and 2008. 
 
Clinical intrauterine 
gestation, spontaneous 
abortion and live birth  
 
First fresh 
embryo cycles 
with autologous 
oocytes 
 
Total 435 cycles 
Non-Hispanic White = 301 
Hispanic = 134  
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Table 4.  Demographic breakdown for included studies 
Study Mean age Mean BMI Infertility diagnosis/duration – Statistically significant differences only 
 
Bendikson et 
al 2005 
White = 35 ±4 
Black (African 
American) = 34 ±5 
Hispanic = 35 ±6 
Asian = 35 ±5 
White = 24 ± 5 
Black = 26 ±4 
Hispanic = 25 
±4 
Asian = 23 ±3 
NS 
Black women more likely than white women to have tubal factor (51.2% vs 
22.0%, p<0.0001).  
 
Csokmay et al 
2011 
 
 
Black (African 
American) = 34.1 
±3.6.  
White = 34.7 ±4.2 
P=0.31 (NS) 
 
Not reported. 
 
Black women had a significantly higher likelihood of tubal factor (64% vs. 
31% p<0.0001) and uterine factor (40% vs. 10% p<0.001) and a lower 
likelihood of anovulation (4% vs. 22% p=0.005) when compared with White 
women. 
 
 
Dayal et al 
2009 
 
Black (African 
American) = 37.1 
±3.8 
White = 36.5 ±4.1 
p=0.28 (NS) 
 
Black = 26.5 
±5.2  
White = 23.7 
±4.8 
P<0.001 
 
Black women were more likely to have tubal infertility than White women 
(23% vs. 9%, p=0.007).  White women were more likely to have unexplained 
infertility (53% vs. 32%, p=0.004) 
 
 
Fujimoto et al 
2010 
 
 
White = 35.3  ±4.6 
Asian = 35.8  ±4.6 
Black = 35.9  ±4.7 
Hispanic = 35.0  ±4.8 
p<0.001 
 
Not reported. 
 
Black women less likely to be diagnosed with endometriosis, PCOS and 
unexplained infertility and more likely to have tubal or uterine factors 
(p<0.0001 for all) 
Hispanic women more likely to have tubal factors and less likely to have 
unexplained factors p<0.0001 
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Lashen et al 
1999 
 
Asian = 32.3 ±0.5 
White = 32.3 ±0.3 
 
 
Not reported. 
 
Significantly longer duration of infertility (P<0.001) and higher incidence of 
polycystic ovaries in Asian group compared to White (OR = 2.7, 95% CI 1.25-
5.8 P=0.01). 
 
 
Jayaprakasan 
et al 2014 
 
 
“Ethnic group” 
(South-East Asian, 
Afro-Caribbean, 
Middle Eastern) = 
33.3± 4.5 
White = 34.4± 4.3 
p<0.001 
 
 
 
“Ethnic Group” = 
25.8± 4.2 
 
White = 24.3± 
3.5 
 
 
Male factor as a cause of infertility was found to be higher amongst the ethnic 
group compared to the White (92 (40.7%) compared with 441 (34.2%) 
p<0.02) 
 
 
Mahmud et al 
1995 
 
 
White = 32.5 ±4.8.  
Asian (Indian) = 32.5 
±4.8 
(Matched by Age) 
 
White 23.1 ±3.1 
Asian (Indian) 
22.8 ±3.5 
(Matched by 
BMI) 
 
More Asian women had experienced infertility for ≥8years than White 
women; 40.9% vs. 21.6% (OR 2.5 [95% CI 1.1, 5.5]) p<0.05. 
 
 
 
 
McCarthy-
Keith et al 
2010 
 
 
Reported as no 
significant difference 
 
 
Not reported 
 
 
Tubal factor was more common in Black (African American) women 
compared against White women (65.4% vs. 32.9%, RR 1.99, 95% CI 1.78-
2.22) 
 
Black women less likely than White women to have; 
- Male factor (25.8% vs. 37.6%, RR 0.69, 95% CI 0.57-0.83) 
- Endometriosis (8.8% vs. 14.2%, RR 0.62, 95% CI 0.43-0.89) 
- Anovulation (5.7% vs. 9.8%, RR 0.51, 95%CI 0.34-0.78) 
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Nichols et al 
2001 
 
Black (African 
American) = 32.8 
±3.7 
White = 32.7 ±4.1 
p=0.84 
 
AA = 27.1 ± 4.6 
White = 24.8 
±5.3 
p=0.004 
 
African American women more likely than White women to have had tubal 
factor 67% vs. 27% (p=0.001).   
 
 
 
 
Purcell et al 
2007 
 
 
Women SART 
database 
Asian = 34.7±4.54 
White = 33.7±4,52 
p<0.001 
 
Women UCSF Clinic  
Asian = 36.1 ±4.09  
White = 36.6 ±4.08  
p=0.24 (NS) 
 
 
Not reported. 
 
 
SART Database; 
Asian women showed statistically significant higher rate of diminished 
ovarian reserve compared with White (11.4% vs 7.9% P<0.01) 
 
UCSF Clinic; 
White women significantly more likely to have diminished ovarian reserve 
(38.5% vs. 29.1%, p=0.03) whereas Asian women were significantly more 
likely to have ovulatory dysfunction (15.8% vs. 8.8%, p=0.01) and 
unexplained infertility (4.6% vs. 1.4%, p=0.02) 
 
 
Seifer et al 
2008 
 
 
 
No significant 
differences between 
Black or White 
women in age for 
either fresh or frozen 
cycles 
 
 
Not reported. 
 
 
Black women twice as likely to have tubal disorder than White women Fresh 
cycles; 62.8% vs. 28.2%, p<0.001, Frozen; 60.2% vs. 31.6% p<0.001  
 
Black women more likely to have uterine factor (Fresh; 11.4% vs. 4.8%, 
p<0.001, Frozen; 11.6% vs. 4.3% p<0.001).   
 
For both fresh and frozen cycles; White women have significantly higher 
likelihood of male factor, endometriosis and ovulatory disorders (p<0.001) 
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Seifer et al 
2010 
 
Significantly higher 
proportion of White 
women <35years 
compared with Black; 
p<0.001 
 
Not reported. 
 
Black women significantly more likely to have tubal factor and uterine factor 
than White women (p<0.001). 
 
White women significantly more likely to have male factor, endometriosis and 
ovulatory disorders (p<0.001) 
 
 
Shahine et al 
2009 
 
White = 36.7 ±3.9 
Asian (Indian) = 
34.03 ±4.09 
p=0.03 
 
White = 24.4 ± 
4.6 
Asian (Indian) = 
25.2 ±3.7 p=0.2  
 
There were no significant differences in infertility diagnosis.  
 
 
Sharara and 
McClamrock 
2000 
 
 
 
White = 33.0 ±3.7 
Black = 32.1 ±3.8  
No significant 
difference 
 
 
White = 26.7 
±7.0  
Black = 28.6 ± 
7.5 
p=0.38 (NS) 
 
 
Black women were more likely to have tubal factor than White women (73% 
vs. 40%, p<0.001).  Duration of infertility, in years, was significantly longer in 
Black women than White women (5.9 ±3.7 vs. 4.6 ±3.2, p=0.03) 
 
 
Sharara et al 
2012 
 
 
White = 33.5 ±3.6 
Asian (South Asian) = 
30.5 ±3.5 
p<0.001 
 
 
Not reported. 
 
 
50% of South Asians had a diagnosis of PCOS compared with 29% of White 
women p=0.004 
 
 
Shuler et al 
2011 
 
 
Reported as no 
significant difference 
in age 
 
 
Stated as no 
difference 
between groups 
 
 
Hispanic women more likely to have tubal factor infertility (p <.001)  
White women higher likelihood of endometriosis (p= 0.02). 
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Black vs. White 
Data from 8 studies2,4,5,23,24,31,41,43 were combined to compare the Black population 
with a White population for live birth and/or clinical pregnancy rates (Figures 3 and 
4).  Results showed Black women were found to have a statistically significant 
reduction in live births (OR 0.62 [95% CI 0.55-0.71] p<0.001) and clinical pregnancy 
(OR 0.74 [95% CI 0.64-0.87] p<0.001) compared to White women.  The results 
showed moderate heterogeneity for live birth data and statistically significant high 
heterogeneity for clinical pregnancy rate.   
 
Of the 8 studies, the two studies by Seifer et al in 20085 and 20104 contributed to 
around 70% of the whole data analysed.  With the results dominated by data from 
these studies, to look to see if the findings were driven by these studies we removed 
them from the meta-analyses.  Results showed that there was still a statistically 
significant reduced chance of live birth with Black women compared to White women 
(OR 0.63 [95% CI 0.41-0.96] p=0.03) however there was no difference seen with 
clinical pregnancy (OR 0.86 [95% CI 0.50-1.48] p=0.6).  
 
There were three studies which recorded data for frozen cycles4,5,26.  For the frozen 
cycles there was no statistically significant difference in live birth or clinical pregnancy 
between the Black and White population (Figures 5 and 6); (OR 0.90 [95%CI 0.80, 
1.01]) and (OR 0.92 [95% CI 0.54, 1.55]) respectively. 
 
Three papers calculated adjusted relative risks (RR) or odds ratios of the chances of 
live birth following a first fresh cycle4–6.  Each paper adjusted for multiple factors, 
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these included; maternal age, body-mass index, number of embryos transferred, 
diagnosis of male factor, endometriosis, PCOS, diminished ovarian reserve, tubal 
factors, uterine factors and other factors.  All three papers found that Black women 
were statistically significantly less likely to have a live birth after first cycle IVF than 
White women.  Both papers by Seifer et al4,5 (in 2008 they analysed 33,888 first 
cycles and in 2010 they analysed 131,348 first cycles) looked at the relative risk of 
not achieving a live birth for Black women vs. White; Seifer et al in 20085 (aRR 1.31 
[95% CI 1.26-1.37] p<0.001) and Seifer et al in 20104 (aRR 1.24 [95% CI 1.12-1.36] 
p<0.001).  Fujimoto et al6 (n=116,387 first cycles) had overlapping data with that of 
Seifer et al 2010, and therefore was not used in the unadjusted meta-analysis, 
however their results were consistent with both Seifer papers in showing a 
statistically significant reduction in live birth for Black women compared with White 
women after adjusting for confounders; (aOR 0.62 [95% CI 0.56-0.68] p<0.001). 
 
Seifer et al in 2008 and 2010 also calculated an adjusted relative risk analysis for 
frozen cycles separately; they calculated the aRR of not achieving a live birth.  
Results showed that even after adjusting for confounders there were no significant 
differences in live birth for Black women compared to White women; Seifer et al 2008 
(aRR 0.94 [95% CI 0.70-1.25] p=0.7) and Seifer et al 2010 (aRR 1.10 [95% CI 1.00-
1.21] p=0.05).   
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Figure 3.  Black vs. White – Live birth (fresh cycles) 
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Figure 4.  Black vs. White – Clinical pregnancy (fresh cycles) 
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Figure 5.  Black vs. White – Live birth (frozen cycles) 
 
 
 
 
Figure 6.  Black vs. White – Clinical pregnancy (frozen cycles) 
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Asian vs. White 
There were 8 studies3,6,24,28,31,40,42,44  comparing Asian ethnicity against a White 
reference group (Figures 7 and 8).  These studies comprised of women both from 
South Asian and Chinese ethnic groups, the meta-analysis showed these women 
had a statistically significant reduction in both live birth (OR 0.67 [95% CI 0.64-0.69] 
p<0.001) and clinical pregnancy rate (OR 0.67 [95% CI 0.65-0.70] p<0.001) 
compared with White women.  The data for live birth and clinical pregnancy showed 
very low heterogeneity, however this was not statistically significant.   
 
The results of the meta-analysis were dominated by one study by Fujimoto et al; 
which contributed to over 85% of the data analysed.  When we removed this study 
from the analysis there was still a statistically significant lower odds of live birth and 
clinical pregnancy in Asian women than in White women (OR 0.69 [95% CI 0.62-
0.76] p<0.001) and (OR 0.70 [95% CI 0.63-0.78] p<0.001) respectively. 
 
Five papers28,31,40,42,44  specified a cohort of South Asian or Indian women.  These 
data were meta-analysed separately and showed a statistically significant reduction 
in live birth and clinical pregnancy: (OR 0.66 [95% CI 0.52-0.85] p=0.001) and (OR 
0.65 [95% CI 0.47-0.90] p=0.008) respectively (Figures 9 and 10). 
 
Three studies3,6,28 calculated adjusted odds ratio for Asian women accounting for 
multiple confounders including age, BMI and diagnosis of PCOS; the results of these 
were pooled.  Even after adjusting for potential confounders there remained a 
statistically significant reduction in live birth rate for Asian women compared with 
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White (aOR 0.70 [95% CI 0.55, 0.86]).  Only one of these studies specified a cohort 
of South Asian women28; the adjusted odds ratio for this study (using age, PCOS and 
BMI as confounders) was (aOR 0.56 [95% CI 0.40-0.79]). 
 
 
 
 
 
 42 
Figure 7.  Asian vs. White – Live birth (fresh cycles) 
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Figure 8.  Asian vs. White – Clinical pregnancy (fresh cycles) 
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Figure 9.  South Asian vs. White – Live birth (fresh cycles) 
 
 
 
Figure 10.  South Asian vs. White – Clinical pregnancy (fresh cycles) 
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Hispanic vs. White 
The findings for the Hispanic population were consistent with those for Black and 
Asian women, four studies2,6,24,29 had data for live birth rate, while only three 
studies2,6,29 also reported clinical pregnancy rate.  The findings for the Hispanic 
population were consistent with those for Black and Asian women showing a 
statistically significant reduction in live birth and clinical pregnancy rate when 
compared to a White population: (OR 0.86 [95% CI 0.82-0.90] p<0.001) and (OR 
0.89 [95% CI 0.85-0.93] p<0.001) respectively (Figures 11 and 12).  Both the live 
birth and clinical pregnancy data for the Hispanic population showed very low 
heterogeneity although this was not statistically significant.  Only one of the four 
papers6 calculated an adjusted odds ratio for the live birth outcome.  They adjusted 
for maternal age, number of embryos transferred and diagnosis of male factor, 
endometriosis, PCOS, diminished ovarian reserve, tubal factors, uterine factors and 
other factors.  This result was consistent in showing that the Hispanic population 
have a lower live birth rate compared with White women (aOR 0.87 [95% CI 0.79, 
0.96] P=0.005). 
 
As seen in the Asian vs. White comparisons, one study (Fujimoto et al) dominated 
the analysis in the Hispanics vs. White comparisons by contributing around 98% of 
the data.  When we removed this study from the analysis there was still a statistically 
significant reduced odds of live birth for Hispanic women compared with White 
women (OR 0.67 [95% CI 0.48-0.94] p=0.02), although this was not the case for 
clinical pregnancy (OR 0.79 [95% CI 0.57-1.10] p=0.2). 
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Figure 11.  Hispanic vs. White – Live birth (fresh cycles) 
 
 
 
Figure 12.  Hispanic vs. White – Clinical pregnancy (fresh cycles) 
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Discussion 
 
Main findings 
Our systematic review suggests that significant ethnic disparities in IVF outcomes 
exist.  The results consistently showed a statistically significant reduction in live birth 
and clinical pregnancy for fresh cycles across all races compared with White women.  
For live birth the Black population were found to have the poorest outcome followed 
by Asian and Hispanic, while for clinical pregnancy Asian women had the lowest 
success.  The Hispanic population only showed a small reduction in live birth 
success compared with White women.  Black women were found to have the poorest 
live birth rate for the fresh cycle data, however interestingly there was no statistical 
significant difference for the frozen data.  This difference between fresh and frozen 
cycle outcome may suggest that treatment protocol has a role to play in the reduced 
success rate for fresh cycles.  Further studies of tailored treatment protocols across 
different racial groups could potentially improve success rates. 
 
There is an argument that the difference in IVF success rates could be influenced 
primarily by socioeconomic factors, such as lack of access to medical treatment 
leading to higher age at first encounter.  As stated in the results only three papers 
found a statistical difference in mean age; Seifer et al4 and Fujimoto et al6 both found 
a statistically significantly higher proportion of White women under the age of 35 
years compared with Black women, while Sharara et al42 found South Asian women 
to have a statistically significant mean younger age compared with White women.  
Further to this, there could be a case for non-White women having a poorer diet and 
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lifestyle leading to reduced chance of pregnancy success, however only two of the 
seven studies which reported BMI found statistically significant differences between 
the racial groups, with the White population having a lower mean BMI compared with 
Black23,41. 
 
Strengths and limitations 
One of the strengths of this study was the thorough methodological approach used.  
It met the quality criteria laid down in the MOOSE statement45.  The analysis 
contained a good sample size with a total of 195,978 fresh cycles and 38,211 frozen 
cycles for overall analysis.  However the papers were heterogeneous with both 
prospective and retrospective methodology.  There was variation between the papers 
with regards to country of origin, differing categories of racial groups, year of 
publication and source of data.  The country from which the data was produced was 
particularly important in this study as it determined which ethnic groups would be 
included and thus introducing a potential population bias. 
 
One of the main limitations in interpreting the findings of this paper was the differing 
definitions used for each racial group.  For the purpose of combining the data for 
analysis only four racial groups were defined; White, Black, Asian and Hispanic. The 
definition of the Asian group proved problematic.  The papers using SART data 
reported patients as “Asian” with no specific definition, therefore incorporating both 
South Asians (e.g. Indian, Pakistani) and South-East Asians (e.g. Chinese). To truly 
examine differences in outcomes between South Asians and South-East Asians and 
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other specific racial groups a more comprehensive definition of race reporting within 
the SART database and other databases used worldwide needs to be implemented. 
A further significant limitation was in the quality of the original data.  Only five of the 
15 studies provided data for adjusted odds ratios3–6,28.  Being unable to account for 
significant confounders i.e. age and body mass index, invariably affects the reliability 
of the results.  As mentioned in the results, two of the largest studies; Seifer et al4 
and Fujimoto et al6 found that Black women had a statistically significant higher mean 
age amongst Black women compared to White women.  Therefore, one could argue 
that higher maternal age is the reason for Black women having lower success rates 
following IVF.  However both Seifer et al4 and Fujimoto et al6 accounted for age in 
their adjusted analyses and the results were consistent with that of the unadjusted 
analysis.  Regarding diagnosis of infertility; across nine studies Black women were 
found to have higher rates of tubal factor and uterine factor infertility and in two 
studies Asian women were found to have higher rates of PCOS compared to White 
women.  However, cause of infertility was adjusted for (in selected studies3–6,28) and 
the results remained unchanged from the unadjusted analysis.     
 
Finally, the bulk of the results of the meta-analyses were dominated by three large 
US studies4–6.  Although the large sample size of these studies adds credibility there 
are still serious limitations.  The Seifer studies only compared outcomes for African 
American women and White women, and although Fujimoto et al included Asian 
women they inappropriately combined South Asian and South-East Asian women.  A 
further limitation of these studies is that as they are based on the ethnic distribution 
of the US and so the findings are not transferrable to a UK population.  For example, 
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the UK does not have a large proportion of Hispanic people and instead South 
Asians contribute a greater percentage of ethnic minorities.   
 
Conclusions and future work 
This meta-analysis provides sound supporting evidence for the hypothesis that there 
is an association between ethnic background and IVF success, although with some 
serious limitations.  It prompts investigation into the mechanisms behind this to 
subsequently allow modification of clinical practice to account for ethnicity.  Given the 
limitation in accounting for confounders within this review and the lack of specificity 
with the ethnic groups, a large cohort study where there are clear definitions of 
ethnicity and a comprehensive range of variables available for analysis, would help to 
explore in closer detail the racial differences in IVF success and thus help to begin to 
investigate ways to minimise this.  Furthermore, given that the existing studies, and 
in particular the largest studies contributing the majority of data to the meta-analyses, 
are all based on women in the US; there is a need for a large UK based study to 
determine the relationship between ethnicity and IVF outcome specific to the UK 
population. 
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CHAPTER 3 
Investigating the effect of ethnicity on IVF outcome: 
an analysis of 13,473 cycles and an updated meta-
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work in this chapter was published in Reproductive Biomedicine Online; 
published online 03.06.15 
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Introduction 
 
 
Although ethnicity is frequently investigated as a prognostic factor in medicine, as 
shown in chapter 2, few studies have been able to clearly explore the association 
between ethnicity and in-vitro fertilisation (IVF) outcomes while accounting for the key 
confounders.  Ethnic minorities contribute to around 13% of the UK population46. 
However, to our knowledge there is no published data on what percentage of couples 
seeking IVF treatment in the UK comes from ethnic minorities.  Nonetheless, it is 
important for couples undergoing assisted conception to be counselled appropriately 
and according to their individual backgrounds.   
 
The existing literature on ethnicity and IVF outcomes, as discussed in the systematic 
review, consists largely of American studies that have used the Society of American 
Reproductive Technologies (SART) database4,5.  Such studies have not been able to 
adjust their findings to key confounders; furthermore, the ethnic mix of the American 
population is quite different from that of the UK.  Therefore, the findings of these 
studies may not be transferrable, thus prompting the need for a large UK study.  In 
the UK, there have been three studies31,40,44 exploring the association between 
ethnicity and in-vitro fertilisation outcome. Two of these were conducted over 10 
years ago40,44, so there is a question about their applicability to today’s population 
given the rapid advances in IVF over the years.  The most recent publication31 in 
2014 was limited by its sample size (n=1517) and consequently had to group all 
ethnic groups into one group in order to perform any meaningful analysis.  This, 
however, significantly limits the findings; as not all ethnic groups will behave the 
same.  
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Aims and objectives 
1. To investigate the effect of ethnicity on live birth, in a large population 
(representative of UK ethnicities), following IVF treatment, while adjusting for 
known important confounders. 
2. To investigate the effect of ethnicity on clinical pregnancy, in a large 
population (representative of UK ethnicities) following IVF treatment, while 
adjusting for known important confounders. 
3. To provide an updated meta-analysis of studies investigating the effect of 
ethnicity on IVF outcome incorporating the findings of our cohort study. 
 
Methods 
 
Study Design 
This observational cohort study included all women undergoing their first non-donor 
cycle of IVF or Intra-cytoplasmic Sperm Injection (ICSI) at any Centres for Assisted 
Reproduction (CARE) clinic in the UK and Ireland, from 2008 to 2012.  CARE is one 
of the UK’s largest independent providers of fertility services and provides treatment 
for both NHS and non-NHS patients.  Permission to utilise an anonymised dataset of 
routinely collected electronic data was granted by the Institution Review Board of 
CARE.  
 
Data were analysed from 12 fertility clinics within the CARE consortium; Nottingham, 
Manchester, Northampton, Sheffield, Dublin, Bolton, Boston, Derby, Leicester, 
Mansfield, Milton Keynes and Peterborough.  Both fresh and frozen assisted 
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conception cycle data were included.  The primary outcome for the study was live 
birth (defined as the birth of one of more living infants), and the secondary outcome 
was clinical pregnancy (defined as the presence of a gestational sac on ultrasound).  
 
All women undergoing treatment at CARE were required to complete their 
demographic profile. This includes ethnicity definitions that were in line with that of 
the Human Fertilisation and Embryology (HFEA) coding.  There were 17 individual 
ethnic groups, which we grouped into seven main categories: White (White British, 
White Irish, any other White), South Asian (Indian, Pakistani, Bangladeshi, any other 
Asian background), Black (Black Caribbean, Black African, other Black), Chinese, 
Mixed (White and Black Caribbean, White and Black African, White and Asian, any 
other mixed), any other and not stated. 
 
Statistical analysis 
The baseline patient characteristics, cycle characteristics and outcome data were 
described giving frequencies with percentages, or means with standard deviations, 
as appropriate.   To estimate the contribution of ethnicity to live birth rate and clinical 
pregnancy, univariate and multiple logistic regression analyses were performed to 
calculate odds ratios and corresponding 95% confidence intervals along with p 
values.  Covariates were preselected when they had a known effect on IVF outcome, 
based on clinical knowledge and experience.  The covariates selected for the 
multivariate model were: age, body mass index, duration of infertility, cause of 
infertility, history of previous live birth, history of previous miscarriage and number of 
embryos transferred.  Ideally a measure of ovarian reserve (i.e. Day 2 Follicle 
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Stimulating Hormone (FSH), Anti-Mullerian Hormone (AMH) or Antral Follicle Count 
(AFC)) would have been included, however these variables were not well recorded in 
the database and so were removed from analysis. 
 
For the continuous variables: age, BMI and duration of infertility, they were assessed 
for their functional form using plots of the observed log odds for live birth.  BMI 
appeared to have a linear relationship with live birth, however in the case of age, and 
duration of infertility there was a non-linear relationship.  The results for age showed 
that below 36 years of age the chances of live birth appeared fairly constant, but 
above 36 there was a sharp linear decline, resulting in two linear variables being 
created for age.  Whereas for duration of infertility from 0-4 years the log odds of live 
birth appeared static.  From 5 years onwards there was a sharp decline, and so it 
was decided to dichotomise duration of infertility into 0-4 years and >5 years.  The 
graphical representation for each continuous variable and the log odds of live birth is 
shown in Figures 13 to 15.   
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Figure 13.  Age plotted against the log odds of the probability of live birth. 
 
 
 
 
 
 
The results for age show that below 36 years of age the chances of live birth appear 
fairly constant, but above 36 there is a sharp linear decline, this resulted in two linear 
variables being created for age.  The first was a continuous variable for age up until 
36 years.  Anyone older than 36 years had the value 36 for this variable.  A second 
age variable equalled zero for all ages ≤36, and equalled age minus 36 for all ages 
>36 years.   
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Figure 14.  BMI plotted against the log odds of the probability of live birth 
 
 
 
 
 
 
BMI shows a linear relationship and so was included in the model as a continuous 
variable.  
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Figure 15.  Duration of infertility plotted against the log odds of the probability 
of live birth 
 
 
 
 
 
For duration of infertility from 0-4 years the log odds of live birth appear static.  From 
5 years onwards there was a sharp decline, and so it was decided to dichotomise 
duration into 0-4 years and >5 years.   
 
Missing data 
All variables included in the regression analysis had 100% of data entry with the 
exception of BMI.  This was only reported in 48% of cases.  A multiple imputation 
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procedure was conducted using an iterative Markov chain Monte Carlo (MCMC) 
method to impute for the missing BMI data.  All predictors and the outcome of live 
birth were included in the imputation process to maximise the precision of the 
imputations.  All univariable models and the multivariable model were fitted to the 20 
imputed datasets arising from the multiple imputation procedure.  The parameter 
estimates and covariance’s arising from the models from each imputed dataset were 
combined to produce inferential results.   
  
A sensitivity analysis was performed analysing the data for frozen cycles separately 
and breaking down causes of infertility to specifically include fibroids.   
 
Finally, the results of unadjusted and adjusted odds ratios from our cohort study were 
combined, where appropriate, with the data from the existing studies to provide an 
updated meta-analysis. 
 
Data were analysed using SPSS (ver. 21.0; SPSS Inc., Chicago) and Review 
Manager (version 5.0 for Windows).      
 
Results 
 
Overall description of data 
A total of 13473 cycles were reported between 2008 and 2012 at the 12 CARE clinics 
in the UK.  The ethnic groupings were as follows; White (10062), Black (212), South 
Asian (1025), Chinese (83), Mixed (476), Other (148) and Not stated (1467).  The 
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total percentage of ethnic minorities who underwent IVF treatment at the CARE 
clinics (including “Other”) was 14.4%.   
 
Tables 5-7 display an overall description of the results including baseline patient 
characteristics, cycle characteristics and cycle outcomes.  The number of cycles that 
had data for each variable is specified within the tables.  It is noted that Black women 
had worse risk factors: they were on average older, with higher BMI, fewer previous 
live births, more previous miscarriages and a longer duration of infertility than White 
women; whereas Asian women were on average younger, with lower BMI, greater 
rates of anovulation, lower rates of previous miscarriage but longer duration of 
infertility than White women.   The group with unstated ethnic group had the highest 
rates of previous live births, lowest rates of previous miscarriage but the longest 
duration of infertility. 
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Table 5.  Baseline characteristics for each ethnic group 
 White 
(n=10062) 
Black 
(n=212) 
South Asian 
(n=1025) 
Chinese 
(n=83) 
 
Mixed 
(n=476) 
Other 
(n=148) 
Not stated 
(n=1467) 
 
Age (in years) 
    <35 
    35.1-40 
    40.1-45 
    >45.1 
 
 
(n=10062) 
5577 (55.4%) 
3166 (31.5%) 
1112 (11.1%) 
207 (2.1%) 
 
 
(n=212) 
103 (48.6%) 
59 (27.8%) 
39 (18.4%) 
11 (5.2%) 
 
(n=1025) 
731 (71.3%) 
223 (21.8%) 
65 (6.3%) 
6 (0.6%) 
 
(n=83) 
49 (59%) 
25 (30.1%) 
9 (10.8%) 
0 
 
(n=476) 
281 (59.0%) 
133 (27.9%) 
53 (11.1%) 
9 (1.9%) 
 
(n=148) 
72 (48.6%) 
61 (41.2%) 
15 (10.1) 
0 
 
(n=1467) 
757 (51.6%) 
459 (31.3%) 
188 (12.8%) 
63 (4.3%) 
 
Body mass index 
    <18.5 
    18.6-25 
    25.1-30 
    30.1-35 
    >35.1 
 
 
(n=5278) 
89 (1.7%) 
3100 (58.7%) 
1625 (30.8%) 
421 (8.0%) 
43 (0.8%) 
 
(n=116) 
3 (2.6%) 
35 (30.2%) 
48 (41.1%) 
28 (24.1%) 
2 (1.7%) 
 
(n=527) 
15 (2.8%) 
293 (55.6%) 
178 (33.8%) 
33 (6.3%) 
8 (1.5%) 
 
(n=45) 
2 (4.4%) 
40 (88.9%) 
2 (4.4%) 
0 
1 (2.2%) 
 
(n= 290) 
16 (5.5%) 
160 (55.2%) 
81 (27.9%) 
30 (10.3%) 
3 (1.0%) 
 
(n=86) 
0 
58 (67.4%) 
25 (29.1%) 
3 (3.5%) 
0 
 
(n=132) 
0 
85 (64.4%) 
32 (24.2%) 
12 (9.1%) 
3 (2.3%) 
Cause of 
infertility* 
     Male factor 
     Tubal factor 
     Anovulation 
     Female other  
(e.g. 
Endometriosis) 
     Unexplained 
*Not mutually excl 
 
(n=10062) 
5896 (58.6%) 
1554 (15.4%) 
1156 (11.5%) 
3014 (30.0%) 
 
2948 (29.3%) 
 
(n=212) 
109 (51.4%) 
36 (17.0%) 
17 (8.0%) 
91 (42.9%) 
 
60 (28.3%) 
 
(n=1025) 
589 (57.5%) 
123 (12.0%) 
197 (19.2%) 
230 (22.4%) 
 
343 (33.5%) 
 
(n=83) 
54 (65.1%) 
22 (26.5%) 
7 (8.4%) 
14 (16.9%) 
 
23 (27.7%) 
 
(n=476) 
296 (62.2%) 
68 (14.3%) 
58 (12.2%) 
146 (30.7%) 
 
130 (27.3%) 
 
(n=148) 
95 (64.2%) 
29 (19.6%) 
17 (11.5%) 
45 (30.4%) 
 
34 (23.0%) 
 
(n=1467) 
548 (37.4%) 
226 (15.4%) 
200 (13.6%) 
319 (21.7%) 
 
437 (29.8%) 
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Prev. live birth 
 
 
(n=10062) 
1907 (19.0%) 
 
(n=212) 
29 (13.7%) 
 
(n=1025) 
190 (18.5%) 
 
(n=83) 
11 (13.3%) 
 
(n=476) 
94 (19.7%) 
 
(n=148) 
21 (14.2%) 
 
(n=1467) 
349 (23.8%) 
 
 
Prev. miscarriage 
 
 
(n=10062) 
2047 (20.3%) 
 
(n=212) 
61 (28.8%) 
 
(n=1025) 
163 (15.9%) 
 
(n=83) 
9 (10.8%) 
 
(n=476) 
98 (20.6%) 
 
(n=148) 
28 (18.9%) 
 
(n=1467) 
98 (6.7%) 
Duration of 
infertility in years 
(Mean ±SD) 
 
 
(n=10062) 
2.71 ±2.1 
 
(n=212) 
3.5 ±2.8 
 
(n=1025) 
3.4 ±2.7 
 
(n=83) 
3.3 ±2.8 
 
(n=476) 
2.6 ±2.3 
 
(n=148) 
3.1 ±2.5 
 
(n=1467) 
4.4 ±3.2 
Day 2 FSH 
(Mean ±SD) 
 
(n=3214) 
8.13 ±21.9 
(n=66) 
7.9 ±3.8 
(n=343) 
7.3 ±6.4 
(n=27) 
5.7 ±2.1 
(n=215) 
6.8 ±2.5 
(n=60) 
6.6 ±2.2 
(n=64) 
6.6 ±1.9 
AMH level 
(Mean ±SD) 
 
(n=1289) 
16.98 ±18.2 
(n=13) 
20.5 ±27.7 
(n=107) 
24.5 ±33.5 
 
(n=8) 
25.0 ±34.9 
(n=44) 
9.3 ±11.3 
(n=15) 
13.6 ±9.9 
(n=17) 
26.7 ±24.9 
Antral follicle 
count 
(Mean ±SD) 
 
(n=3987) 
20.7 ±12.5 
(n=91) 
18.4 ±13.5 
(n=359) 
20.3 ±14.7 
(n=24) 
15.5 ±7.4 
(n=199) 
19.3 ±12.8 
(n=69) 
18.1 ±13.5 
(n=42) 
27.6 ±16.3 
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      Table 6.  Cycle characteristics for each ethnic group 
 White 
(n=10062) 
Black 
(n=212) 
South Asian 
(n=1025) 
Chinese 
(n=83) 
Mixed 
(n=476) 
Other 
(n=148) 
Not stated 
(n=1467) 
        
Treatment: 
IVF 
ICSI 
FET 
Not recorded 
(n=10062) 
2704 (26.9%) 
5010 (49.8%) 
1853 (18.4%) 
495 (4.9%) 
(n=212) 
60 (28.3%) 
106 (50.0%) 
34 (16.0%) 
12 (5.7%) 
(n=1025) 
252 (24.6%) 
556 (54.2%) 
183 (17.9%) 
34 (3.3%) 
(n=83) 
26 (31.3%) 
30 (36.1%) 
20 (24.1%) 
7 (8.5%) 
(n=476) 
96 (20.2%) 
270 (56.7%) 
99 (20.8%) 
11 (2.3%) 
(n=148) 
38 (25.7%) 
81 (54.7%) 
25 (16.9%) 
4 (2.7%) 
(n=1467) 
359 (24.5%) 
598 (40.8%) 
428 (29.2%) 
82 (5.5%) 
 
No. of oocytes 
retrieved 
(mean ±SD) 
(n=10062) 
7.4 ±6.3 
 
 
(n=212) 
8.1 ±9.4 
(n=1025) 
8.1 ±6.8 
(n=83) 
6.9 ±6.8 
(n=476) 
7.8 ±6.5 
(n=148) 
7.9 ±5.9 
(n=1467) 
6.0 ±6.2 
No. of mature 
oocytes  
(mean ±SD) 
 
(n=10062) 
5.7 ±5.1 
(n=212) 
5.9 ±7.8 
(n=1025) 
6.2 ±5.5 
(n=83) 
5.4 ±5.6 
(n=476) 
5.9 ±5.2 
(n=148) 
6.1 ±4.9 
(n=1467) 
4.7 ±5.0 
No. 
inseminated 
(mean ±SD) 
 
(n=10062) 
6.2 ± 5.5 
(n=212) 
6.4 ±8.3 
(n=1025) 
6.7 ±5.8 
(n=83) 
5.9 ±5.9 
(n=476) 
6.2 ±5.5 
(n=148) 
6.6 ±5.1 
(n=1467) 
5.1 ±5.4 
2 Pronuclei  (n=10062) 
4.01 ± 3.8 
  
(n=212) 
4.2 ±6.3 
(n=1025) 
4.2 ±3.9 
(n=83) 
3.6 ±3.8 
(n=476) 
4.1 ±4.0 
(n=148) 
4.2 ±3.8 
(n=1467) 
3.4 ±3.7 
 
3 Pronuclei  (n=10062) 
0.2 ±0.5 
 
(n=212) 
0.3 ±0.8 
(n=1025) 
0.2 ±0.5 
(n=83) 
0.3 ±0.7 
(n=476) 
0.2 ±0.6 
(n=148) 
0.2 ±0.5 
(n=1467) 
0.2 ±0.6 
 
Total no. of 
embryos 
(n=10062) 
4.9 ±3.9 
(n=212) 
5.4 ±6.6 
(n=1025) 
5.3 ±4.1 
(n=83) 
4.9 ±3.9 
(n=476) 
5.1 ±4.0 
(n=148) 
5.1 ±3.7 
(n=1467) 
4.5 ±3.7 
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Fertilisation 
rate* 
(mean ±SD) 
 
(n=7522) 
0.73 ±0.24 
 
 
(n=157) 
0.73 ±0.23 
 
(n=784) 
0.71 ±0.24 
 
(n=56) 
0.69 ±0.24 
 
(n=357) 
0.72 ±0.26 
 
(n=114) 
0.71 ±0.25 
 
(n=933) 
0.74 ±0.24 
 
No. of 
embryos 
transferred 
0 
1 
2 
3 
 
 
(n=10062) 
 
1395 (13.9%) 
3157 (31.4%) 
5250 (52.2%) 
260 (2.6%)) 
 
 
(n=212) 
 
48 (22.6%) 
55 (25.9%) 
102 (48.1%) 
7 (3.3%) 
 
 
(n=1025) 
 
128 (12.5%) 
302 (29.5%) 
580 (56.6%) 
15 (1.5%) 
 
 
(n=83) 
 
12 (14.5%) 
25 (30.1%) 
46 (55.4%) 
0 
 
 
(n=476) 
 
60 (12.6%) 
160 (33.6%) 
242 (50.8%) 
14 (2.9%) 
 
 
(n=148) 
 
20 (13.5%) 
46 (31.1%) 
81 (54.7%) 
1 (0.7%)  
 
 
(n=1467) 
 
183 (12.5%) 
222 (15.1%) 
1021 (69.6%) 
41 (2.8%) 
 
No. of 
embryos 
frozen 
(Mean±SD) 
 
 
 
1.1 ± 2.5 
 
 
1.9 ±6.1 
 
 
1.2 ±2.5 
 
 
0.9 ±2.6 
 
 
1.1 ±2.4 
 
 
1.2 ±2.2 
 
 
0.8 ±2.2 
 
*Fertilisation rate is the number of embryos over the total number of oocytes retrieved 
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Table 7.  Outcome data for each ethnic group 
 
 White 
(n=10062) 
Black 
(n=212) 
South Asian 
(n=1025) 
Chinese 
(n=83) 
 
Mixed 
(n=476) 
Other 
(n=148) 
Not stated 
(n=1467) 
Implantation 
rate* 
(Mean ±SD) 
(n=8667) 
0.38 ±0.46 
(n=164) 
0.24 ±0.39 
(n=897) 
0.38 ±0.46 
(n=71) 
0.35 ±0.53 
(n=416) 
0.33 ±0.42 
(n=128) 
0.30 ±0.41 
(n=1284) 
0.36 ±0.44 
 
Biochemical 
pregnancy rate 
 
 
4634 (46.1%) 
 
57 (26.9%) 
 
477 (46.5%) 
 
33 (39.8%) 
 
215 (45.2%) 
 
54 (36.5%) 
 
676 (46.1%) 
Clinical 
pregnancy 
rate** 
 
3970 (39.5%) 
 
48 (22.6%) 
 
409 (39.9%) 
 
27 (32.5%) 
 
175 (36.8%) 
 
48 (32.4%) 
 
591 (40.3%) 
 
Live birth ratea 
 
3492 (34.7%) 
 
 
42 (19.8%) 
 
 
341 (33.3%) 
 
26 (31.3%) 
 
 
149 (31.3%) 
 
 
42 (28.4%) 
 
 
530 (36.1%) 
 
Other 
pregnancy 
outcomes 
    Miscarriageb 
    Terminationb  
    Still birthb 
    NNDb 
 
 
 
 
379 (9.5%) 
20 (0.5%) 
15 (0.4%) 
24 (0.6%) 
 
 
 
6 (12.5%) 
0 
0 
0 
 
 
 
 
45 (11.0%) 
3 (0.7%) 
4 (1.0%) 
2 (0.5%) 
 
 
 
1 (3.7%) 
0 
0 
0 
 
 
 
18 (10.2%) 
1 (0.6%) 
1 (0.6%) 
1 (0.6%) 
 
 
 
3 (6.3%) 
0 
0 
0 
 
 
 
49 (8.3%) 
3 (0.5%) 
4 (0.7%) 
4 (0.7%) 
 
*Defined as the number of foetal hearts divided by the number of embryos transferred, per cycle 
** Defined as the presence of a gestational sac by ultrasound during first trimester 
a Expressed as a percentage of all cycles   b Expressed as a percentage of clinical pregnancies
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Univariate and multivariate analyses for live birth for all cycles 
The live birth rate was statistically significantly lower in Black women than White 
women (19.8% vs. 34.7% p<0.001).  The rates in South Asian women and White 
women were similar (33.3% vs. 34.7% p=0.4).  The difference between Black and 
White women remained statistically significant when differences in age, BMI, cause 
and duration of infertility, previous live birth, previous miscarriage and number of 
embryos transferred were adjusted for; (OR 0.53 [95% CI 0.37-0.76] p<0.001).  
Adjustment for differences, using the same variables, showed that the adjusted odds 
of having a live birth rate for South Asian women was significantly lower than for 
White women (OR 0.79 (0.68-0.91) p<0.001).  The univariate analysis and 
multivariate logistic regression model for live birth is shown in Tables 8 and 9 
respectively.  
 
Table 8.  Univariate analysis for live birth (all cycles) 
   
      95% CI     
Ethnic Group No. of cycles Odds ratio Lower Upper P value 
      
White 10062 Reference --- --- --- 
South Asian 1025 0.94  0.82 1.08 0.4 
Black 212 0.47  0.33 0.65 <0.001 
Chinese 83 0.86  0.54 1.40 0.5 
Mixed  476 0.86 0.70 1.05 0.1 
Other 148 0.75 0.52 1.07 0.1 
Not stated  1467 1.07 0.95 1.19 0.3 
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Table 9.  Multivariate logistic regression model for live birth (n=13473) 
 
 
Parameter 
Estimate 
S.E. P value Odds Ratio 95% CI 
    
Lower Upper 
Age:    
≤36 years (per increasing year) -0.056993 0.006 <0.001 0.95 0.93 0.96 
>36 years (per increasing year) -0.114606 0.010 <0.001 0.89 0.87 0.91 
       
Body mass index -0.012935 0.007 0.08 0.99 0.97 1.00 
       
Cause of infertility:       
Male factor -0.077805 0.048 0.1 0.93 0.84 1.02 
Tubal factor  -0.298338 0.059 <0.001 0.74 0.66 0.83 
Anovulation -0.023018 0.063 0.7 0.98 0.86 1.11 
Unexplained -0.153625 0.058 0.008 0.86 0.77 0.96 
Other (e.g. Endo) -0.112451 0.051 0.03 0.89 0.81 0.99 
       
Ethnicity:       
White 0   Reference   
South Asian -0.240432 0.074 <0.001 0.79 0.68 0.91 
Black -0.640090 0.184 <0.001 0.53 0.37 0.76 
Chinese -0.205110 0.253 0.4 0.82 0.50 1.34 
Other -0.289247 0.193 0.1 0.75 0.51 1.09 
Not stated -0.062196 0.065 0.4 0.94 0.83 1.07 
Mixed -0.220246 0.107 0.04 0.80 0.65 0.99 
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Table 9. continued 
 
 
 Parameter 
Estimate 
S.E. P value Odds Ratio 95% CI 
    
Lower Upper 
Previous Live Birth 
No 
Yes 
 
0 
0.068248 
 
0.051 
 
0.2 
Reference 
1.07 
 
 
0.97 
 
 
1.18 
       
Previous Miscarriage 
No 
Yes 
 
0 
0.016775 
 
 
0.052 
 
 
0.8 
 
Reference 
1.02 
 
 
0.92 
 
 
1.13 
       
       
Duration of infertility:       
0-4 years 0   Reference   
≥5 years -0.167231 0.056 0.003 0.85 0.76 0.94 
       
No. of embryos transferred 1.000064 0.031 <0.001 2.72 2.56 2.89 
Constant 0.372027 0.267 0.2 1.45 0.86 2.45 
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Univariate and multivariate analyses for clinical pregnancy for all cycles 
The unadjusted results for clinical pregnancy for Black women compared with White 
women were similar to that of live birth: 22.6% and 39.5% respectively (p<0.001); the 
odds ratios for univariate analysis of ethnic group and live birth is shown in Table 10.  
This difference was maintained after accounting for known confounders (aOR 0.50 
[95% CI 0.35-0.71] p<0.001), as shown in the logistic regression model in Table 11.  
The crude rates for implantation rate were also much lower for Black women 
compared with White women: 0.24 vs. 0.38.   
 
Unlike for live birth, South Asian women had similar clinical pregnancy rates to White 
women (39.9% vs. 39.5% clinical pregnancy and 0.38 vs 0.38 for implantation rates).  
After adjustment in multivariate analyses for differences in confounding variables, 
there remained no significant difference in clinical pregnancy rates between South 
Asian women vs. White women (aOR = 0.86 [95% CI 0.75-1.00) p=0.05).  
 
Table 10.  Univariate analysis for clinical pregnancy (all cycles) 
   
      95% CI     
Ethnic Group No. of cycles Odds ratio Lower Upper P value 
      
White 10062 Reference --- --- --- 
South Asian 1025 1.02  0.89 1.16 0.8 
Black 212 0.45  0.33 0.62 <0.001 
Chinese 83 0.74 0.47 1.17 0.2 
Mixed  476 0.89 0.74 1.08 0.2 
Other 148 0.74 0.52 1.04 0.08 
Not stated  1467 1.04 0.93 1.16 0.5 
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Table 11.  Multivariate logistic regression model for clinical pregnancy (n=13473) 
 
 
 
 Parameter 
Estimate 
S.E. P value Odds Ratio 95% CI 
    
Lower Upper 
Age:    
≤36 years (per increasing year) -0.050964 0.006 <0.001 0.95 0.94 0.96 
>36 years (per increasing year) -0.114273 0.010 <0.001 0.89 0.88 0.91 
       
Body mass index -0.019096 0.007 0.1 0.99 0.98 1.00 
       
Cause of infertility:       
Male factor -0.074553 0.047 0.1 0.93 0.85 1.01 
Tubal factor  -0.246090 0.058 <0.001 0.78 0.70 0.88 
Anovulation 0.075815 0.062 0.2 1.08 0.96 1.22 
Unexplained -0.119439 0.057 0.04 0.89 0.79 0.99 
Other (e.g. Endo) -0.086382 0.050 0.09 0.92 0.83 1.01 
       
Ethnicity:       
White 0   Reference   
South Asian -0.150521 0.072 0.05 0.86 0.75 1.00 
Black -0.690810 0.177 <0.001 0.50 0.35 0.71 
Chinese -0.363738 0.252 0.1 0.70 0.42 1.14 
Other -0.311138 0.188 0.1 0.84 0.69 1.03 
Not stated -0.113980 0.064 0.08 0.89 0.79 1.01 
Mixed -0.173671 0.104 0.1 0.84 0.69 1.03 
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Table 11. continued 
 Parameter 
Estimate 
S.E. P value Odds Ratio 95% CI 
    
Lower Upper 
Previous Live Birth 
No 
Yes 
 
0 
0.075909 
 
0.050 
 
0.1 
Reference 
1.08 
 
 
0.98 
 
 
1.19 
       
Previous Miscarriage 
No 
Yes 
 
0 
0.016938 
 
 
0.051 
 
 
0.7 
 
Reference 
1.02 
 
 
0.92 
 
 
1.12 
       
       
Duration of infertility:       
0-4 years 0   Reference   
≥5 years -0.161055 0.055 0.003 0.85 0.77 0.95 
       
No. of embryos transferred 1.085808 0.030 <0.001 2.96 2.79 3.14 
Constant 0.176627 0.261 0.5 1.19 0.71 2.00 
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Sensitivity analysis accounting for fibroids 
The causes of infertility were grouped into tubal, ovulatory, male, unexplained and 
other.  A sensitivity analysis was performed to specifically look at whether fibroids 
could explain the effects on live birth outcome in the Black population.  Fibroids were 
included in the heterogenous group termed ‘other’ that included endometriosis and 
structural abnormalities.  We created a separate variable for fibroids alone, adding 
this to the model including all the other covariates; this actually increased the 
magnitude of the effect of Black ethnicity on lower live birth rates (Black OR 0.33 
[95% CI 0.14-0.77] p<0.001).  
 
Analysis of frozen cycles 
When exploring the live birth and clinical pregnancy rates specifically for 
cryopreserved (frozen) cycles, we performed the same multivariate analysis, using 
the same covariates on the frozen cycles alone. We found similar significant 
differences, as seen in the overall analysis, for live birth and clinical pregnancy rates 
between South Asian women and White women; South Asian women showed a 
reduced odds of achieving live birth compared to White women (OR 0.69 [95% CI 
0.48-0.99]) and a comparable odds of achieving clinical pregnancy (OR 0.88 [95% CI 
0.63-1.23] p=0.5).  
 
However, in contrast to the results seen for the overall analysis when the frozen 
cycles were analysed separately there appeared to be no difference in live birth or 
clinical pregnancy rates between Black women and White women; live birth (OR 0.42 
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[95% CI 0.16-1.10] p=0.08) and clinical pregnancy (OR 0.41 [95% CI 0.17-1.02] 
p=0.06). 
 
Discussion 
 
Main findings 
The results of our study show that there are significant disparities between ethnic 
groups for IVF outcomes.  
 
Within our study both the Black and South Asian population showed a statistically 
significant reduced chance of live birth for women undergoing their first fresh cycle, 
after adjustment for confounding factors.  When exploring clinical pregnancy rates, 
the Black population once again showed a statistically significant reduced chance of 
clinical pregnancy; furthermore implantation rates were much lower for Black women 
than White women.  Interestingly, when looking at implantation rates and clinical 
pregnancy rates for the South Asian population there was no statistically significant 
difference compared with White women.  This could suggest that although the South 
Asian population have a similar chance of achieving a pregnancy as the White 
population, they are more likely to lose the pregnancy (i.e. have a higher miscarriage 
rate) resulting in a lower chance of live birth.  This is consistent with data from a 
systematic literature review presented recently at an international conference for 
reproductive medicine (ASRM), which looked at the relationship between ethnicity 
and miscarriage47.  Women of mixed race were also found to have statistically 
significantly reduced odds of live birth compared with White women, however as 
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seen with South Asian women this difference was not seen for clinical pregnancy.  It 
may be that mixed race women are also at higher risk of pregnancy loss; although 
this has not been demonstrated in existing literature. 
 
One of the most interesting findings of this study was seen when the cycles for frozen 
data were removed and analysed separately from the overall dataset.  For Black 
women there were no significant differences in live birth or clinical pregnancy 
compared with White women, even after adjusting for confounders; although the 
numbers of cycles included in the frozen analysis was small (n=34).  However, for 
South Asian women the reduced odds of live birth were maintained in the frozen 
cycle analysis. 
 
Other predictors in the model that showed statistically significant reduced odds of live 
birth were age, tubal factor and duration of infertility greater than 5years.  Increasing 
age has been long established as strongly correlated to poorer IVF (and natural 
conception) success.  Similarly a review of predictors for IVF success by 
Loendersloot et al found duration of infertility greater than 5years also to be linked to 
poorer IVF success48.  Cause of infertility, specifically tubal factor, has also been 
implicated in predicting poorer chance of IVF success48.  The only factor which was 
significantly associated with increased IVF success was number of embryos 
transferred; this variable consisted of a scale from 0-3, however current practice 
guidelines dictate that no more than 2 embryos should be transferred at one time.  
The model shows that the more embryos transferred the greater the chance of live 
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birth, this increased odds is most likely highlighting the distinction between 
transferring one or two embryos compared with none.  
 
Strengths and limitations 
One of the main strengths of our cohort study is the sample size (n=13473).  With the 
benefit of this large sample size, the size of the ethnic groups were large enough to 
analyse individually, thus allowing for detailed exploration into the effects on specific 
racial groups.  Another strength is the specificity of the ethnic groups.  No study to 
date has been able to analyse data for specific ethnic groups in detail.  The largest 
American studies4,5 compared only Black women with White women.  Other 
studies2,6,24 only used four main ethnic groups (Black, Asian, Hispanic and White) 
which meant combining certain racial groups like South Asian with Chinese, who are 
genetically different and so would not necessarily behave in the same way.  
Furthermore there has previously been no study that has accounted for the mixed 
race population.  Due to the large number of variables recorded within the database 
we were able to account for a large majority of the known confounders in the 
multivariate analysis, which other studies previously have failed to do.   
 
We acknowledge there is significant unequal distribution of cycles amongst each 
ethnic group, furthermore a substantial number of patients (n=1467) have not stated 
ethnicity. This group constitutes more than 10% of the study population, plus all the 
ethnic minority groups are smaller than this 'not stated' group and so this may have 
influenced the data and added bias to the results.   
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A further limitation of the study is that we were unable to account for smoking status 
or alcohol consumption, it could be that these factors play a role in the lower 
pregnancy success rates seen in certain ethnic groups.  In addition we were unable 
to adjust for ovarian reserve or embryo quality as known confounders when 
performing multivariate analysis, this was due to the insufficient numbers recorded.  
There is an argument that the difference in IVF success rates could be influenced 
primarily by socioeconomic factors, such as lack of access to medical treatment 
leading to higher age at first encounter.  Unfortunately, our cohort study was unable 
to explore socio-economic factors in detail, furthermore the large majority of the 
patient population from our cohort study were non-NHS patients (75%) paying for 
their own treatment, which adds a population bias. 
 
We observed differences in findings between unadjusted and adjusted estimates in 
our analyses.  For example, South Asian women were found to have no significant 
difference in live birth rate compared with White women in the univariate analysis; 
however following adjustment for confounders a statistically significant reduced odds 
of live birth was seen.  These differences have arisen because of clear differences in 
the characteristics of women from different ethnic groups who underwent infertility 
treatment (Tables 5 and 6).  As South Asian women and those with “not stated” 
ethnicity had less risk factors than White women, adjusting for the risk factors 
increased the difference between these groups (Tables 9 and 11). 
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Comparison of results with existing literature and an updated meta-analysis 
 
We compared the results of this cohort study with the meta-analysed existing data, 
as identified in the systematic review outlined in Chapter 2.  We then added the 
results from our cohort study to the existing study data, to provide an updated meta-
analysis. 
 
Black vs. White 
Results of the meta-analysis of 9 studies2,4,5,23,24,31,40,41,43 (in chapter 2) showed Black 
women were found to have a statistically significant reduction in live birth and clinical 
pregnancy, these findings were in keeping with those of our cohort study.  
 
Data from the existing 9 studies2,4,5,23,24,31,40,41,43, plus the data from our cohort study 
were combined to provide an updated meta-analysis comparing Black women with 
White women for live birth and clinical pregnancy rates following fresh cycle of 
treatment; the results were (OR 0.60 [95% CI 0.52-0.69] p<0.001) and (OR 0.69 
[95% CI 0.58-0.82] p<0.001) respectively. The results showed moderate 
heterogeneity for live birth data and statistically significant high heterogeneity for 
clinical pregnancy rate.   
 
There were three studies which recorded data separately for frozen cycles4,5,26 these 
studies only investigated Black women and White women.  The meta-analysed 
results showed no difference in live birth or clinical pregnancy rates for Black women 
compared with White women: (OR 0.90 [0.75-1.07] p=0.23) and (OR 0.94 [1.03-1.12] 
p=0.54) respectively.  This finding was consisted with our cohort study.  We 
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combined the three studies which looked at frozen data4,5,26 with the data from our 
cohort study to provide an updated unadjusted meta-analysis; live birth (OR 0.89 
[95% CI 0.74-1.08] p=0.24) and clinical pregnancy (OR 1.01 [95% CI 0.82-1.24] 
p=0.92) respectively.  
 
More importantly than the unadjusted live birth rates were the adjusted rates.  Three 
papers4–6 calculated adjusted live birth rates (for fresh cycles) accounting for multiple 
factors, these included; maternal age, BMI, number of embryos transferred, 
diagnosis of male factor, endometriosis, PCOS, diminished ovarian reserve, tubal 
factors, uterine factors and other factors.  Two papers from the systematic review, 
both by Seifer et al, calculated adjusted relative risks4,5; they found a statistically 
significant increased adjusted relative risk of Black women not having a live birth 
compared with White women.  One paper, by Fujimoto et al, calculated an adjusted 
odds ratio for live birth6.  As was found with our cohort study, there were statistically 
significant reduced odds of live birth for Black women compared with White women 
after adjustment for confounders.  We pooled the adjusted odds ratios from Fujimoto 
et al with our cohort study; this is displayed in Figure 16. 
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Figure 16.  White vs. Black – adjusted odds ratio for live birth (fresh cycles) 
 
 
The two studies that provided an adjusted analysis for frozen cycles used the 
adjusted relative risk (aRR) of not achieving a live birth and so we were unable to 
calculate a pooled odds ratio combining our adjusted data for frozen cycles.  
However; as outlined in chapter 2 both of these studies found no statistical difference 
in achieving a live birth for Black women compared to White women after adjusting 
for confounders; this was in keeping with the finding from our adjusted analysis. 
 
In practical terms, the main difference between fresh cycle treatment and frozen 
cycle is that no stimulation is required for a frozen cycle i.e. no use of follicle 
stimulating hormone (FSH).  It could be that there is something within the stimulation 
process that does not suit Black women.  This finding should prompt further research 
to investigate the biological plausibility.   
 
Asian vs. White 
Regarding the comparison between Asian and White women, eight studies in the 
systematic review comprised of women both from South Asian and Chinese ethnic 
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groups3,6,24,28,31,40,42,44.  Of these eight studies five papers specified a cohort of Indian 
or South Asian women28,31,40,42,44.  To directly compare the results of these five 
studies with our own cohort study, data were meta-analysed separately in a specific 
“South Asian” group.  The meta-analysis showed a statistically significant reduction in 
live birth for South Asian women compared with White women, this was also seen in 
our cohort study.  For clinical pregnancy, the unadjusted meta-analysed data showed 
a statistically significant reduction for South Asian women compared with White 
women, however our cohort study did not; (OR 0.65 [95% CI 0.47-0.90] p=0.008) vs. 
(OR 1.02 [95% CI 0.89-1.16] p=0.8).  We performed the following statistical 
calculations to see if the difference between these odds ratios was significant: 
 
Se1 = (Log(upper limit OR) – Log(lower limit OR) / (2 x 1.96)  
   = (Log0.90 – Log0.47) / (2 x 1.96) 
   = 0.166   
Se2 = (Log(upper limit OR) – Log(lower limit OR) / (2 x 1.96)  
 = (Log1.16 – Log0.89) / (2 x 1.96) 
 = 0.068 
 
diff = LogOR1 – LogOR2 
 = Log0.65 – Log1.02 
 = -0.450 
Se(diff) = √(Se1)
2 + (Se2)
2 
 = √0.027 + 0.004 
 = 0.179 
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  diff   = -2.517 
Se(diff)  
 
A value below -1.96 indicates that there is a significant difference between the two 
odds ratios (p<0.01). 
 
We combined the results from our cohort study with the existing studies to provide an 
updated unadjusted meta-analysis for South Asian women vs. White women; results 
showed significant reduced odds of live birth for South Asian women (OR 0.73 [95% 
CI 0.60-0.89] p=0.002) and no difference in clinical pregnancy (OR 0.78 [95% CI 
0.56-1.08] p=0.1).  The results of our cohort study contributed to around 38% of the 
total data in the updated meta-analysis, therefore we can be reassured it does not 
dominate the results.  Given that the clinical pregnancy rates are comparable 
between South Asian women and White women but the live birth rates are much 
lower for South Asian women; this suggests that South Asian women have higher 
miscarriage rates.  This finding is consistent with results from a systematic review 
presented at a recent international conference looking at the effect of ethnicity on 
miscarriage47.  
 
The more important analysis was the adjusted odds ratios for live birth.  Three 
existing studies3,6,28 calculated adjusted odds ratio for Asian women vs. White 
women, accounting for multiple confounders including; age, BMI and diagnosis of 
PCOS.  However, only one of these studies specified a “South Asian” cohort28.  We 
pooled the adjusted odds ratios for the South Asian population from our cohort study 
 82 
with both the broader termed “Asian” group and the specific “South Asian” group.  
The results of the updated meta-analysis in Figures 17 and 18 show that both “Asian” 
women and specifically “South Asian” women have reduced adjusted odds of live 
birth compared with White women.  None of the existing published studies calculated 
an adjusted odds ratio for clinical pregnancy for South Asian vs. White women. 
 
Figure 17.  White vs. Asian – adjusted odds ratio for live birth  
 
 
Figure 18.  White vs. South Asian – adjusted odds ratio for live birth  
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Hispanic vs. White 
Given the UK population of our cohort study we did not specifically account for the 
Hispanic population.   
 
Exploring reasons for differences 
The data from both our cohort study and meta-analysis of existing studies shows that 
Black women and South Asian women have the poorest outcomes following fresh 
IVF treatment.  One might argue that these differences could potentially be explained 
by the different diagnoses of infertility seen in different ethnic populations, which is 
shown in (Table 4 in chapter 2).  However one of the strengths of our cohort study is 
that we were able to adjust for cause of infertility.  It is also well known that fibroids 
are more common amongst the Black population and so would be the obvious 
explanation for the lower live birth rates seen in black women.  In our analysis 
fibroids were adjusted for within a heterogenous group of infertility termed ‘other’, 
which included endometriosis, structural abnormalities and multiple fibroids.  
Furthermore, a sensitivity analysis adjusting for fibroids specifically, maintained a 
lower live birth rate for Black women.  Therefore, it is unlikely that causes of infertility 
alone can explain the differences in live birth seen across ethnic groups.  In addition, 
there were inconsistent findings across the existing papers for any differences in age 
and body-mass index for each ethnicity (as seen in Table 4 in chapter 2) and so this 
is also not likely to explain the differences seen in live birth or clinical pregnancy 
rates. 
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Regarding the finding that Black women appear to do worse with fresh cycles 
compared with frozen cycles, this adds support for the growing interest in a "freeze-
all" embryo policy in IVF.  Such an approach, which would aim to freeze all embryos 
generated in a fresh IVF cycle, with a view to transferring later in a non-stimulated 
(natural) cycle.  The theory behind this approach is that it would avoid the adverse 
effects which ovarian stimulation might have on endometrial receptivity during the 
treatment cycle.  The effect of ovarian stimulation on endometrial receptivity could be 
a contributing factor to why Black women appear to perform worse with fresh 
(stimulated) cycles.  A systematic review of 64 relevant studies (including three 
randomised trials) showed that the probability of a clinical pregnancy is significantly 
higher from “freeze-all” cycles than in fresh embryo transfers (a relative risk of 1.31, 
which was statistically significant)49.  It may be worth considering a “freeze-all” policy 
for Black women in the first instance, if not women of all ethnicities. 
 
Conclusions and future work 
Research on assisted conception has predominantly been performed on cohorts of 
White women.  Existing published studies have found inconclusive results for 
assisted conception success rates amongst women from different ethnic 
backgrounds.  The results of the systematic review, cohort study and updated meta-
analysis provide robust evidence for the hypothesis that there is an association 
between ethnic background and IVF success.  More importantly, the commonly 
known confounders cannot explain this.   
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The findings of the work presented in this thesis should prompt investigation into the 
mechanisms underpinning such disparities to allow modification of laboratory and or 
clinical practice to improve IVF outcome for all ethnic groups.  In particular, one of the 
interesting findings was the suggestion that Black women appear to perform worse 
with fresh cycles than frozen cycles.  It may be worth exploration into trialling a 
change of clinical practice, i.e. routine elective freeze for Black women to then have a 
frozen embryo transfer (FET) at a later date, followed by evaluation of results to see 
if this can improve overall success rates for Black women.  Furthermore, future 
research should also look to try and explain the apparent higher miscarriage rate 
seen in South Asian women compared to White women and look for ways to reduce 
this.  
 
The work of this thesis has focused solely on the ethnicity of the female, to further 
investigate the effects of ethnicity on IVF outcome it would be useful to also take into 
consideration the male ethnicity to see what affect this has on the results.  
 
Finally, there needs to be careful consideration of whether information regarding 
ethnicity and its potential affect on IVF outcome should be routinely provided to 
patients as part of pre-treatment counselling.  Although this is not a factor that 
women are able to change, it may still have implications on their decision-making. 
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CHAPTER 4  
Body mass index and IVF outcome: a prediction 
model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work in this chapter was presented as an oral presentation at ESHRE 
Lisbon June 2015 and has been published in Human Reproduction; published 
on 25.10.15 
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Introduction 
 
The number of couples seeking in-vitro fertilisation (IVF) in the U.K. continues to rise 
year upon year (“Fertility treatment in 2013.  Trends and figures. HFEA.”).  Contrary 
to common perception, IVF does not guarantee success; between 38–49% of 
couples who start IVF will remain childless, even after undergoing up to six IVF 
cycles50.  It is therefore important that subfertile couples are well informed about their 
chances of success with IVF.  Based on their specific probability of success, the 
couple can decide whether the risks of the treatment and the emotional and, in many 
cases, financial burden can be justified.  To optimise counseling for couples on their 
chances of a live birth after IVF, clinical prediction models, which estimate the 
chance of an outcome adjusted for a patient’s characteristics, may play a role since 
clinicians’ judgments can often be inaccurate51,52.  Reliance on annually published 
validated age-stratified national success rates53,54 has meant that clinicians often 
tend to base predictions solely on age.  
 
There have been many attempts to build prediction models to aid clinicians in 
predicting IVF success 56–62.  The two most widely recognised models, which used 
live birth as the primary outcome, are those by Templeton et al 58 and Nelson et al 61.  
A study by a Dutch team, te Velde et al 63, used their cohort to validate both these 
models to assess the effects of time trends on model performance.  They found that 
the Templeton model underestimated success rates, as one may expect given that it 
is a much older study and the Nelson model over-estimated success rates.  The 
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study showed that the calibration of both models considerably improved when the 
models were adjusted for the changing success rates over time. 
 
A recent study by Smith et al also performed external validation of the Templeton and 
Nelson models using a large dataset of over 130,000 cycles64.  They found that the 
discriminative power (assessed using area under receiver operator curve) was 
comparable between the models; but that the Nelson model had markedly better 
calibration.  They also found both models underestimated the live birth rate, although 
as seen with te Velde et al 63, this improved when the models were updated to reflect 
improvements in live birth rates over time. 
 
A recent report by HFEA (Human Fertilisation and Embryology Authority) recognised 
that IVF practice and outcomes have seen significant changes between 2008-2012, 
primarily because of the introduction of day 5 (blastocyst) embryo transfer1.  Given 
these advancements in technology, and the fact that the existing most noted models 
were built before 2008, there is a need for a new model to be built from more recent 
data (Figure 19).   
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Figure 19.  Live birth rate per cycle started (1991-2012) 
 
 
 
Data taken from HFEA report 'Fertility treatment 2013: trends and figures' 
released 17th December 2014. 
 
Another major further pitfall of the existing models is that they have not been able to 
account for certain key predictors of IVF treatment outcome.  In particular, the most 
recent of these models61 built using a large dataset provided by the Human 
Fertilisation Embryology Authority (HFEA) was not able to account for body-mass 
index (BMI), any measure of ovarian reserve or ethnicity.   
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A systematic review in 2011 which looked at 33 studies exploring BMI and IVF 
outcome concluded that a raised BMI has an adverse effect on pregnancy outcomes 
for women underdoing IVF treatment13.  They also found that this negative 
association was apparent for both obese and overweight women13.  However, recent 
studies have challenged this finding and have shown that raised BMI does not 
appear to reduce clinical pregnancy or live birth rates; nor is it that women with raised 
BMI require higher doses of gonadotrophins in their treatment compared with normal 
BMI women9,10.  BMI is the only pre-treatment factor that can be controlled and 
changed by the patient to help improve their chances of success.  Often in the clinical 
setting clinicians will advise patients to lose weight, and if the patient is obese the 
advice is to reach a target BMI of 30 or below; in order to meet government NHS 
funding criteria.  This arbitrary value set for funding criteria is based on the 
knowledge and experience of knowing that high BMI’s result in poorer pregnancy 
outcomes7,8.  What is currently lacking in the field of reproductive medicine is a tool 
that can be used by patients and clinicians to demonstrate how body mass index 
affects pregnancy success and also the interplay of BMI with other important factors 
that affect success rates, i.e. female age. 
 
Other important variables that have yet to be included in previous clinical prediction 
models in assisted reproduction are ovarian reserve and ethnicity.  There is strong 
evidence to suggest that women with a diminished ovarian reserve generally result in 
a poor response to gonadotropin therapy and therefore the chance of a successful 
pregnancy65,66.  A recent study found specifically that antral follicle count (AFC) 
correlated strongly with the number of mature oocytes retrieved in IVF/ICSI cycles67, 
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which can dictate the chances of pregnancy, moreover another study found that AFC 
significantly added prognostic value to female age in predicting response to ovarian 
hyperstimulation68.  Regarding ethnicity and IVF outcome, there have been several 
large cohort studies that have shown ethnicity has an association with IVF outcome, 
in particular showing that Black and South Asian races appear to have the poorest 
outcomes following fresh cycle IVF treatment4–6,25,36.  The work presented in this 
thesis thus far also provides robust evidence to show that disparities exist in IVF 
outcomes amongst women of different ethnicities, both in the UK and worldwide.  
Despite this evidence, ethnicity is a factor that is yet to be included as a predictor in 
any model predicting live birth following IVF.  
 
Finally, to-date there is no model available for use before a couple embarks on their 
first treatment utilising pre-treatment factors alone.  Both the Templeton and Nelson 
models use data from previous cycles and the Nelson model includes treatment 
factors such as hormonal preparation58,61.  Frequently in clinical consultations 
couples will ask the clinician what their chance of IVF success is; based on personal 
experience this is more common amongst couples seeking treatment for the first 
time.  The vast majority of clinicians will base their estimates on the age-related 
success rates produced by national HFEA data; however, these success rates may 
not be directly applicable to the patient.  What is currently lacking in this field is a 
prediction model to provide a more personalised approach to counseling and allow 
for a more accurate estimate of success.  Consequently, the aim of this study is to 
derive, assess and validate a novel predictive model that will estimate the chance of 
live birth for women undergoing their first IVF non-donor cycle.  This model will use 
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only pre-treatment factors and include previously unrecorded predictors such as BMI, 
ovarian reserve and ethnicity.   
 
Aims and objectives 
1. To investigate the relationship between BMI and IVF outcome. 
2. To build a novel prediction model, incorporating BMI, to estimate the chance 
of live birth for women before undergoing their first fresh IVF cycle. 
3. To incorporate novel factors into prediction the model, such as ovarian reserve 
and ethnicity. 
 
Methods 
 
Derivation cohort 
The study population was derived from a database of all patients who had undergone 
their first fresh non-donor cycle of IVF (including ICSI) at any of the Centres for 
Assisted Reproduction (CARE) clinics across the UK and Ireland, between 2008 and 
2012.  CARE is one of the UK’s largest independent providers of fertility services, 
where both NHS and non-NHS patients are treated, approximately 25% of patients 
are NHS funded and 75% fund themselves.  The CARE database consists of 
routinely collected baseline demographics, cycle data and outcome data for all 
patients.  
 
Within the variable for previous IVF, any woman with a history of IVF treatment, 
whether it was at a CARE clinic or elsewhere, were assigned a “1”, women without 
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any history of IVF treatment were assigned “0”.  All women with a “1” were excluded 
from analysis.  The reason for this was to exclude previous treatment as a 
confounder and also because the primary use of the model is for couples seen at 
their very first clinic appointment, prior to embarking on IVF treatment.  The decision 
to include IVF and ICSI as one variable was because the authors agreed that 
success rates are comparable for the two treatment modalities and so it was 
reasonable to include them together.  Also, the model is designed for use before 
patients undergo treatment, because occasionally in the cases of “mild male factor” 
clinicians will often decide to cross-over from IVF to ICSI once the patient has come 
through for treatment we felt it was better to keep IVF and ICSI as one variable. 
 
Baseline demographics, cycle data and outcome data were retrieved from 12 CARE 
clinics across the UK.  The CARE consortium is composed of five main fertility 
clinics; Nottingham, Manchester, Northampton, Sheffield and Dublin, and a further 
seven satellite centres; Bolton, Boston, Derby, Leicester, Mansfield, Milton Keynes 
and Peterborough.  For patients seen initially at the satellite clinics, they are seen up 
to the point of egg collection; egg collection, all embryology and embryo transfer is 
then performed at the nearest main clinic.  Following the embryo transfer the satellite 
clinic resumes full care of the patient.   
 
The original database contained information on over 50,000 cycles dating back to 
1998.  A decision was made to limit the dataset from 2008 onwards due to advances 
in technology over time and improvements in clinical practice such as greater 
numbers of blastocyst transfer and single embryo transfer, as detailed in the recent 
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HFEA report, which in turn have effected success rates (“Fertility treatment in 2013.  
Trends and figures. HFEA.”).  Data from the first cycle only were used to eliminate 
the bias from previous cycle failures.  Furthermore, by limiting to only first cycle we 
were able to express the probability of live birth outcome per individual woman.   
 
Primary outcome 
The primary outcome for the model was live birth.  The definition was consistent with 
that of Nelson et al61; “at least one baby was born alive and survived for more than 
one month”.  
 
Statistical analyses: 
Model development 
Univariable logistic regression analyses were performed to assess the association of 
each of the predictive factors with live birth.  A multivariable logistic regression model 
was used to derive the final prediction model for live birth.  The predictors included in 
the multivariable model were pre-selected based on knowledge from the existing 
literature 48 and clinical knowledge and were as follows: age, body mass index (BMI), 
ethnicity, cause of infertility, duration of infertility, antral follicle count (AFC), previous 
live birth and previous miscarriage.  AFC was selected in preference to early follicular 
follicle stimulating hormone (FSH) as it is a more accurate measure of ovarian 
reserve65,68.  Anti-mullerian hormone (AMH) has similar accuracy to AFC65,68 and is a 
more objective measure of ovarian reserve. However as AMH is a fairly recent test it 
was not available for most patients in the derivation cohort, therefore AFC was 
selected in preference. 
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The continuous variables: age, BMI, duration of infertility and AFC were assessed for 
their functional form using plots of the observed log odds.  As was shown in chapter 
3; BMI had a linear relationship with the log odds of the probability of live birth (Figure 
14).  In the case of age, duration of infertility and AFC there was a non-linear 
relationship with live birth.  Appropriate transformations were carried out, to produce 
linear relationships, and subsequently included in the model.  For age and duration of 
infertility these are shown on the same dataset in chapter 3 (Figures 13 and 15), AFC 
is shown in Figure 20. 
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Figure 20.  AFC plotted against the log odds of the probability of live birth 
 
 
 
 
 
For AFC a quadratic relationship with the log odds of live birth was observed. 
 
 
 
 
Regarding categorical variables; for ethnicity a reference population of White was 
selected and each ethnic group was compared to this.  For cause of infertility, each 
cause was categorised as yes or a no, with no reference group; the causes of 
infertility were not mutually exclusive. 
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Missing data 
The whole dataset contained 9915 women, data entry was complete in all variables 
except for BMI and AFC.  The total number of cases with compete data was 2911. 
Two separate models were created; one using the entire dataset (n=9915) and a 
second model using patients with complete data only (n=2911).  For the larger 
dataset we were required to impute the missing data.  A multiple imputation 
procedure was conducted using an iterative Markov chain Monte Carlo (MCMC) 
method.  All predictors and the outcome of live birth were included in the imputation 
process to maximise the precision of the imputations.  All univariable models and the 
multivariable model were fitted to the 20 imputed datasets arising from the multiple 
imputation procedure.  The parameter estimates and covariance’s arising from the 
models from each imputed dataset were combined to produce inferential results.  For 
the purpose of this study the primary model was that built using the whole dataset 
(n=9915 women) and will be referred to as the “final model”.      
 
Predictive ability 
Initially the model was assessed for predictive ability using apparent validation.  
Apparent validation is when the model performance is assessed directly in the same 
cohort from which it was derived69.  The two performance measures used were 
discrimination and calibration.  Discrimination is the ability of the model to correctly 
discriminate between those who had the outcome and those that did not i.e. correctly 
distinguish between the women who had a live birth (for whom the model assigns a 
higher probability) and women who do not have a live birth (for whom the model 
assigns a lower probability).  The area under receiver operating characteristics 
 98 
(AUROC) curve (also known as a c-statistic) was used as a measure of 
discrimination; a model with an AUROC curve of 0.5 would have no discriminative 
power at all, while 1.0 would reflect perfect discrimination.  Calibration refers to the 
agreement between the predicted probabilities of live birth and the observed (actual) 
probabilities.  The predicted probabilities from the final model were assessed for 
accuracy across increasing tenths of predicted probabilities using calibration plots.  
The mean observed probability is plotted against the mean predicted probability in 
each tenth and perfect calibration is displayed as a straight line passing through zero 
with a gradient of one.    
 
Model validation 
Before any prediction model can be utilised in clinical practice to aid decision-making, 
it is essential to confirm that the developed model also predicts well in a “similar but 
different” population outside of the development cohort, i.e. external validation 
(generalisability)69.  There are three different types of external validation: temporal 
validation, geographical validation, and domain validation. In temporal validation, the 
model is validated on new patients that are from the same centre as the development 
cohort, but in a different time period69.  This is the form of external validation 
performed on our final model. 
 
External validation of the model was performed on a cohort of women undergoing 
their first fresh IVF cycle at any CARE clinic during the year of 2013 (temporal 
validation)69,70.  The missing data in the validation cohort were also imputed using the 
same method as the derivation cohort.  For ease of computation and interpretation, 
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the average measures of the imputed values were taken across all 20 imputed 
datasets for women who had values imputed, so that validation was performed on 
only one dataset.  The model was fitted to the validation cohort (2013 population) 
using the same parameter estimates derived from the study cohort (2008-2012 
population).  The predictive ability of the model was assessed on the external 
validation cohort. The AUROC under the curve was determined to assess 
discriminatory ability and calibration plots were presented.   
 
As a formal test of calibration we assessed “calibration-in-the-large” to compare the 
mean predicted probability of live birth with the mean observed probability of live 
birth.  This is essentially the intercept from the model, which is only adjusted for the 
linear predictors from the final model, applied to the patients in the external cohort.  A 
significant deviation from zero indicates that predictions are systematically too low or 
too high71.  The calibration slope was also calculated, where a perfect slope (i.e. 
perfect agreement between predicted and observed probabilities) would have a 
gradient of one.  Significant deviations from one would suggest that low predicted 
probabilities were too low or too high, and high predicted probabilities were too high 
or too low. 
 
All statistical analyses were performed using SPSS (ver. 21.0; SPSS Inc., Chicago) 
and SAS (ver.9.2; SAS Institute, Cary, North Carolina).   
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Ethical approval 
Permission for use of the database was granted by the CARE IRB following review of 
the study protocol. The dataset was anonymised according to the ICO's (Information 
Commissioner’s Office) guide on non-identifiable data.  Furthermore the CARE data 
protection certificate allows for their data to be used for survey and research 
purposes.     
 
Results 
 
A total of 9915 women were used to build the final model.  Figure 21 shows how we 
established the eligible cohort of IVF (including ICSI) treatment cycles.  We used 
both the whole dataset, which included missing data (n=9915 women), and the 
complete data only dataset (n=2911 women) to build two independent models; 
however we did not perform external validation on the model created using the 
complete data only dataset.  Table 12 shows a comparison of the baseline 
characteristics of the two cohorts.  Since the characteristics were similar between the 
two cohorts we could be satisfied that there were no significant differences between 
the two cohorts and so it was reasonable to use the larger dataset to build the “final 
model”.  A description of the whole dataset including cycle data and overall outcome 
data can be found in Table 13.  The overall rate of at least one live birth, from the 
whole dataset, was 31.5%.   
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Figure 21.  Definition of eligible cohort and analysis samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = 13,473 
Non-donor Treatment cycles on CARE database 1998-2013 
n = 50,062 
 
n = 25,782 
Treatment not between 
2008-2012 
n = 24,280 
History of previous IVF 
n = 12,309 
Treatment using frozen 
embryos (elective FET) 
n = 3558 
 
n = 9915 
 
n = 9915 (whole dataset) 
 
n = 2911 (complete dataset with no missing data) 
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Table 12.  Baseline characteristics of the cohort for whole dataset and the 
complete cases dataset  
 Cohort n (%) or  
 
Mean (SD) 
  
 
Whole dataset  
(n=9915) 
 
Complete cases 
dataset (n=2911) 
 
Age 34.6 (5.4) 34.2 (5.0) 
Duration of infertility  
(in completed years) 2.0 (2.0) 2.5 (1.8) 
BMI* 24.8 (4.0) 24.7 (3.8) 
AFC* 18.7 (13.6) 19.2 (14.0) 
Previous miscarriage 1818 (18.3%) 621 (21.3%) 
Previous live birth  1578 (15.9%) 415 (14.3%) 
Cause of infertility   
Tubal factor 1442 (14.5%) 481 (16.5%) 
Anovulation 1088 (11.0%) 342 (11.7%) 
Unexplained  2950 (29.8%) 681 (23.4%) 
Other (E.g Endometriosis, 
fibroids) 3005 (30.3%) 1060 (36.4%) 
Male factor  5611 (56.6%) 1953 (67.1%) 
Ethnicity   
White 7530 (75.9%) 2437 (83.%) 
Asian 768 (7.7%) 214 (7.4%) 
Black 162 (1.6%) 51 (1.8%) 
Chinese 60 (0.6%) 13 (0.4%) 
Other 115 (1.2%) 47 (1.6%) 
Not stated 924 (9.3%) 27 (0.9%) 
Mixed 356 (3.6%) 122 (4.2%) 
 
* Variable contains missing data. 
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Table 13.  Descriptive data for whole dataset (n=9915) 
  
N (%) or Mean (SD) 
 
 
Other ovarian reserve markers 
 
AMH (n=1212) 
Day 2 FSH (n=2911) 
 
 
 
 
16.2 (18.8) 
7.49 (5.2) 
 
Cycle data 
 
IVF 
ICSI 
No. of oocytes retrieved  
No. of mature oocytes inseminated 
2pn 
3pn 
Total no. of embryos 
No. of embryos transferred 
       0 
       1 
       2 
       3 
No. of embryos frozen 
 
 
 
3829 (38.6%) 
6086 (61.4%) 
9.0 (5.9) 
6.9 (4.8) 
4.8 (3.8) 
0.2 (0.6) 
5.3 (4.1) 
 
1591 (16.0%) 
2911 (29.4%) 
5127 (51.7%) 
286 (2.9%) 
1.3 (2.7) 
 
Outcome data 
 
Biochemical pregnancy 
Clinical pregnancy  
Pregnancy outcome 
       Live birth 
       Miscarriage 
       Termination 
       Still birth 
       Neonatal death 
 
 
 
 
4144 (41.8%) 
3514 (35.4%) 
 
3121 (31.5%) a 
328 (9.3%) b 
18 (0.5%) b 
7 (0.2%) b 
9 (0.1%) b 
 
      a Overall live birth rate for whole cohort 
      b Calculated as a % of those with a clinical pregnancy 
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Missing data 
As mentioned previously, only two of the variables selected for use in the multivariate 
model had missing data, these were BMI and AFC.  Descriptive characteristics of 
women with missing and non-missing data for BMI and AFC can be found in Table 
14.  The data across each baseline characteristic were comparable between the two 
groups.  However, more women with a BMI measurement were of white ethnicity 
(81.7% versus 70.5%) and had partners with male factor infertility (65.1% versus 
48.5%) than women without a BMI measurement. 
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Table 14.  Display of missing and valid data 
 
 
BMI missing 
(n=5101, 51.4%) 
BMI Valid 
(n=4814, 48.6%)   
AFC Missing 
(n=6365, 64.2%) 
AFC Valid 
(n=3550, 35.8%) 
Age (Mean +SD) 35.0 (5.7) 34.3 (5.1)   34.9 (5.6) 34.2 (5.0) 
Duration of inf in years (Mean, SD) 3.0 (2.0) 2.0 (2.0)   3.0 (2.0) 2.0 (2.0) 
AFC (Mean, SD)  19.1 (13.3) 18.4 (13.7)    --- 18.6 (13.5) 
BMI (Mean, SD) --- 24.8 (4.0)   25.0 (4.3) 24.7 (3.8) 
Previous miscarriage  840 (16.5%) 978 (20.3%)   1064 (16.7%) 754 (21.2% 
Previous live birth  880 (17.3%) 698 (14.5%)   1038 (16.3%) 540 (15.2%) 
IVF 1726 (33.8%) 1444 (30.0%)   2099 (33.0%) 1071 (30.2%) 
ICSI  2995 (58.7%) 3091 (64.2%)   3772 (59.3%) 2314 (65.2%) 
Tubal factor  706 (13.8%) 736 (15.3%)   856 (13.4%) 586 (16.5%) 
Anovulation  473 (9.3%) 615 (12.8%)   687 (10.8%) 401 (11.3%) 
Unexplained  1670 (32.7%) 1280 (26.6%)   2122 (33.3%) 828 (23.3%) 
Other  1458 (28.6%) 1547 (32.1%)   1708 (26.8%) 1297 (36.5%) 
Male factor  2476 (48.5%) 3135 (65.1%)   3265 (51.3%) 2346 (66.1%) 
Ethnicity - White 3596 (70.5%) 3935 (81.7%)   4562 (71.7%) 2698 (83.6%) 
Ethnicity - Asian 372 (7.3%) 396 (8.2%)   502 (7.9%) 266 (7.5%) 
Ethnicity - Black 81 (1.6%) 81 (1.7%)   98 (1.5%) 64 (1.8%) 
Ethnicity - Chinese 26 (0.5%) 23 (0.7%)   41 (0.6%) 19 (0.5%) 
Ethnicity - Other 48 (0.9%) 67 (1.4%)   60 (0.9%) 55 (1.5%) 
Ethnicity - Not stated 836 (16.4%) 88 (1.8%)   893 (14.0%) 31 (0.9%) 
Ethnicity - Mixed 143 (2.8%) 213 (4.4%)   209 (3.3%) 147 (4.1%) 
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Univariate and multivariate analyses 
The univariate associations of live birth for the original whole dataset and complete 
cases dataset are shown in Table 15.  Results from both datasets showed similar 
findings.  The multivariable logistic regression model predicting live birth for the 
imputed dataset (final model) is displayed in Table 16.  The final model (n=9915) 
shows that the odds of a successful live birth decrease with age.  This reduction in 
the odds of live birth is greater with each increasing year of age past the age of 36 
compared with up to the age of 36.  Other variables which showed a statistically 
significant reduction in odds of live birth in the multivariate final model were; tubal 
factor, unexplained infertility, and being Asian or Black. The univariate analysis 
suggested that increasing BMI, duration of infertility greater than 5 years and 
previous miscarriage was associated with decreased odds of live birth, however 
these associations became non-significant in the multivariate analysis.   
 
The model built from the complete data only dataset (n=2291) can be found in 
Appendix 1.  Findings were consistent with that of the “final model”, although there 
was also a statistically significant reduction in live birth associated with duration of 
infertility greater than 5 years (p=0.04). 
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Table 15.  Univariate associations of potential predictors for live birth following 
IVF for cases that have a non-missing value for each predictor (whole dataset) 
and cases with complete data for all predictors (complete cases) 
  Whole dataset Complete cases 
 
OR (95% CI) 
n=9915 
p 
value 
OR (95% CI) 
n=2911 
 
p value 
Age 0.94 (0.93-0.94) <0.001 0.93 (0.91-0.94) <0.001 
Duration of infertility 
(in completed years) 0.97 (0.95-0.99) 0.003 0.94 (0.90-0.99) 0.02 
BMI*  0.98 (0.97-0.99) 0.01 0.98 (0.96-1.00) 0.06 
AFC* 1.01 (1.01-1.02) <0.001 1.01 (1.01-1.02) <0.001 
Prev Misc 0.84 (0.74-0.94) 0.002 0.83 (0.68-1.01) 0.07 
Prev LB  0.93 (0.83-1.05) 0.2 1.10 (0.88-1.37) 0.4 
Cause of infertility 
 
   
Tubal factor 0.90 (0.80-1.01) 0.08 0.94 (0.76-1.17) 0.6 
Anovulation 1.21 (1.07-1.40) 0.003 1.13 (0.89-1.44) 0.3 
Unexplained  1.01 (0.92-1.11) 0.8 1.09 (0.9-1.30) 0.4 
Other (E.g 
Endometriosis, 
fibroids) 0.70 (0.63-0.77) <0.001 0.76 (0.64-0.90) 0.001 
Male factor  1.02 (0.94-1.11) 0.7 1.08 (0.92-1.28) 0.3 
Ethnicity 
 
    
White Reference   Reference   
Asian 0.95 (0.81-1.12) 0.6 1.00 (0.74-1.36) 0.9 
Black 0.44 (0.29-0.67) <0.001 0.36 (0.16-0.80) 0.01 
Chinese 0.84 (0.48-1.48) 0.5 1.92 (0.65-5.75) 0.2 
Other 0.68 (0.44-1.05) 0.08 0.46 (0.21-0.99) 0.05 
Not stated 1.00 (0.86-1.16) 1 1.12 (0.50-2.51) 0.8 
Mixed 0.86 (0.68-1.09) 0.2 0.98 (0.66-1.45) 0.9 
 
* Variable contains missing data 
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Table 16.  Final multivariate logistic regression model for Live birth (n=9915) 
 
 
Parameter 
Estimate 
S.E. P value Odds Ratio 95% CI 
    
Lower Upper 
Age:    
≤36 years (per increasing year) -0.035589 0.008 <0.001 0.97 0.95 0.98 
>36 years (per increasing year) -0.106139 0.012 <0.001 0.90 0.88 0.92 
       
Body mass index -0.010881 0.009 0.2 0.99 0.97 1.01 
       
Cause of infertility:       
Male factor -0.085967 0.056 0.1 0.91 0.82 1.02 
Tubal factor  -0.254369 0.069 <0.001 0.78 0.68 0.89 
Anovulation -0.138708 0.082 0.09 0.87 0.74 1.02 
Unexplained -0.133782 0.067 0.04 0.88 0.77 0.99 
Other (e.g. Endo) -0.118451 0.062 0.05 0.89 0.79 1.00 
       
Ethnicity:       
White 0   Reference   
Asian -0.171572 0.084 0.04 0.84 0.71 0.99 
Black -0.683648 0.214 <0.001 0.51 0.33 0.77 
Chinese -0.181580 0.293 0.5 0.83 0.47 1.48 
Other -0.355212 0.222 0.1 0.70 0.45 1.08 
Not stated -0.005533 0.083 0.9 0.99 0.84 1.17 
Mixed -0.192857 0.122 0.1 0.83 0.65 1.05 
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Table 16. continued 
 
 
 
 Parameter 
Estimate 
S.E. P value Odds Ratio 95% CI 
    
Lower Upper 
Previous Live Birth 
No 
Yes 
 
0 
0.093953 
 
 
0.063 
 
 
0.1 
 
Reference 
1.10 
 
 
0.97 
 
 
1.24 
       
Previous Miscarriage 
No 
Yes 
 
0 
-0.023788 
 
 
0.060 
 
 
0.7 
 
Reference 
0.98 
 
 
0.87 
 
 
1.10 
       
AFC 0.015095 0.008 0.06 1.02 1.00 1.03 
AFC (squared) -0.000142 0.000 0.2 1.00 1.00 1.00 
       
Duration of infertility:       
0-4 years 0   Reference   
≥5 years -0.093313 0.066 0.2 0.91 0.80 1.04 
       
Constant 0.811547 0.355 0.02 2.25 1.12 4.54 
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Predictive ability 
The AUROC curve test for discriminatory ability of the final prediction model for odds 
of live birth was 0.62 (95% CI 0.61-0.63).  In general, the AUROC curve value for 
prediction models in reproductive medicine is quite low, ranging between 0.59 and 
0.6472.  In view of this the more reliable and widely accepted measure of 
performance of a prediction model is the calibration following validation72.  The ROC 
curve and calibration plots are displayed in Figures 22 and 23 respectively. 
 
Internal validation was performed on the model built from the complete data only 
(n=2911 women) using the bootstrapping technique and the AUROC curve was 
calculated.  For this model, built using complete cases only, the performance 
measures after internal validation were similar to the final model (see Appendix 2).  
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Figure 22.  Receiver Operating Curve for final model 
 
 
 
 
 
 
 
Following apparent validation, the c-statistic, or AUROC curve, for the final model 
was 0.62 (95% CI 0.61 - 0.63). 
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Figure 23.  Calibration plot for final model 
 
 
 
 
 
 
 
 
This figure shows the observed (actual) proportion of live births (y axis) plotted 
against the predicted probability of having a live birth (x axis), as predicted by our 
model, and split into deciles.  This calibration was performed on the derivation cohort 
(apparent validation).   
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Model validation 
Our external cohort consisted of 2723 patients who had undergone their first fresh 
assisted treatment cycle at any CARE clinic in the year of 2013. 
 
The baseline characteristics, cycle characteristics and outcome data for the 
validation cohort are displayed in Table 17.  The overall live birth rate for this cohort 
was 31.7%.  The baseline characteristics of the both the derivation and validation 
cohorts were comparable, as were the overall live birth rates.   
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Table 17.  Baseline characteristics, cycle characteristics and outcome data for 
external cohort (n=2723) 
Variable 
 
 
Validation cohort, n (%) or 
Mean (SD) 
 
Age 34.3 (4.9) 
Duration of infertility (in completed years) 2.6 (2.3) 
BMI 24.8 (3.9) 
AFC 19.7 (13.8) 
AMH 17.7 (20.7) 
FSH 7.0 (3.3) 
Previous miscarriage 658 (24.2%) 
Previous live birth  558 (20.5%) 
Cause of infertility  
Tubal factor 385 (14.1%) 
Anovulation 389 (14.3%) 
Unexplained  773 (28.4%) 
Other (E.g. Endometriosis, multiple fibroids) 806 (29.6%) 
Male factor  1760 (64.6%) 
Ethnicity 
 
 
White 2190 (80.4%) 
Asian 262 (9.6%) 
Black 31 (1.1%) 
Chinese 21 (0.8%) 
Other 33 (1.2%) 
Not stated 61 (2.2%) 
Mixed 125 (4.6%) 
 
Cycle data 
IVF 
ICSI 
Number of oocytes retrieved  
Number of mature oocytes inseminated 
2pn 
3pn 
Total number of embryos 
 
 
1043 (38.3%) 
1680 (61.7%) 
7.0 (6.6) 
5.3 (5.4) 
3.6 (4.0) 
0.2 (0.6) 
4.6 (4.1) 
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Variable Validation cohort, n (%) or 
Mean (SD) 
Number of embryos transferred 
       0 
       1 
       2 
       3 
Number of embryos frozen 
 
375 (13.8%) 
1501 (55.3%) 
799 (29.3%) 
42 (1.5%) 
1.0 (2.1) 
 
 
Outcome data 
 
Biochemical pregnancy 
Clinical pregnancy  
Pregnancy outcome 
       Live birth 
       Miscarriage 
       Termination 
       Still birth 
       Neonatal death 
 
 
 
 
1149 (42.2%) 
914 (33.6%) 
 
863 (31.7%)a 
76 (8.3%)b 
7 (0.8%)b 
2 (0.2%)b 
5 (0.5%)b 
 
a Overall live birth rate for whole cohort 
b Calculated as a % of those with a clinical pregnancy 
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The AUROC for the final model applied to the external cohort was 0.62 (95% CI 0.60 
to 0.64).  Calibration-in-the-large showed a systematic over-estimation of the 
predicted probability of live birth (Intercept (95% CI) = -0.168 (-0.252 to -0.084), 
p<0.001). However, the calibration slope test was not significant (slope (95% CI) = 
1.129 (0.893 to 1.365) p=0.28) meaning that the over-estimation was uniform across 
the range of predicted probabilities (Figure 24).  Due to the calibration-in-the-large 
test being significant we recalibrated the final model.  This was done by scaling the 
linear predictor from the final model, using the slope and intercept (y=-0.078 + 
1.129); we then adjusted for the final model linear predictor and applied this to the 
external cohort.  The recalibrated model is shown in Figure 25 and shows a much-
improved calibration. 
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Figure 24.  Calibration slope plot following external validation 
 
 
 
 
 
Note: Patients were ranked into order of predicted probability of live birth and divided 
into tenths.  The circles represent the mean risks for each tenth; the dotted line 
represents the perfect relationship; the dashed line represents the smooth non-
parametric Loess calibration curve fitted through the circles; the plus symbols across 
the bottom of the graph represent the spread of patients across predicted risks. 
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Figure 25.  Calibration plot following recalibration 
 
 
 
 
Following recalibration; using the intercept and slope from the linear predictor (-0.078 
and 1.129 respectively) we can see the calibration is much improved. 
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Discussion 
 
Main findings 
To date, successful prediction of live birth after assisted reproductive technology 
(ART) has been limited.  We have developed a novel model, which encompasses 
prognostic factors that have not previously been used, such as body mass index, 
ovarian reserve and ethnicity.  The key predictors in our model that have shown to 
have a significant effect on the chances of live birth are: age, tubal factor, 
unexplained causes of infertility and being South Asian or Black.  Although BMI was 
shown to be significantly associated with reduced chances of live birth in the 
univariate analysis, this association was weakened when other confounders were 
accounted for. 
 
Strengths and limitations 
This is the first successfully derived and externally validated prediction model for live 
birth following assisted conception for women before undergoing their first fresh non-
donor cycle of treatment.  This prediction model is purposefully simple, in that its use 
is only for women undergoing their first fresh non-donor cycle.  We believe this 
prediction tool holds an important role as an adjunct in the counseling process for 
women at the critical decision-making point in their journey, i.e. before they embark 
on their first treatment cycle.  The advantage of using data from a first IVF cycle 
means that the calculated probabilities are expressed per woman/couple and not per 
cycle.   
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Our model has highlighted key predictors for IVF success, including ethnicity, which 
has not been used in any previous prediction models.  Ethnicity has been recognised 
in many American papers4–6,25,30,36 as a confounding factor in affecting IVF success 
and we have seen this also in the work presented in this thesis so far.  There 
appears to be a strong association between being South Asian or Black and having a 
lower chance of live birth even when accounting for the other predictors in the 
multivariate analysis.  The work in chapters 2 and 3 has attempted to explore 
potential reasons for this ethnic disparity in IVF success. However, no firm 
conclusions can be drawn, as the differences remain even when known confounders 
(such as age, fibroids in Black women etc.) have been adjusted for.  Despite the 
addition of ethnicity as a novel key predictor to our model, given the large variation in 
ethnic groups across the globe, our model is somewhat restricted to representing the 
ethnic distribution and outcomes for the UK population only.  It would be useful to 
externally validate this model on a dataset from a different country to see if ethnic 
variability affects the performance measures of the model. A further limitation of the 
inclusion of ethnicity within the model is that the group with “not stated” ethnicity 
constitutes more than 10% of the study population, in addition all the ethnic minority 
groups are smaller than this “not stated” group and so this may have influenced the 
data and added bias to the results.  
 
In addition to ethnicity, no previous models have accounted for BMI or AFC.  As 
mentioned in the results the univariate analysis for BMI and live birth outcome was 
statistically significant, showing that increasing BMI reduces the odds of live birth, 
however this association became non-significant in the final model.  This could be 
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explained by the fact that other predictors in the model carry more weight in 
influencing live birth when looked at in combination, one of the strongest predictors 
as we would expect was female age.  It appears from our data that BMI increases 
with increasing age and so this would explain why in multivariate analysis, where age 
is accounted for, the effect of BMI on live birth is not significant.  In addition to this, it 
appears that in general Black women have higher BMI than White women, knowing 
that Black ethnicity is a strong predictor for lower chances of IVF success, when 
performing multivariate analysis this could be another reason why the association 
between BMI and reduced IVF success is lost.   
 
Similarly as for BMI, the univariate analysis for AFC and live birth was significant, 
showing that increasing AFC is associated with a higher odds of live birth, however 
this became non-significant in the final model.  Furthermore, we acknowledge that 
AFC is a subjective measure and therefore open to intra-observer variability, 
however it has been shown that even with this variability, its ability to predict IVF 
success is comparable with anti-mullerian hormone (a non-subjective measure of 
ovarian reserve)73,74.  Furthermore, recording of AMH was very poor within the 
database and so in view of using a variable with fewer missing entries AFC was 
selected over AMH.      
 
Inevitably, in any prediction model, one is unable to account for the residual 
confounding effect of the unavailable variables.  In our prediction model we have 
been unable to account for confounders such as smoking status, alcohol intake or 
socioeconomic status.  A recent systematic review and meta-analysis on predictive 
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factors in IVF evaluated nine predictive factors: female age, duration of subfertility, 
type of subfertility, indication for IVF, basal follicle stimulating hormone, fertilisation 
method, number of oocytes, number of embryos transferred, and embryo quality 48.  
As our model is for pre-treatment counseling only, we did not include any oocyte or 
embryo factors.  We have, however, accounted for the other mentioned factors with 
the exception of basal FSH, where instead we have used a more accurate ovarian 
reserve measure in AFC.  Given the complexities of assisted conception there are 
many other confounders that can have an effect at different time points.  For example 
there are prognostic factors which are only determined once a cycle has begun, such 
as oocyte number and embryo quality.  For this reason, this model is restricted to use 
prior to starting treatment only.  We appreciate that IVF success rates depend on 
more than the factors in this model alone.  Therefore it is important for clinicians who 
may use the model, to ensure their patients understand that their probability of 
having a successful outcome will invariably change as they progress through their 
treatment and thus should be interpreted as a baseline prediction only. 
 
Comparison to existing models 
Using our novel model, one is able to predict the chances of live birth following IVF, 
and this predictive ability has been assessed by the AUROC curve.  Our model is not 
directly comparable with that of the Templeton and Nelson models, given its inclusion 
of different predictors and for use at a different clinical time point.  Furthermore, the 
Nelson model predicts live birth for different cycles, whereas our model predicts live 
birth in the first cycle only, before embarking on the treatment.  Therefore, we felt that 
directly comparing the performance measures (i.e. performing statistical analyses) 
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was not appropriate; however we have provided a crude comparison.  Following 
apparent validation Templeton et al found the AUROC curve to be 0.62 (95% CI 
0.61-0.62) and Nelson et al 0.63 (95% CI 0.62-0.64), whilst our model showed an 
AUROC curve of 0.62 (95% CI 0.61-0.63).  Following external validation the AUROC 
curve was 0.62 (95% CI 0.60 to 0.64), the recently externally validated Nelson model 
(IVFpredict) and Templeton model had an AUROC of 0.63 (0.62-0.63) and 0.62 
(0.61-0.62) respectively64, showing that our model has comparable discriminatory 
ability with these previous models.  The Dutch study 63 and the more recent study by 
Smith et al 64 showed improvements in the performance of the Nelson and Templeton 
models when taking into account the effect of time trends.  However, for our model 
there was no significant difference in live birth rates between 2008-2013 (p=0.2).  
Adding treatment year to our model made no difference in the performance (AUROC 
0.62 95% CI 0.61-0.62) and so it was not included.  A likely explanation is that both 
the Templeton and Nelson models were built on considerably older datasets 
compared with our model, pre-dating significant changes in clinical practice that 
occurred from 2008 onwards, therefore requiring an adjustment for time.  
 
For IVF prediction models, calibration is deemed to be a more important measure of 
predictive ability than discrimination.  A systematic review by Coppus et al concluded 
that prediction models in reproductive medicine will be limited to an AUROC of no 
greater than 0.65 due to the relatively homogeneous group of subfertile patients72.  
The calibration assessments for our model showed that there was a small systematic 
over-estimation in the predicted probabilities.  After recalibration to correct for this, 
the calibration plot was much improved. 
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Clinical implications 
Examples of how our novel prediction model could be utilised in clinical practice to 
provide couples with a personalised estimated probability of having a live birth is 
shown in Table 18.  We have presented the predicted probabilities for both the 
original externally validated model and the recalibrated model; reassuringly the 
results show that the predicted probabilities from the recalibrated model were only 
slightly lower than those from the original model.  An example of how probabilities 
(including re-calibrated probabilities) are calculated using the model follows Table 18.   
 
In addition, as BMI is the only variable within the model that the patient is able to 
change, we have explored this further.  Table 19 shows an example of a 
woman/couple from whom we would expect better than average success rates, and 
how the probability of success changes with altered BMI alone.  
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Table 18.  Examples of predicted probabilities using the final model and 
calibrated model 
 
 
Example Couples 
Predicted 
probability 
of live 
birth 
Recalibrated 
predicted 
probability 
of live birth 
A. A 38 year old White woman and her partner 
have been trying to conceive for over 5 years.   
She has a body mass index of 35 and an antral 
follicle count of 14.  The couple had a miscarriage 
in the past following a natural conception. The 
couple's cause of infertility is male factor infertility. 
 
 
0.25 
 
 
0.21 
 
 
B. If we take the same couple as in A but change 
the body mass index to 25 
 
 
 
0.27 
 
 
0.24 
 
C. If we take the same couple as in A but change 
the age to 30 and ethnicity to Black. 
 
 
0.21 
 
0.18 
 
D. A 28 year old White woman with unexplained 
fertility.  She has a BMI of 22 and AFC of 15.  The 
couple have had a child after a previous natural 
conception and have been trying for 2 years. 
 
 
0.43 
 
 
0.41 
 
 
 
Note: These examples are plausible in terms of the types of patients that are seen in 
IVF clinics, and they show the influence of couple characteristics.  Example D shows 
the characteristics that result in a greater chance of success. 
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The calculation of the predicted probability of live birth and an example of how 
to use the model based on example D: 
 
XB = 0.8115 + Previous live birth (Yes=1, No=0) x 0.0940 - Previous miscarriage 
(Yes=1, No = 0) x 0.0238 - BMI x 0.0109 – tubal infertility (Yes=1, No=0)  x 0.2544 – 
anovulatory infertility (Yes=1, No=0) x 0.1387 - unexplained infertility (Yes=1, No=0) 
x 0.1338 – male factor infertility (Yes=1, No=0) x 0.0860 - other infertility (Yes=1, 
No=0) x 0.1185 – Asian ethnicity (Yes=1, No=0) x 0.1716 – Black ethnicity (Yes=1, 
No=0) x 0.6836 – Chinese ethnicity (Yes=1, No=0) x 0.1816 – Other Non-White 
ethnicity (Yes=1, No=0) x 0.3552 – No stated ethnicity (Yes=1, No=0) x 0.0055 – 
Mixed ethnicity (Yes=1, No=0) x 0.1929 - Age1 x -0.0356 - Age2 x 0.1061 + AFC x 
0.0151 - AFC squared x -0.00014 - Duration of infertility (0-4 years=0, >5years = 1) x 
0.0933 
 
Where Age1 is the woman’s age if the age is ≤36 years or is 36 years if the age is 
>36 years; Age2 is the difference (woman’s age - 36 years) if the woman’s age is 
>36 years and zero if ≤36 years. 
 
Probability of live birth = EXP(XB) / (1+EXP(XB)) 
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Example D 
 
The highlighted parts of the model are the only non-zero terms relating to this 
example: 
 
XB = 0.8115 + Previous live birth (Yes=1, No=0) x 0.0940 - Previous miscarriage 
(Yes=1, No = 0) x 0.0238 - BMI x 0.0109 – tubal infertility (Yes=1, No=0)  x 0.2544 – 
anovulatory infertility (Yes=1, No=0) x 0.1387 - unexplained infertility (Yes=1, 
No=0) x 0.1338 – male factor infertility (Yes=1, No=0) x 0.0860 - other infertility 
(Yes=1, No=0) x 0.1185 – Asian ethnicity (Yes=1, No=0) x 0.1716 – Black ethnicity 
(Yes=1, No=0) x 0.6836 – Chinese ethnicity (Yes=1, No=0) x 0.1816 – Other Non-
White ethnicity (Yes=1, No=0) x 0.3552 – No stated ethnicity (Yes=1, No=0) x 0.0055 
– Mixed ethnicity (Yes=1, No=0) x 0.1929 - Age1 x -0.0356 - Age2 x 0.1061 + AFC x 
0.0151 - AFC squared x -0.00014 - Duration of infertility (0-4 years=0, >5years = 1) 
x 0.0933 
 
XB = 0.8115 + 1 x 0.0940 - 22 x 0.0109 - 1 x 0.1338 - 28 x 0.0356 + 15 x 0.0151 - 
225 x -0.00014  
XB = -0.2696 
Predicted probability = EXP(XB)/(1+EXP(XB)) 
    = 0.7637 / 1.7637    = 0.433  = 43.3% 
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Recalibrated probability:  
Recalibrated XB = -0.2696*1.129 – 0.078 = -0.3824 
Recalibrated Pred Prob = EXP(-0.3824)/(1+EXP(-0.3824))  
            = 0.68222/1.68222   = 0.405  = 40.5 
 
Table 19.  The effect of BMI on predicted probabilities within the model 
 
 
Example Couples 
Predicted 
probability 
of live 
birth 
Recalibrated 
predicted 
probability 
of live birth 
A. A 28 year old white woman and her partner 
have male factor infertility.  She has a BMI of 20 
and AFC of 15.  The couple have had a child after 
a previous natural conception and have been 
trying for 2 years. 
 
 
 
 
0.45 
 
 
0.42 
B. If we take the same couple as in A but change 
the body mass index to 25 
 
 
 
0.44 
 
0.41 
C. If we take the same couple as in A but change 
the body mass index to 30. 
 
 
 
0.42 
 
0.39 
D. If we take the same couple as in A but change 
the body mass index to 35. 
 
 
 
0.41 
 
0.38 
E.  If we take the same couple as in A but change 
the body mass index to 40. 
 
 
0.39 
 
0.36 
 
As discussed previously, BMI has less of an effect on IVF outcome when other 
predictors are accounted for.  However, we have shown in Table 19 that for a woman 
who has a good chance of success with a normal BMI, there is still between a 4-6% 
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reduced chance of success if this woman had a BMI above 35; keeping all other 
factors the same. 
 
We have illustrated not only the clinical use of this model but also how a couples 
characteristics influence their prognosis.  This model provides a personalised 
prediction of a couple’s chances of IVF success, in favour of using crude age related 
success rates based on national HFEA data.  The idea would be for clinicians to use 
the model routinely when counselling couples seen in outpatient clinics for the first 
time, as the vast majority of UK hospital clinics will have computers with internet 
access.  This should ensure that all patients have the opportunity to use the model at 
some point, which is particularly important for those patients who may have limited 
access to the internet or a mobile phone.  
 
Future research 
The next step for our model will be to further externally validate by performing 
geographical validation.  We plan to do this using the data collected from the 
Birmingham Women’s Hospital Fertility Centre, as well as other assisted conception 
units.  The subsequent use of our model will be implementation into clinical practice 
as an up-to-date counseling tool (in the form of a user-friendly freely available web-
page and/or mobile application) for use by the relevant clinicians and patients in 
aiding decision making before commencing their first IVF cycle.   
 
The third and final stage in the pathway of producing a clinical prediction model is 
impact analysis.  This establishes whether the prediction model improves decisions, 
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in terms of quality or cost-effectiveness of patient care69,70.  None of the existing IVF 
prediction models have yet reached the impact analysis stage.  We intend to 
evaluate the impact of our model by conducting a feasibility study to explore patient 
experience of the tool and its impact on their counselling and decision-making.  
 
Collaboration statement: 
This work was done as part of a collaboration between the University of Birmingham 
and the University of Aberdeen.  Statistical assistance was provided by Dr David 
McLernon (post-doctoral researcher in medical statistics).  Dr McLernon provided 
hands-on teaching and performed the external calibration using SAS (ver.9.2; SAS 
Institute, Cary, North Carolina). 
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CHAPTER 5 
National study of prevalence of thyroid dysfunction 
in women of reproductive age 
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Introduction 
 
Thyroid disorders are one of the most prevalent of all medical conditions, especially 
in women of reproductive age.  Thyroid disease comprises a spectrum of disorders, 
broadly speaking this can be categorised into three main groups; abnormal thyroid 
function, thyroid autoimmunity and thyroid tumours (benign or malignant).  The focus 
of the work in this chapter will be on thyroid dysfunction.  Thyroid dysfunction 
involves an abnormality of hormone levels (i.e. free thyroxine (fT4), thyroid 
stimulating hormone (TSH) or free tri-iodothyronine (fT3)).  The two most common 
problems with the thyroid are; overactive thyroid (hyperthyroidism) and underactive 
thyroid (hypothyroidism).   
 
All types of hyperthyroidism are due to an overproduction of thyroid hormones (in 
particular an increase of fT4); active hyperthyroidism is present in around 0.1-0.4% of 
pregnant women.  The most common cause of hyperthyroidism is Graves disease75 
(an autoimmune condition) but the condition can develop in several ways.  It has 
been shown that Graves disease is associated with adverse pregnancy outcomes 
such as miscarriage, pre-eclampsia, pre-term birth, placental abruption and foetal 
hyperthyroidism76,77.  Other causes of hyperthyroidism include; toxic adenomas, 
subacute thyroiditis, pituitary gland malfunctions or growths in the thyroid gland. 
 
Hypothyroidism, in contrast, stems from an underproduction of thyroid hormones.  
The prevalence of overt hypothyroidism is around 0.5-0.7% in women of reproductive 
age78.  In women of reproductive age the most common cause of hypothyroidism is 
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an autoimmune thyroiditis and Hashimoto’s disease15 (excluding iodine deficient 
populations).  As with hyperthyroidism, hypothyroidism has also been associated with 
adverse pregnancy outcomes such as miscarriage, placental abruption, higher rates 
of neonates being admitted to intensive care units and lower intelligence scores (IQ) 
in the offspring31.   
 
Subclinical hyperthyroidism and subclinical hypothyroidism (SCH) are diagnoses that 
are essentially based on laboratory reference ranges; the majority of patients do not 
have clinical signs or symptoms.  Subclinical hyperthyroidism is defined as a 
decrease in serum TSH below the reference range with normal serum fT4 and fT3 
concentrations; subclinical hypothyroidism (SCH) is defined as an elevation in serum 
thyroid-stimulating hormone (TSH) above the upper limit of the reference range with 
normal serum fT4 concentration.  The “normal reference range” is dependent on the 
reference range for the assay used.   It is known that these conditions represent the 
earliest stages of thyroid dysfunction, more so for subclinical hypothyroidism and it’s 
progression to overt disease79; however the benefits of detecting and treating 
subclinical thyroid disease are not well established.    
 
Subclinical hyperthyroidism has been found to be linked to several conditions such 
as atrial fibrillation, reduced bone mineral density, cardiac dysfunction, and 
progression to overt hyperthyroidism80–83; however the association with progression 
to overt disease is much less than that seen with hypothyroidism84.  Although it has 
been shown that that treatment of subclinical hyperthyroidism can slow the loss of 
bone mineral density there is no strong evidence to show any benefits from treating it 
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in pregnancy.  Due to evidence showing that there are no adverse effects associated 
with subclinical hyperthyroidism in pregnancy it is not screened for or treated pre-
conception or in pregnancy85. 
 
The prevalence of subclinical hypothyroidism (SCH) is thought to be around 9% in all 
adults (including non-pregnant women); the prevalence is around 3-5% in pregnant 
women15.  This figure is higher in women with infertility15.  In contrast to subclinical 
hyperthyroidism, evidence has shown that subclinical hypothyroidism is linked to 
negative pregnancy outcomes such as miscarriage, pre-term birth, pre-eclampsia, 
gestational hypertension and peri-natal mortality17,86.  Consequently, the Endocrine 
Society Clinical Practice Guideline (ESCPG) regarding “Management of Thyroid 
Dysfunction during Pregnancy and post-partum” recommends the use of hormone 
replacement therapy, in the form of Levothyroxine (LT4) treatment, for pregnant 
women with subclinical hypothyroidism as well as those with overt disease.  The 
guideline reports that there is “fair” evidence on improvements with LT4 replacement 
in SCH for most pregnancy outcomes, although no differences have been seen for 
neurological outcomes in the offspring15. 
 
One of the main challenges in defining SCH is agreeing on the upper limit of TSH, 
consequently this has also lead to debate over when to treat SCH.  The most widely 
accepted reference range for a “normal” TSH in non-pregnant women is 0.4-4.5mU/l.  
For women who have known overt hypothyroidism (TSH >4.5mU/l and fT4 <21mU/l), 
and are already on LT4 treatment pre-conception, it is generically accepted that a 
target TSH of 0.1-2.5mU/l, 0.2-3.0mU/l and 0.3-3.0mU/l should be maintained in the 
 135 
first, second and third trimester respectively (in the absence of laboratory specific 
reference ranges).  These recommended reference ranges are taken from the 
American Endocrine Society (AES)87 and American Thyroid Association (ATA)16 
guidelines and are endorsed by most other international endocrine societies, 
including the British Thyroid Association88.  
 
 There is much less clarity and consensus on when to treat SCH; both pre-
conception and in pregnancy.  The British Thyroid Association, recommends the 
following: “If the serum TSH concentration is above the reference range but 
<10mU/L, then serum thyroid peroxidase (TPO) antibodies should be measured. If 
the serum antibody concentration is high, then serum TSH should be measured 
annually or earlier if symptoms develop; thyroxine (LT4) therapy should be started if 
the serum TSH concentration rises above 10mU/L. If the serum antibody 
concentration is not raised, then repeat measurement of serum TSH approximately 
every three years is all that is required.  There is no evidence to support the benefit 
of routine early treatment with thyroxine in non-pregnant patients with a serum TSH 
above the reference range but <10mU/L.  Physicians may wish to consider the 
suitability of a therapeutic trial of thyroxine on an individual patient basis” 88.   
 
In contrast the recent ATA and AACE (American Association of Clinical 
Endocrinologists) guideline states: “treatment with L-thyroxine should be considered 
in women of childbearing age with serum TSH levels between 2.5mU/l and the upper 
limit of normal or a given laboratory’s reference range if they are in the first trimester 
of pregnancy or planning a pregnancy, including assisted reproduction in the 
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immediate future” 89.  However, the American Congress of Obstetricians and 
Gynaecologists have not supported these recommendations.     
 
This debate regarding pre-conception thresholds of TSH is of particular growing 
interest in the assisted reproduction setting.  In the United States recent guidelines 
proposed by the National Association of Clinical Biochemistry (NACB) have stated 
that it is likely that in the future the upper limit serum TSH euthyroid reference range 
will be reduced to 2.5mU/L; but that this will be for all adults including pre-conception 
women in the fertility setting.  However, in the UK the British Thyroid Association 
maintains that a TSH level up to 4.5mU/L is normal.   
 
As mentioned, there is currently a shift in clinical practice, in certain parts of the 
world, towards routinely treating women with SCH who are trying for a pregnancy, 
particularly the infertility population, and aiming for a pre-conception target TSH of 
<2.5mU/l.  Despite this suggestion of aiming for a rigid pre-conception TSH threshold 
below 2.5mU/l, it is not currently recommended routine practice for universal thyroid 
function screening in women trying for a pregnancy, or even in women who are 
pregnant, by any of the major endocrine societies (ATA, AACE, ACOG or the 
Endocrine society).  This is because there is limited conclusive evidence to suggest 
that treatment with Levothyroxine for women with TSH 2.5-4.5mU/l has any benefit 
on pregnancy outcomes compared with untreated women18.  However, it should be 
noted that other endocrine societies, including the Spanish society of endocrinology 
and nutrition (SEEN), argue that universal screening is warranted based on the 
impact of undiagnosed thyroid dysfunction on pregnancy.  The 2012 Endocrine 
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society guidelines reflected the lack of agreement over universal versus “case 
finding” screening, by producing two different recommendations as the committee 
could not reach a unanimous decision87.  Furthermore, in 2011 the AES/ATA 
recommendations for thyroid function screening was that it should be universal, but 
this was retracted in the 2012 guideline; this was almost certainly in part to do with 
the results of the Antenatal Thyroid Screening and Childhood cognitive function 
(CATS) study90 published in the New England Journal of Medicine which showed no 
difference in cognitive function of offspring born to women with treated 
hypothyroidism compared with untreated.   
 
There are certain “high risk” groups whom most major international bodies agree 
should be considered for routine thyroid screening, these are; 1) women with a 
history of risk factors for thyroid dysfunction (i.e. cervical irradiation, 1st degree family 
history), 2) women with poor obstetric history which could be attributable to thyroid 
dysfunction (i.e. recurrent miscarriage, previous still birth, baby with congenital 
defects) and 3) women with a history of metabolic disorders (i.e. diabetes).  The 
AES/ATA guideline also includes women with infertility as a “high risk” group of 
people who should be screened routinely prior to pregnancy16; however this is not 
endorsed by British guidelines.  Outside of these agreed “high risk” groups there is 
little known about the benefit to screening asymptomatic women with potentially 
undiagnosed subclinical disease.   
 
One of the largest epidemiological studies of thyroid disease, which assessed thyroid 
function and thyroid autoimmunity in over 17,000 people was conducted over 
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20years ago and was restricted to the geographic and ethnic distribution of the U.S. 
population, furthermore it did not look specifically at women of reproductive age91.  
Another large study was the Whickham study in the UK, this survey looked at the 
prevalence of thyroid disorders in a randomly selected sample of 2779 adults, which 
represented the population of Great Britain in age, sex and social class92.  To date 
there have been no large-scale epidemiological studies in the UK identifying the 
prevalence of undiagnosed thyroid disease in women of reproductive age who are 
actively trying for a pregnancy.  Given the effects of thyroid disease in pregnancy this 
is an important area of research to establish.   
 
Women with symptoms of thyroid disease will generally present in primary care and 
thus 
 
 be investigated by their general practitioner (GP), however many women with overt 
hypothyroidism and almost all with SCH are asymptomatic; and so there is a cohort 
of undiagnosed women with thyroid disease that will not routinely have their thyroid 
function tested prior to conception. It is therefore important to investigate if there may 
be a specific subset of women with undiagnosed thyroid disease who are likely to be 
at higher risk and in whom we could provide screening and/or treatment to optimise 
their pregnancy outcomes. 
 
As increasing numbers of UK clinicians (endocrinologists, fertility specialists and 
obstetricians) are moving towards empirically treating subclinical thyroid disease, and 
adhering to stricter thresholds for reference ranges, there is a need to establish the 
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prevalence of undiagnosed thyroid disease, using these different thresholds, and 
identify which women will benefit most from pre-conception screening and 
subsequent treatment.  
 
 
Aims and objectives 
1. To study the distribution of undiagnosed thyroid dysfunction in women of 
reproductive age in the UK. 
2. To study the distribution of undiagnosed thyroid dysfunction in demographic 
subgroups; age, body-mass index, ethnicity and originating population (i.e. 
history of 1 or 2 miscarriages (early pregnancy unit setting); recurrent 
miscarriage; infertility). 
3. To examine the relationship between demographic characteristics (age, BMI, 
ethnicity and population) and TSH concentration. 
 
Methods 
 
This was a large prospective epidemiological prevalence study conducted at 42 
hospitals across the UK between December 2013 and February 2015. 
 
This study directly linked to an on-going large multi-centre randomised controlled trial 
called TABLET.  The aim of the TABLET trial is to determine if 50micrograms of LT4, 
started pre-conceptually in women who are euthyroid and positive for TPO antibodies 
(TPOab), can reduce the risk of miscarriage and pre-term birth.  All women gave 
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written consent to have their blood taken (for thyroid function and TPOab) and used 
for research purposes, prior to their blood samples being taken.  The consent form 
can be found in Appendix 3.  Pre-screening logs were completed for all women who 
were approached and asked to take part.  
 
Eligibility criteria 
The eligibility criteria were as follows: 
- Aged between 16-41 
- Trying for a pregnancy in the next 12 months 
- Not known to have any history of or current thyroid problems 
- Not known to have any cardiac problems  
- Not taking Amiodarone or Lithium 
 
All patients were screened from any one of the following clinical settings:  
- Early pregnancy assessment unit (EPAU) – women with a recent diagnosis of 
miscarriage, including women who may have had one miscarriage previously. 
- Recurrent miscarriage clinics - recurrent miscarriage defined as three 
consecutive losses with the same partner. 
- Infertility clinics -  women being investigated or treated for infertility problems. 
- Other – these were women who fell into any of the above categories but had 
not been routinely seen in the clinical setting and instead had contacted the 
trial as self-referrals via the trial website. 
(http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/womens/t
ablet/index.aspx) 
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Thyroid function test reference ranges 
The reference range for a normal thyroid function for the purpose of the TABLET trial 
was set according to Roche Diagnostics manufacturer’s recommended reference 
ranges published in 2004, which was derived from 269 healthy non-pregnant females 
of the reproductive age (20-39years).  This range was 0.44mU/L – 3.63mU/L with a 
Free T4 of 10.0 – 21.0 pmol/L.   
 
For the purpose of the analysis for this study, to be consistent with the generic 
accepted upper limit for TSH in the UK, we used an upper limit of 4.5mU/L for TSH.  
Values above this were considered abnormal.  A subgroup analysis was done to look 
at those with TSH 2.5-4.5mU/L.  This was done as reproductive medicine clinicians in 
the UK and endocrinologists in the United States, are moving towards a pre-
conception TSH of <2.5mU/L for women undergoing fertility treatment based on the 
hypothesis that these women could have better success rates, however evidence for 
this is very limited.  
 
Thyroid function was grouped into mutually exclusive groups with the exception of 
the euthyroid group, which was further sub-grouped into euthyroid 1a and 1b to 
explore differences in prevalence using a stricter threshold for normal compared with 
the traditional upper end of normal.  Subclinical hypothyroidism was also split into 
two groups; moderate (TSH 4.51-10mU/L) and severe (>10mU/L).  The rationale for 
creating two separate groups was because they are treated differently; it is widely 
accepted to treat subclinical hypothyroidism when the TSH is greater than 10mU/L, 
however there is disagreement over TSH values between 4.50-10mU/L.   
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The groups were as follows:  
- Euthyroid (1): TSH 0.44-4.5mU/L and fT4 10-21pmol/L 
o Euthyroid (1a): TSH 0.44-2.49mU/L and fT4 10-21pmol/L 
o Euthyroid (1b): TSH 2.50-4.50mU/L and fT4 10-21pmol/L 
- Overt hypothyroidism: TSH >4.50mU/L and fT4 <10pmol/L 
- Overt hyperthyroidism: TSH <0.44mU/L and fT4 >21pmol/L 
- Moderate subclinical hypothyroidism (SCH): TSH 4.51-10mU/L and fT4 10-
21pmol/L 
- Severe subclinical hypothyroidism (SCH): TSH >10mU/L and fT4 10-21pmol/L 
- Subclinical hyperthyroidism: TSH <0.44mU/L and fT4 10-21pmol/L 
 
Demographic data 
The following demographic characteristics were recorded for each screened patient: 
age, body-mass index (BMI), ethnicity and originating population.  
 
Age and BMI were grouped in categories for the purpose of presenting the 
prevalence data.  Ethnicity was selected from a list of 17 options, for the purpose of 
analysis these were grouped accordingly: “White”; “South Asian” 
(Indian/Pakistani/Bangladeshi/Other South Asian); “Black” (African/Caribbean/Other 
Black); “Mixed” (mixed White/Asian, mixed White/Black African, mixed White/Black 
Caribbean, other mixed background); “Chinese” and “Other” ethnic group.  
Originating population referred to the clinical setting from where the patients was 
screened, as previously stated this was; women with a history of one or two 
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miscarriages (i.e. EPAU setting), women with history of recurrent miscarriage, 
women seen in the fertility setting or other. 
 
Sample size 
A sample size of 5000 would be large enough to have small uncertainty around our 
point estimate; our 95% confidence interval would be of width 1.5% (in absolute 
terms).  Increase to the sample would reduce uncertainty further but 5000 was the 
minimum we aimed for in this study.  We anticipated we would achieve this minimum 
number over a 14month period based on individual centre capacities within the 
relevant clinical settings, research staff numbers and our experience of recruitment 
figures into the TABLET trial thus far. 
 
Statistical analyses 
Using the binomial exact method (http://statpages.org/confint.html), crude proportions 
and percentages with 95% confidence intervals were calculated to show the 
prevalence of each thyroid dysfunction group.  The prevalence’s for each thyroid 
function group were further explored by examining the prevalence within each 
demographic subgroup: age, BMI, ethnicity and originating population.   Age and BMI 
were created as categorical variables.  
 
Further analysis was performed, presented in graphical format, looking at the 
relationship between each demographic outcome and TSH concentration to assess 
for any trends.  The R2 value was calculated to determine how well each 
demographic factor was at predicting TSH concentration; with a value near to 1 
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representing a perfect fit, and a value near to 0 as near to no fit.    Age and BMI were 
treated as continuous variables, for ethnicity and population box plots were created 
showing the median TSH concentration, along with the interquartile range and range, 
for each ethnic group and originating population.  
 
Ethical approval  
Ethical approval was obtained from Berkshire B Research Ethics Committee (REC) 
in December 2013.  The study protocol and letter of approval can be found in 
Appendix 4 and Appendix 5 respectively.  
 
Results 
 
A total of 7022 women had thyroid function testing across the UK between December 
2013 and the end of February 2015.   
 
Geographical distribution of population 
A list of the 42 centres is presented geographically in Figure 26.  The distribution of 
patients in the study, classified into groups of thyroid dysfunction, is shown in Figure 
27 and the numbers of women screened at each site is presented in Figure 28. 
 
The pre-screening logs did not show any obvious disparities in age, BMI or ethnicity 
between those who gave consent and those who did not.  The most common reason 
for declining consent was that the patient stated they would prefer not to know; this 
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contributed to less than 0.5% of all women approached, we therefore feel satisfied 
that the cohort is representative of women seen in the corresponding clinical settings.   
 
Figure 26.  Geographical distribution of recruiting centres 
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Figure 27.  Flowchart of patients in prevalence study 
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Figure 28.  Numbers screened by each participating centre; grouped by 
geographical region 
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Overall description of data for each demographic subgroup 
 
Table 20.  Overall description of dataset (n=7022) - delete 
Demographic Subgroup Number and % of whole population 
Age (n=7022) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
181 (2.58%) 
888 (12.64%) 
2016 (28.71%) 
2515 (35.82%) 
1422 (20.25%) 
 
BMI (n=6325) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
132 (1.88%) 
3117 (44.39%) 
1862 (26.52%) 
769 (10.95%) 
445 (6.34%) 
 
Ethnicity (n=7022) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
4863 (69.25%) 
506 (7.21%) 
1236 (17.60%) 
96 (1.37%) 
146 (2.08%) 
175 (2.49%) 
 
Population (n=6898) 
History of 1 or 2 miscarriages (EPAU) 
Infertility 
Recurrent miscarriage 
Other 
 
 
2231 (31.77%) 
3171 (45.16%) 
1419 (20.21%) 
77 (1.10%) 
 149 
Overall prevalence of each thyroid function group for whole population 
The raw numbers are presented along with percentages and 95% confidence 
intervals in Table 21 below. 
 
Table 21.  Overall prevalence’s for whole dataset 
    95% CI  
Thyroid function Proportion Prevalence Lower Upper 
 
Euthyroid 
Euthyroid 1 (TSH 0.44-4.50) 
Euthyroid 1a (TSH 0.44-2.49) 
Euthyroid 1b (TSH 2.50-4.50) 
 
 
6717/7022 
5490/7022 
1227/7022 
 
 
95.66% 
78.18% 
17.47% 
 
 
95.15% 
77.20% 
16.59% 
 
 
96.12% 
79.14% 
18.38% 
 
Overt thyroid disease 
Hypothyroid 
Hyperthyroid 
 
27/7022 
9/7022 
18/7022 
 
0.38% 
0.13% 
0.26% 
 
0.25% 
0.06% 
0.15% 
 
0.56% 
0.24% 
0.41% 
 
Subclinical hypothyroid 
Mod. SCH (TSH 4.51-10.0) 
Severe SCH (TSH >10.0) 
TSH >4.50 
TSH >2.50 
 
 
147/7022 
5/7022 
152/7022 
1379/7022 
 
 
2.09% 
0.07% 
2.16% 
19.64% 
 
 
1.77% 
0.02% 
1.84% 
18.72% 
 
 
2.46% 
0.17% 
2.53% 
20.59% 
 
Subclinical hyperthyroid 
 
90/7022 
 
1.28% 
 
1.03% 
 
1.57% 
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Prevalence of each thyroid dysfunction group subgrouped into age, BMI, ethnicity 
and originating population 
 
For each main group of thyroid function listed in Table 21, the prevalence’s were 
explored further and broken down into demographic subgroups, each presented as 
raw proportions, percentages and corresponding 95% confidence intervals.  For BMI, 
ethnicity and originating population these fields were not compulsory to be completed 
within the study electronic database and so there are missing cases; the total cases 
used to present the prevalence for each demographic characteristic is shown with “n” 
values in each table.  The prevalences are displayed in tables in appendices 6-13. 
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Relationship between TSH concentration and each demographic subgroup  
These are displayed in graphical format in Figures 29-32. 
 
Figure 29.  The relationship between age and TSH concentration 
 
Equation for line of best fit: y = 1.55 + 0.01*x  
R2 linear = 0.0006636 
 
The graph shows there appears to be no significant relationship between age and 
TSH concentration. 
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Figure 30.  The relationship between BMI and TSH concentration 
 
Equation for line of best fit: y = 1.41 + 0.02*x  
R2 linear = 0.004 
 
The graph shows there appears to be a relationship between increasing BMI and 
higher TSH concentration.  This is consistent with the analyses done thus far.  
However the R2 value is still low suggesting that BMI is not a strong predictor for TSH 
concentration.   
 
For women who had moderate SCH (as seen in Appendix 11), 1.51% of them had a 
normal BMI (18.5-24.9), there was a significantly higher prevalence of women with 
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BMI 25-29.9 (2.31%; p=0.04), 30-34.9 (2.73%; p=0.02) and ≥35 (2.92%; p=0.03).  
The same pattern was found for severe SCH.  In addition the mean BMI for overt 
hypothyroidism (28.0 SD ±7.7) was significantly higher than the mean BMI for the 
corresponding euthyroid women (25.9 SD ±5.4) (p<0.001).  The reverse findings 
were found for hyperthyroidism (subclinical and overt).   
 
Figure 31.  The relationship between ethnicity and TSH concentration 
 
 
 
The numbers on the graph represent the case numbers for outliers, as far as 
possible the extreme outliers have been removed, purely for graphical presentation 
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purposes, all values were included in the actual analysis.  The boxplot shows the 
median, interquartile range and range; South Asian women appear to have the 
highest levels of TSH for all parameters and Black women have the lowest. 
 
Figure 32.  The relationship between originating population and TSH 
concentration 
 
 
 
 
The infertility population appear to have the highest median TSH concentration and 
higher limits for the interquartile range and range (upper end and lower end).  
 
 155 
Discussion 
 
Main findings 
The aim of this study was to present the prevalence of thyroid function (in specific 
categories) across the UK in pre-conception women not known to have thyroid 
disease who are actively trying for a pregnancy.   
 
The overall prevalence of the generically accepted reference range for biochemical 
euthyroidism (TSH 0.44-4.50, T4 10-21) was 95.66% (95% CI 95.15-96.12%), for 
overt thyroid disease it was 0.38% (95% CI 0.25-0.56%) and for subclinical thyroid 
disease it was 3.45% (95% CI 3.03-3.90%).  This study shows that there are a small 
proportion of women who have undiagnosed thyroid disease, and prompts the 
question of whether women should routinely have screening performed pre-
conception to avoid missing these women and improving pregnancy outcomes.  
 
Strengths and limitations 
One of the strengths of this study is the large sample size.  By having a large sample 
size it has allowed us to report the prevalence’s with greater precision.  Another 
strength is the fact that the population is a good geographic representation of the 
whole of the UK, rather than being limited to one area. 
 
A further strength was the implementation of pre-screening logs.  These ensured that 
entries were made for all patients approached for screening, including those who 
declined.  When looking at the baseline demographics for those women who declined 
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there were no significant differences between the demographics for those who gave 
consent; consequently we can be reassured that the sample of women screened was 
representative of the women seen in the selected clinical settings.   
  
By collecting demographic data on age, body-mass index, ethnicity and originating 
population it has allowed us to explore in detail which group of women may be more 
likely to have thyroid disease.  However, the reality is that all the women who were 
screened belonged to a selected population; whether it was history of miscarriage or 
infertility.  Therefore these women would not necessarily represent the thyroid 
function of true unselected “low risk” women with no gynaecological or obstetric risk 
factors.  It would be interesting to see comparisons between the women screened 
from our study and the “normal” or “low risk” population of women trying for a 
pregnancy with no known history of gynaecological/obstetric or medical problems.  
 
A further limitation of the study is that there are no outcome data to allow us to 
investigate the relationship between thyroid dysfunction and pregnancy outcomes 
using a large sample size.  This would be particularly useful in examining any 
potential differences in outcomes for women with TSH 0.44-2.50mU/L and those with 
TSH 2.50-4.50mU/L.  We obtained ethical approval to use the outcome data from 
one centre (Birmingham Womens Hospital); a cohort study looking at the effect of 
subclinical hypothyroidism on IVF outcome is presented in chapter 7. 
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Comparisons to existing literature 
The overall prevalence of thyroid disease in our study was very similar to the 
reported prevalence in the National Health and Nutrition Examination Survey 
(NHANES III) in the US; which studied an unselected population of over 17,000 
people aged 12 or above, between 1988 and 199491.  The US study used the upper 
limit of normal for TSH as 4.5mU/L, the reported prevalence’s were 4.3% for 
subclinical thyroid disease and 0.3% for overt91 (our study reported 3.5% and 0.4% 
respectively).     
 
Iodine deficiency is the leading cause of hypothyroidism in developing countries, due 
to insufficient iodine dietary intake.  A cross-sectional survey published in the Lancet 
in 2011 looked at the iodine status in 810 schoolgirls aged 14–15 years attending 
secondary school in nine UK centres93.  The findings of this study suggested that the 
UK is iodine deficient; 51% of participants were found to have mild iodine deficiency, 
16% were classified as moderate and 1% had a severe deficiency93.  These numbers 
are not consistent with the small percentage of women diagnosed with 
hypothyroidism in our prevalence study (0.13%).  It may be that mild and moderate 
iodine deficiencies do not contribute to the development of hypothyroid disease in the 
same way as severe deficiencies.  Or it may also be that the dietary intake of older 
women of reproductive age is more iodine sufficient than that of younger girls.  It is 
important to note that the findings of our study are not transferrable to iodine 
insufficient populations, where the prevalence of thyroid disease will be much higher. 
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One of the core topics of debate at present is the cut off value for TSH to define 
euthyroidism.  As mentioned in the introduction, there is a trend amongst 
reproductive medicine clinicians in the UK and endocrinologists in the US towards 
using the definition of abnormal TSH as values above 2.5mU/L.  The prevalence 
overall in our study of women with a TSH 2.5-4.5mU/L was 19.64% (this was as high 
as 21.60% in South Asian women).  There is an on-going debate regarding treatment 
of these women, particularly in the fertility setting.  The National Association of 
Clinical Biochemistry (NACB) have recently suggested that the upper limit of serum 
TSH in adults should be reduced to 2.5mU/L, this was based on the serum TSH 
findings from 95% of healthy euthyroid volunteers which ranged between 0.4mU/L 
and 2.5mU/L13.  However, the findings of our study are not consistent with this figure 
and in fact it is much lower; the prevalence of a TSH between 0.44-2.49mU/L in our 
study was 78.18% (95% CI 77.20-79.14%).  Using the figures from our study this 
allows us to challenge policy makers and clinicians who are leaning towards routinely 
commencing LT4 treatment for around 20% of their asymptomatic women, based on 
no conclusive evidence that the treatment has benefit.   
 
When examining the relationship between increasing age and thyroid dysfunction, 
specifically exploring TSH concentration, there appeared to be no association.  With 
an increase in age, marked changes in thyroid hormone production, metabolism and 
action also occur; furthermore there is substantial evidence that increasing age 
above 60 is associated with higher prevalence of thyroid disease.  The prevalence of 
overt hyperthyroidism in the elderly is increased in populations older than 60 years of 
age91,95,92,96 and the frequency of overt hypothyroidism has an increased prevalence 
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of up to 5% in subjects over 60 years of age95,97.  Furthermore, the largest 
epidemiological study in the UK assessing thyroid function, the Whickham survey, 
showed markedly increased levels of TSH in women over 4592.  However as the 
upper limit for age in our study was 41 (limited to women of reproductive age only) 
this increased prevalence with advancing age was not seen; thus it appears that for 
women of reproductive age, age itself is not a risk factor for thyroid disease. 
 
Regarding the relationship between increasing BMI and thyroid dysfunction our study 
did find an association.  There have been similar findings in other studies98–100 and so 
it is thought that TSH could represent a marker of altered energy balance in obese 
women101.  Interestingly, the most recent ATA guidelines suggest that routine 
screening should be considered in morbidly obese women (≥40); this was based on 
results of two cohort studies which found prevalence’s of SCH and overt 
hypothyroidism of 13.7% and 19.5% respectively99,100.  However our study has 
shown that women with BMI >25 are also at higher risk of subclinical hypothyroidism 
compared with women of normal BMI.   
 
When looking at the association between ethnicity and thyroid dysfunction it appears 
that for the “controversial” group of TSH 2.5-4.5mU/L the prevalence across all 
ethnicities is high (ranging from 11.6% in the mixed group to 21.6% in South Asians).  
When comparing the ethnicities to a reference group of White women, results 
showed that South Asian women have a higher prevalence of TSH 2.5-4.5mU/L 
(p=0.006) and moderate SCH, TSH 4.51-10mU/L (p=0.008).  The reverse was true 
for Black women; they showed a lower prevalence of TSH 2.5-4.5mU/L (p<0.001) 
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and a higher prevalence of TSH 0.44-2.5mU/L compared to White women.  This is in 
keeping with results from the National Health and Nutrition Examination Survey 
(NHANES III) where they found serum TSH concentrations were higher in White 
women than in Black women, independent of serum anti-thyroid antibody 
concentrations91.  A more recent U.S. study also identified that Graves disease is 
more common in Black women compared with White women102.  In addition to this, 
our study also showed Black women appear to have statistically significant higher 
rates of subclinical hyperthyroidism compared with White women.  Subclinical 
hyperthyroidism can be graded as mild or severe, depending on the level of TSH: 
Grade 1 (mild) TSH 0.1–0.4 μU/mL and suppressed TSH concentration < 0.1 μU/mL 
would be Grade II (severe)103.  Subclinical hyperthyroidism is not known to have 
serious adverse effects on pregnancy and the chances of progression to overt 
hyperthyroidism, particularly for mild hyperthyroidism is very low; therefore further 
research is needed to explore reasons for why Black women have lower TSH 
concentrations and the exact clinical implications.   
The box-plot in Figure 31 shows that the median, interquartile range and range 
values for TSH concentration for Black women are lower compared to White women, 
and higher for South Asian women compared to White women.  It could be in fact 
that these differences in TSH values are variants of normal; i.e. what may be 
considered “abnormal” for a White woman may be “normal” for a South Asian or 
Black woman.  Unfortunately, as we do not have any outcome data we cannot 
confirm whether the variation in TSH concentrations between the ethnic groups has 
any clinical implications or if they are simply ethnic variations of normal.  A Dutch 
study looked at ethnic differences in maternal thyroid function during pregnancy, the 
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study population consisted of 2765 Dutch, 308 Moroccan, 421 Turkish and 609 
Surinam/Antillean women104.  This was not representative of a UK population, 
however their findings were interesting.  Results showed that 19% of women who 
were initially diagnosed as having an abnormal thyroid were found to have a normal 
thyroid when the reference range applied was ethnicity specific rather than 
population based104.  Furthermore, of all women who were considered euthyroid 
using population-based reference ranges, 1.3% had an abnormal thyroid function test 
when ethnicity-specific reference ranges were used104.  Their results showed that 
ethnic differences in serum TSH and T4 within one population from one geographical 
area resulted in considerable misclassification of thyroid disease104.   The results 
from existing studies and our study highlight the need for population-based reference 
ranges to account for the relevant ethnic groups. 
 
Finally, when looking at the relationship between originating population and thyroid 
dysfunction the results shown in the boxplot (Figure 32) shows the median TSH 
value for women with infertility is higher than women from the other originating 
populations.  The results of our study suggest that TSH concentrations are arguably 
higher in women with infertility compared to other populations.  This finding will be of 
particular interest to clinicians working in assisted reproduction in the UK given the 
current trend towards offering Levothyroxine treatment for women with TSH values 
>2.5mU/L.  However, as stated in the introduction, this is yet to be proven as 
beneficial in improving fertility outcomes. 
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Conclusions and future work 
As discussed throughout this chapter, the lack of clarity over whether thyroid function 
testing should be performed routinely pre-conception is largely based on the lack of 
evidence to suggest benefit from treating undiagnosed subclinical disease; for most 
women with overt disease they would be symptomatic and so this would be detected 
in primary care.  The definition of screening is: “the systematic and active search of a 
health problem by applying a test on a large scale in otherwise healthy people”105.  
There are a series of criteria that should be met in order for a screening programme 
to be deemed appropriate, in a recent paper by Vila et al, discussing the controversy 
regarding universal thyroid screening in pregnancy, three broad categories were 
used; “1) the disease or health problem should be serious, highly prevalent and have 
a detectable preclinical stage 2) the screening test should be sensitive and specific, 
simple and inexpensive, safe, acceptable, reliable, easy to perform and ideally cause 
minimal discomfort and lastly 3) the diagnosis of the health problem requires facilities 
with the equity of access and availability to effective, acceptable and harmless 
treatment” 105.   
 
It is important to note that screening should not be implemented if early treatment is 
ineffective and does not have any effect on the natural progression of the disease.  
Based on the findings of this prevalence study, in conjunction with the criteria for a 
screening programme and the absence of conclusive evidence to suggest benefit 
from treating subclinical thyroid disease in pregnancy; we would recommend that 
screening for thyroid disease should be performed as “case finding” rather than 
universal.   
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If conclusive evidence emerges to suggest that pre-conception treatment of thyroid 
disease (particularly subclinical) has beneficial effects on pregnancy outcomes, then 
it may be worth considering, as a starting point, routine screening for South Asian 
women and women with BMI above normal.  The findings of this study show that 
around 4% of women have undiagnosed thyroid disease; of which 85% have 
subclinical disease.  If evidence shows benefit in treating pre-conception women with 
a TSH of >2.5mU/L then the prevalence of subclinical thyroid disease increases to 
>20% for all women; resulting in a significant proportion of the population requiring 
treatment and monitoring of thyroid disease pre-conception and in pregnancy.  
 
There needs to be careful calculation by all stake holders, including health 
economists, to decide if a burden of 4% (potentially as high as 20%) of the population 
potentially having pregnancy complications as a result of undiagnosed and untreated 
thyroid disease outweighs the potential benefit of early detection and treatment 
through universal screening.  Large randomised controlled trials are needed to help 
answer the question of whether pre-conception treatment of subclinical thyroid 
disease (in particular using an upper limit TSH value of 2.5mU/L) improves 
pregnancy outcomes when compared with no treatment.  The findings of such 
studies will then guide decision-making on whether pre-conception thyroid screening 
should become more widely available. 
 
As mentioned previously, this prevalence study is directly linked to the national 
TABLET trial.  The TABLET trial is continuing recruitment until December 2015.  We 
intend to use all the data collected within the study, this is anticipated to be >10,000 
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cases, to give provide a greater sample size and examine any differences in more 
detail.   
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CHAPTER 6 
National study of prevalence of thyroid 
autoimmunity in women of reproductive age 
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Introduction 
 
 
Anti-thyroid antibodies (collectively known as thyroid autoimmunity, TAI) are 
autoantibodies that are targeted against the thyroid; thyroid peroxidase antibodies 
(TPOAb), thyroglobulin antibodies (TgAb) and thyrotropin receptor antibodies (TRAb) 
are the three most clinically important.  Thyroid peroxidase (TPO) is the primary 
enzyme involved in the production of thyroid hormones and is stimulated by TSH106.  
TPOAb work against the function of the TPO enzymes and as a result cause thyroid 
inflammation106.  The majority of TPOAb are produced by lymphocytes that infiltrate 
the thyroid, along with small contributions from the bone marrow and regional lymph 
nodes106.  TPOAb cause thyroid cell damage through activation of the complement 
system and cell cytotoxicity107.  However, it isn’t thought that anti-TPO antibodies 
contribute significantly to thyroid destruction108.  TPOAb are the most common anti-
thyroid autoantibody; for Hashimoto's thyroiditis TPOAb are present in 90% cases, 
for those with Graves' disease the prevalence is 75% and with nodular goitre or 
thyroid carcinoma around 10-20%107,109.  Also, around 10-15% of biochemically 
euthyroid individuals can have high TPOAb titres107,109.  
 
Current evidence shows that TAI is an important risk factor for poor obstetric 
outcomes, such as miscarriage and pre-term birth; even in women with biochemically 
normal thyroid function110,111.  A systematic review, published in the British Medical 
Journal, showed that the presence of thyroid autoantibodies leads to a significantly 
increased odds of miscarriage for women from all populations compared to women 
without autoantibodies, the meta-analysed results showed: subfertility population (OR 
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3.15 [95% CI 2.23-4.44] p<0.001); recurrent miscarriage population (OR 4.22 [95% 
CI 0.97-18.44] p=0.06) and “unselected” or other (OR 4.28 [95% CI 2.06-8.92] 
p<0.001)19.  There were similar findings for pre-term birth, with increased odds for 
women with thyroid autoantibodies compared to women without (OR 2.07 [95% CI 
1.17-3.68])19.  Evidence has also shown an association between thyroid 
autoantibodies, specifically thyroid peroxidase antibodies (TPOAb), with subfertility 
(OR 1.5 [95% CI 1.1-2.0]) but there was no association with clinical pregnancy rates 
following IVF treatment17.  TPO antibody (TPOAb) positivity is also associated with a 
significantly increased risk of post-partum thyroiditis (OR 11.5 [95% CI 5.6-24])17.  
 
The presence of thyroid autoantibodies is thought to be relatively common in women 
of reproductive age; it is particularly high in women with a history of subfertility 
(prevalence ranging between 10-31%)112–114 and those with a history of recurrent 
miscarriage (prevalence ranging between 17-33%)20,21.  For the general population 
the prevalence ranges from 6-20%115,116.  Table 22 shows the pooled prevalences of 
TPOab across women of differing originating populations taken from existing studies.  
The prevalences were pooled with a random effects model, with Wolfs method for 
confidence intervals; given the substantial clinical and statistical heterogeneity as 
well as threshold variations, the pooled prevalences should be interpreted with 
caution.   
 
The average prevalence across all studies was 19%, indicating that thyroid 
autoimmunity is common in women of reproductive age. 
 168 
 
Table 22.  Pooled prevalence of thyroid antibodies across various populations 
Population Study and year Thyroid 
antibodies 
tested 
TPO 
threshold for 
test 
positivity 
Prevalence Pooled 
prevalence 
(95% CI) 
Unselected 
women 
Stagnaro-Green 1990 
Glinoer 1991 
Iijima 1997 
Bagis 2001 
TPO, TG 
TPO, TG 
TPO, TG 
TPO, TG 
Not stated 
>100u/ML 
≥1:100 titre 
>35IU/ml 
108/552 (19.6%) 
45/726 (6.2%) 
125/1179 (10.6%) 
108/876 (12.3%) 
11.3% 
(7.7%, 17.0%) 
      
History of 
miscarriage 
Rushworth 2000 TPO, TG >1:400 titre 163/870 (19%) 19% 
      
History of 
recurrent 
miscarriage 
Pratt 1993 
Bussen 1995 
Esplin 1998 
Kutteh 1999 
Dendrinos 2000 
TPO, TG 
TPO, TG 
TPO, TG 
TPO, TG 
TPO, TG 
Not stated 
>100IU/ml 
Not stated 
≥65IU/ml 
Not stated 
13/42 (31%) 
11/66 (17%) 
49/149 (33%) 
187/900 (20.8%) 
15/45 (32.5%) 
25.9% 
(19.5%, 34.3%) 
      
History of 
infertility 
Singh 1995 
Kim 1998 
Muller 1999 
Bussen 2000 
Poppe 2003 
Poppe 2004 
Negro 2005 
Negro 2007 
TPO, TG 
TPO, TG 
TPO 
TPO, TG 
TPO 
TPO 
TPO 
TPO 
Not stated 
>100U/ml 
>80U/ml 
>100IU/ml 
>100IU/ml 
>100IU/ml 
>100IU/ml 
>100IU/ml 
107/487 (22%) 
23/79 (29.1%) 
24/173 (14%) 
15/48 (30.6%) 
33/234 (14%) 
9/35 (25.7%) 
73/484 (15%) 
42/416 (10.1%) 
18.1% 
(13.9%, 23.5%) 
 
TPO – Thyroid peroxidase antibody; TG – Thyroglobulin antibody 
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Despite this apparent clear association between TPOAb positivitiy and miscarriage 
and pre-term birth, finding an association does not automatically imply a causal 
relationship.  In fact, the aetiology of increased pregnancy loss and pre-term birth in 
women with TAI remains unknown. 
 
Several “working hypotheses” have been proposed117–119.  The first hypothesis holds 
the view that the presence of circulating thyroid antibodies is not directly related to 
the pregnancy loss, but instead represents a marker of an underlying generalised 
autoimmune imbalance.  An imbalance which, in turn, could explain a greater 
rejection rate of the foetus117.  The second hypothesis proposes that despite 
apparent euthyroidism, the presence of TAI could be associated with a reduced 
ability of the thyroid gland to adapt adequately to the necessary changes associated 
with pregnancy118; due to the reduced functional reserve characteristic of chronic 
thyroiditis111.  The third hypothesis suggests that as increasing age has been 
associated with increasing titres of TPOAb; that age itself is the risk factor rather than 
the TPOAb119.  Although this third hypothesis seems the least plausible, it is most 
likely that the increased risk of pregnancy loss associated with TAI is of multifactorial 
origin. 
 
Studies have shown that euthyroid women, who are positive for TPOAb, are more 
likely to develop impaired thyroid function during pregnancy; in particular subclinical 
hypothyroidism114,120.  It is uncertain whether it is the TPOAb or TPO-specific T cells 
which are the primary cause of thyroid inflammation; which then leads to thyroid 
failure and hypothyroidism in select individuals106.  Consequently, the Endocrine 
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Society Clinical Practice Guidelines (ESCPG) and the American Thyroid Association 
(ATA) guidelines recommend thyroid function monitoring for women with known 
thyroid autoimmunity during pregnancy because of the risk of developing 
hypothyroidism22.  However, there is no consensus on whether Levothyroxine 
treatment of euthyroid women with TAI improves pregnancy outcomes.  To date 
there have only been two small randomised controlled trials (n=86 and n=115) which 
have looked at this research question; the results did not provide sufficient evidence 
to support treatment with Levothyroxine in a euthyroid women114,120.  As discussed in 
Chapter 5, a large multi-centre randomised controlled trial (TABLET trial) is currently 
on going in the UK and will help to provide more robust findings to help answer this 
question. 
 
Owing to the lack of evidence suggesting any benefit from Levothyroxine treatment 
solely for the presence of TPOAb, there is an on-going debate regarding whether 
women should be routinely screened for TPOAb prior to- or during early pregnancy.  
There is an argument that states if we know TPOAb positive women are at higher 
risk of developing thyroid impairment and/or adverse pregnancy outcomes that we 
should be aiming to identify these women pre-conception with a view to at least 
offering thyroid monitoring during pregnancy, with or without Levothyroxine 
treatment.  At present the ATA and ESCPG do not recommend routine screening for 
thyroid antibodies in euthyroid women during pregnancy or prior to undergoing 
assisted reproduction121.   
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To date there has been no large epidemiological study to identify an accurate 
prevalence of thyroid autoimmunity in women trying actively for a pregnancy in the 
UK.  Aside from the suggestion that there may be higher rates of TPOAb in women 
with infertility and recurrent miscarriage, there has been no specific identification of 
“high risk” women using demographic characteristics such as age and body-mass 
index (BMI).  If we can determine a subset of women who may be at higher risk of 
having TPOAb this would allow for “case finding” of these women pre-conception; 
this information would then be useful in helping to determine which women may 
benefit from thyroid monitoring during pregnancy (if treatment with Levothyroxine 
proves beneficial in the TABLET trial). 
 
The aim of this study was to determine an accurate prevalence of TPOAb in women 
aiming to conceive across the UK; furthermore we aimed to identify if there are “high 
risk” women who may benefit from routine pre-conception thyroid autoantibody 
screening.  
 
Aims and objectives 
1. To study the prevalence of thyroid peroxidase antibodies (TPOAb) in pre-
conception women of reproductive age in the UK overall.  
2. To study the prevalence of TPOAb in combination with normal and abnormal 
thyroid function, in pre-conception women of reproductive age. 
3. To study the prevalence of TPOAb in demographic subgroups; age, body-
mass index, ethnicity and originating population. 
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4. To investigate the prevalence of TPOAb positivity with increasing TSH 
concentrations. 
 
Methods 
 
This was a large prospective epidemiological prevalence study conducted at 42 
hospitals across the UK between December 2013 and February 2015.  TPOAb 
testing was performed in conjunction with thyroid function testing and the work was 
directly linked to the TABLET trial.  Ethical approval was obtained from Berkshire B 
Research Ethics Committee (letter of approval in Appendix 5).  
 
Eligibility criteria and recruitment setting 
The eligibility criteria and clinical settings in which patients were recruited are as 
stated in the methods for chapter 5. 
 
Thresholds for thyroid antibody tests  
There are various assays for TPO antibodies available, each assay has different 
specified detection limits and differing numerical thresholds for test positivity; these 
are pre-determined by the assay manufacturer and the sensitivity and specificity of 
the assays are comparable.  For example a result of 35iu in assay A may be positive 
for that assay, but for assay B the threshold for positivity may be >50iu; the result of 
35iu on assay A would be equivalent to >50iu on assay B making the results 
comparable, and so it is not that assay B only becomes positive at a higher TPOAb 
level.  These variations are an accepted part of normal practice in the UK. Quality 
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assurance for assays in the laboratories for all the participating centres is provided by 
UK NEQAS, which shows over 99% concordance in the classification of samples as 
either positive or negative for TPO antibodies across all assays.  Levels that were 
considered as “indeterminate” by the assay were taken to be positive for the purpose 
of this study.   
 
Thyroid function grouping and demographic data  
The TPOAb status was looked at overall and in individual thyroid dysfunction 
subgroups as classified in chapter 5; euthyroid 1a and 1b, overt 
hypo/hyperthyroidism, subclinical hyperthyroidism and subclinical hypothyroidism 
further split into moderate and severe.  The demographic data collected was the 
same as for the thyroid function study in chapter 5; i.e. age, BMI, ethnicity and 
originating population. 
 
 
Statistical analyses 
Crude proportions and percentages with 95% confidence intervals were calculated, 
using the binomial exact method, to show the prevalence of thyroid autoimmunity 
overall and within each thyroid function group (both normal and abnormal).  For the 
overall TPOAb positive group prevalence’s were examined within each demographic 
subgroup: age, BMI, ethnicity and originating population (where age and BMI were 
created as categorical variables).  
 
Finally, an analysis was performed to look at the relationship between TSH 
concentration and TPOAb positivity.  TSH values were split into 9 clinically relevant 
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groups (<1.00; 1.00-1.49; 1.50-1.99; 2.00-2.49; 2.50-2.99; 3.00-3.49; 3.50-3.99; 4.00-
4.49; >4.50).  A 2x2 table was created with TSH concentration against TPOAb 
positivity as the outcome.  For each of the 9 groups of TSH concentration, 
prevalence of TPOAb positivity was calculated and presented in tabular and 
graphical format. 
 
Calculation of the 95% confidence intervals of prevalence’s was performed manually 
using the binomial exact method, while all other statistical analyses were performed 
using SPSS (ver. 21.0; SPSS Inc., Chicago). 
 
Results 
 
A total of 6974 women had TPO and thyroid function test results available across the 
UK between December 2013 and February 2015.  This figure is slightly less than the 
7022 women who had thyroid function results alone, as seen in chapter 5.  This was 
due to incomplete data entry for all TPOAb results onto the database; 0.68% of 
cases did not have a TPOAb result entered.  The data manager for the TABLET trial 
chases incomplete data entry on a monthly basis and requests reasons for missing 
data from each centre; this 0.68% constitutes the women who had insufficient blood 
samples taken in the first instance and declined repeat testing, consequently they 
had no result for TPOAb. 
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Distribution of patients in study and regional prevalence’s 
Figure 33 shows the distribution of patients in the study, classified into relevant 
groups of TPO status and thyroid dysfunction; percentages are expressed for the 
whole cohort.  Table 23 shows the percentage prevalence of TPOAb by geographical 
region. 
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Figure 33.  Flowchart of patients in study 
 
 
 
 
Euthyroid 1 
(TSH 0.44-4.50) 
n = 536 
Overt thyroid disease 
 
n = 18 
Subclinical thyroid disease 
 
n = 81 
 
Overt 
Hyperthyroid 
 
n = 11 
Overt 
Hypothyroid 
 
n = 7 
Subclinical 
Hyperthyroid 
 
 
n = 14 
Subclinical 
Hypothyroid 
(SCH) TSH 
>4.5 
n = 67 
Euthyroid 1a 
(TSH 0.44-2.49) 
 
n = 336 
Euthyroid 1b 
(TSH 2.50-4.50) 
 
n = 200 
Severe SCH 
TSH >10.0 
 
n = 4 
Moderate SCH 
TSH 4.51-10.0 
 
n = 63 
TPOAb positive 
 
n = 635 (9.11%) 
95% CI 8.44 - 9.80 
 
TPOAb negative 
 
n = 6339 (90.89%) 
95% CI 90.20 - 91.56 
Total number of women who had results for thyroid function and TPOAb testing across all centres 
n=6974 
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Table 23.  TPOAb positivity by geographical region 
 
 
 
 
 
 
 
Region 
Numbers 
screened 
Number of 
TPOAb positive 
Regional % 
TPOAb positivity 
    
Scotland 196 28 14.3% 
North West 62 4 6.5% 
North East 101 17 16.8% 
Yorkshire 267 20 7.5% 
Manchester and District 1105 111 10.0% 
Merseyside 519 40 7.7% 
West Midlands 1246 90 7.2% 
East Midlands 407 46 11.3% 
London and Essex 2394 207 8.6% 
Home Counties 244 20 8.2% 
West Country 367 46 12.5% 
Southern England 66 6 9.1% 
Overall 6974 635 9.1% 
 178 
 
The overall prevalence for TPOAb positivity for all screened patients was 9.1%.   
 
There does appear to be some geographical variation in TPOAb positivity; Scotland, 
North East, West Country and East Midlands appear to have a higher prevalence of 
TPOAb positivity compared to the rest of the UK.  The West Midlands and North 
West have the lowest prevalence of TPOAb positivity. 
 
Overall description of data and prevalences of TPOAb grouped by thyroid 
function 
The data presented in Tables 24 and 25 show an overall description of the data and 
prevalence’s of TPOAb grouped by thyroid function.  The prevalence of TPOAb in 
women with a normal thyroid function (according to the generically accepted TSH 
range of 0.44-4.50mU/L) was 7.98% (95%CI 7.34-8.65%).  When the euthyroid group 
were split into 1a (TSH 0.44-2.5mU/L) and 1b (TSH 2.5-4.5mU/L), the prevalence of 
TPOAb was statistically significantly higher in the euthyroid 1b group; 16.30% vs. 
6.12% (p<0.001).  There was also clear indication of higher prevalence of TPOAb 
positivity with increasing TSH concentration; prevalence in the moderate SCH group 
was 42.86% and for severe SCH it was 80.00%.  The prevalence of TPOAb was high 
in both overt disease groups; 61.11% for overt hyperthyroidism and 77.78% in overt 
hypothyroidism.     
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Table 24.  Overall description of dataset 
Subgroup Number and %  
  
Age (n=6974) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
180 (2.56%) 
882 (12.56%) 
2006 (28.57%) 
2502 (35.63%) 
1404 (19.99%) 
 
BMI (n=6325) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
131 (2.07%) 
3092 (48.89%) 
1851 (29.26%) 
763 (12.06%) 
443 (7.00% 
 
Ethnicity (n=6974) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
4834 (68.84%) 
503 (7.16%) 
1222 (17.30% 
96 (1.37%) 
144 (2.05%) 
175 (2.49%) 
 
Population (n=6898) 
History of 1 or 2 miscarriages (EPAU) 
Infertility 
Recurrent miscarriage 
Other 
 
 
2210 (32.04%) 
3164 (45.87%) 
1403 (20.34%) 
76 (1.10%) 
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Table 25.  Prevalence of TPOAb positivity within each thyroid function group 
     95% CI  
Thyroid autoimmunity 
status and function 
Proportions Prevalence Lower Upper 
 
Euthyroid 1 (TSH 0.44-4.5) 
Euthyroid 1a (TSH 0.44-2.49) 
Euthyroid 1b (TSH 2.5-4.5) 
 
536/6717 
336/5490 
200/1227 
 
7.98% 
6.12% 
16.30% 
 
7.34% 
5.50% 
14.27% 
 
8.65% 
6.79% 
18.49% 
 
Mod. SCH (TSH 4.51-10) 
Severe SCH (TSH 10.0<) 
Overt Hypothyroid 
 
63/147 
4/5 
7/9 
 
42.86% 
80.00% 
77.78% 
 
34.74% 
28.36% 
39.99% 
 
51.27% 
99.49% 
97.19% 
 
Subclinical hyperthyroid 
Overt hyperthyroid 
 
14/90 
11/18 
 
15.56% 
61.11% 
 
8.77% 
35.75% 
 
24.72% 
82.70% 
 
Prevalence of TPOAb within demographic subgroups 
The data presented in Table 26 shows the prevalence of TPOAb within the 
demographic subgroups.     
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Table 26.  TPOAb positive prevalence within demographic subgroups 
   95% CI  
Subgroup Proportions % Prevalence Lower Upper 
Age (n=633) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
14/180 
69/882 
177/2006 
227/2502 
146/1404 
 
7.78% 
7.82% 
8.82% 
9.07% 
10.40% 
 
4.32% 
6.14% 
7.62% 
7.98% 
8.85% 
 
12.71% 
9.80% 
10.15% 
10.27% 
12.12% 
 
BMI (n=580) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
11/131 
275/3092 
160/1851 
73/763 
61/443 
 
 
8.40% 
8.89% 
8.64% 
9.57% 
13.77% 
 
 
4.27% 
7.91% 
7.40% 
7.57% 
10.70% 
 
 
14.53% 
9.95% 
10.02% 
11.88% 
17.33% 
 
Ethnicity (n=633) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
446/4834 
20/503 
131/1222 
10/96 
5/144 
21/175 
 
 
9.23% 
3.98% 
10.72% 
10.42% 
3.47% 
12.00% 
 
 
8.42% 
2.45% 
9.04% 
5.11% 
1.14% 
7.58% 
 
 
10.08% 
6.07% 
12.59% 
18.32% 
7.92% 
17.76% 
 
Population (n=622) 
EPAU 
Infertility 
Recurrent misc. 
Other 
 
 
213/2210 
273/3164 
127/1403 
9/76 
 
 
9.64%  
8.63% 
9.05% 
11.84% 
 
 
8.44% 
7.67% 
7.60% 
5.56% 
 
 
10.94% 
9.66% 
10.68% 
21.29% 
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Results show that increasing age appears to be associated with higher prevalence of 
TPOAb.  When making comparisons between women with TPO antibodies and those 
without (not accounting for thyroid function) there was a statistically significant higher 
mean age for women with TPOAb, however this was small; mean difference 
0.5years, p=0.02. 
 
When looking at BMI; the results show that the prevalence of TPOAb was 
significantly higher in women with BMI ≥35 (13.8%) compared to women with normal 
BMI (8.9%) (p<0.001); furthermore the mean BMI for TPOAb positive women (26.4 
(±5.8)) was significantly higher than the mean BMI for TPOAb negative women (25.9 
(±5.4)) (p=0.04). 
 
When assessing the relationship between ethnicity and TPOAb status the prevalence 
ranged from 3.5% in the mixed population to 12% in “other”.  When comparing the 
prevalence for each ethnic group to a reference White population (9.23%), there was 
a statistically significant lower prevalence of TPOAb in Black women (3.98%, 
p<0.001) and mixed race women (3.47%, p=0.02).   
 
Finally there appeared to be no significant relationship between originating 
population and TPOAb positivity. 
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Relationship between TSH concentration and prevalence of TPOAb positivity 
Finally, an analysis was performed to look at the relationship between TSH 
concentration and the prevalence of TPOAb positivity.   Table 27 and Figure 34 show 
that increasing TSH is strongly associated with increased prevalence of TPOAb 
positivity, particularly TSH values above 2.50mU/l.  
 
 
Table 27.  TSH concentration and probability of being TPOAb positive 
 
TSH concentration 
(mU/L) 
% Prevalence of TPOAb 
 
1 <1.00 5.3 
2 1.00-1.49 5.6 
3 1.50-1.99 5.8 
4 2.00-2.49 9.7 
5 2.50-2.99 12.4 
6 3.00-3.49 18.7 
7 3.50-3.99 19.1 
8 4.00-4.49 25.8 
9 ≥4.50 45.2 
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Figure 34.  Graphical representation of TSH and prevalence of TPOAb positivity 
 
 
 
Discussion 
 
Main findings 
The aim of this study was to present the prevalence of thyroid autoimmunity across 
the UK in pre-conception women (without and without thyroid dysfunction) who are 
actively trying for a pregnancy.  The overall prevalence of TPOAb positivity was 
9.11% (95%CI 8.44-9.80).  Increasing age, body mass index and TSH concentrations 
are all associated with higher rates of TPOAb positivity.  
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Strengths and limitations 
The strengths and limitations for this study are in line with those discussed in chapter 
5.  The large sample size, good geographical distribution of recruiting centres across 
the UK along with the use of pre-screening logs to ensure a representative 
population was recruited were all study strengths. 
 
As mentioned in chapter 5 one of the limitations in not having true “low risk” women 
means that we are unable to accurately compare the prevalence in “high risk” women 
vs. “low risk”.  We have instead compared the higher risk women, as stated in 
existing studies these are women from the infertility and recurrent miscarriage 
populations, against women with a history of only one or two miscarriages as the “low 
risk” control.  It would be interesting to see comparisons of TPOAb prevalence 
between the women screened from our study and the “normal” or true “low risk” 
population of women trying for a pregnancy with no known history of 
gynaecological/obstetric or medical problems.  
 
A further limitation of the study is that there is no outcome data to allow us to 
investigate the relationship between thyroid autoimmunity and dysfunction and 
pregnancy outcomes using a large sample size.  However, this study is directly linked 
to the TABLET trial; this trial will provide evidence for or against the hypothesis that 
treatment using 50mcg of Levothyroxine for euthyroid women with TPOAb improves 
live birth rates by 10% compared to placebo. 
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Comparisons with existing literature 
When looking at the relationship between age and TPOAb positivity we found there 
was a statistically significant higher mean age for women with TPOAb.  This finding is 
in keeping with results from a meta-analysis of 22 studies looking at thyroid 
autoimmunity and miscarriage122.  The results of the meta-analysis showed that 
women with TAI were found to have slightly higher mean age [age difference, 
1·29 years] (95% CI 0·43–2·16, p=0.003) compared with those without TAI122.  
However, a different systematic review and meta-analysis published in the British 
Medical Journal found no significant difference between the groups (weighted mean 
difference 0.87 years, −0.06 to 1.80 years; p=0.07)19.  As the results of our study 
suggest only a marginal increase in prevalence of TPOAb with increasing age, it is 
difficult to determine a cut off age at which the prevalence of TPOAb becomes higher 
to help identify which women may benefit from screening.  In our study the 
prevalence for women in the highest age group (37-41) was 10.40% compared to 
8.82% in the reference age group (27-31).  In practical terms a difference of 1.58% in 
prevalence of TPOAb between older women and younger women is of questionable 
relevance.  This finding in conjunction with conflicting evidence from existing meta-
analyses looking at age and TPOAb prevalence provides little support for routine 
screening of “older” women. 
 
Existing literature looking at the relationship between thyroid autoimmunity and body-
mass index is limited. A recent large Danish study of over 70,000 participants found 
that BMI is positively correlated with autoimmune diseases; in particular Type 1 
Diabetes123.  However they found no significant relationship between raised BMI and 
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thyroid autoimmune diseases such as Hashimoto’s or Graves disease123.  The 
results of our study have shown that the prevalence of TPOAb was significantly 
higher in women with BMI ≥35 compared to women with normal BMI; furthermore the 
mean BMI for TPOAb positive women was significantly higher than the mean BMI for 
TPOAb negative women.  If evidence from the awaited TABLET trial shows benefit in 
treating euthyroid women with TPOAb then based on the findings of our study it 
would be worth considering offering routine pre-conception TPOAb screening for 
women with BMI ≥35. 
 
When looking at the relationship between ethnicity and TPOAb status the prevalence 
ranged from 3.5% in the mixed population to 12% in “other”.  Both Black and “Other” 
ethnic groups were found to have a statistically significant lower prevalence of 
TPOAb positivity compared to White women.  This finding was consistent with the 
results of the NHANES III study; where a lower prevalence of TPOAb was found in 
African American women compared with White women.  These differences in thyroid 
disease prevalence’s between ethnic groups may be due to different environmental 
exposures, genetics, or a combination of both.  Future work needs to explore 
potential reasons to explain these differences and the corresponding clinical 
implications.  Regarding the implication of universal screening for TPOAb, on the 
basis of the findings of our study and existing literature we can advise against routine 
screening for TPOAb in Black women or mixed race women.  As for South Asian 
women, given the higher prevalence of subclinical thyroid disease in this group (as 
shown in chapter 5), it may be worth testing for TPOAb pre-conception as a 
surrogate marker of potential thyroid disease progression in pregnancy. 
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The final demographic explored was originating population.  Existing literature has 
suggested that the prevalence of TPOAb in women of reproductive age is relatively 
common.  The prevalence in an “unselected” population ranges from 6% to 
20%115,116.  The prevalence is considered to be even higher in women with a history 
of recurrent miscarriage (17-33%)20,21,124 and in women with a history of infertility (10-
31%)112–114.  In contrast to the existing studies the findings of our study suggest no 
significant differences in the prevalence of TPOAb between “lower risk” women i.e. 
those with history of 1 or 2 miscarriages compared with “higher risk” women i.e. with 
infertility or history of recurrent miscarriage.  Furthermore the prevalence of TPOAb 
in all of the main populations (excluding “other”) was much lower than the 
prevalence’s stated in the literature.  The existing literature and table of pooled 
prevalence’s across different populations for TPOAb (as shown in Table 22 in the 
introduction) have shown the prevalence to be around 19%; this is much higher than 
the 9.11% observed in our study.  Furthermore we looked at the prevalence’s for 
select centres that recruited from specific populations.  Guys Hospital in London 
solely recruit from their fertility centre, while St Marys Hospital in Manchester and St 
Bartholomews Hospital in London recruit >90% of their patients from the fertility 
setting; the corresponding prevalence of TPOAb in these centres was 7.5%, 8.4% 
and 9.6% respectively.  These prevalence’s are much lower than the pooled 
prevalence from existing studies showing the prevalence of TPOAb for the infertility 
population to be 18.1% (Table 22).  St Marys Hospital in Paddington is a tertiary 
referral unit and one of the leading centres for recurrent miscarriage, they solely 
recruit from their recurrent miscarriage clinics; the prevalence of TPOAb in this 
population was 7.4%.  Again this is much lower than the data from existing studies 
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suggesting a pooled prevalence of 25.9% for women with recurrent miscarriage.  
Surprisingly, this figure is also much lower than the 19% thyroid antibody prevalence 
found by the team at St Mary’s Paddington themselves in a study they conducted in 
2000125; however that study was focused on thyroglobulin antibodies and thyroid 
microsomal antibodies rather than TPOAb.  It could also be that if the screening was 
not being offered routinely to all patients that there may be some selection bias, 
resulting in a lower than expected prevalence. 
 
As discussed in Chapter 5 one of the central challenges with defining thyroid function 
at present is agreeing on the cut off TSH value to define euthyroidism.  If we 
compare the prevalence of TPOAb in those with TSH 0.44-2.49 (euthyroid 1a) to 
those with TSH 2.5-4.5mU/L (euthyroid 1b) there is a statistically significant greater 
odds of being TPO positive for those with TSH 2.5-4.5mU/L; 6.12% vs. 16.30% (OR 
2.99 (2.48-3.60) p<0.001).  A prevalence of 16.30% indicates that TPOAb are 
common amongst women who have a TSH 2.5-4.5mU/L i.e. an otherwise normal 
thyroid function.  Given the association between TPOAb positivity and increased risk 
of developing thyroid disease in pregnancy, this result supports the notion that 
women with a TSH of >2.5mU/L should potentially be offered routine testing for 
TPOAb and subsequent monitoring of their thyroid function in pregnancy.  
 
Finally we looked at the relationship between TSH concentration and the prevalence 
of TPOAb positivity.  Results showed that overall increasing TSH concentration was 
strongly correlated with a higher prevalence of TPOAb positivity.  This was also 
reflected by the higher prevalences of TPOAb positivity seen in women with 
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moderate SCH and severe SCH.  The graph presented in Figure 34 shows that there 
appears to be a large increase in probability of being TPOAb positive beyond a TSH 
concentration of 2.50mU/L; this increase is even more marked above 4.50mU/L.  
This relationship between increasing TSH concentrations and increased likelihood of 
TPOAb positivity is consistent with what has been shown in existing studies91.  As 
mentioned previously, it may be useful to consider pre-conception TPOAb testing in 
women with TSH values above 2.5mU/L (or even 4.5mU/L as a starting point), 
especially if treatment is not being offered.  Knowing the TPOAb status may then 
help to decide whether the patients thyroid function should be monitored through 
their pregnancy. 
 
Conclusions and future work 
The lack of clarity over whether thyroid antibody testing should be performed 
routinely pre-conception is largely based on the lack of evidence for a treatment with 
known benefit (should the patient test positive). 
 
For a screening test to be offered universally, as mentioned in Chapter 5, a detailed 
list of strict pre-requisites must be met.  Realistically, with the prevalence of TPOAb 
in women of reproductive age shown to be much lower than existing studies 
suggested, there is less of a case for universal screening.  As with thyroid function 
testing, there would have to be careful calculation to decide if the burden of 9.11% of 
the population potentially having pregnancy complications, as a result of 
undiagnosed thyroid autoimmunity, warrants the potential benefit of early detection 
and treatment through implementation of universal screening.  The results of the 
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TABLET trial will inevitably guide decision-making on whether screening should be 
offered more widely; dependent on whether Levothyroxine is proven to be beneficial 
or not.  If Levothyroxine is proven to have benefit in women with TPOAb, based on 
the findings of this study and collated findings from existing studies, we would 
recommend routine TPOAb screening for women with BMI ≥35 and South Asian 
women with TSH concentrations >2.5mU/L.  Given the low prevalence of TPOAb in 
Black women and mixed race women there is no case for universal screening in 
these populations.  Finally, there appears to be no benefit to targeting “high risk” 
populations such as women with infertility or history of recurrent miscarriage in favour 
of women with a history of just one or two miscarriages. 
 
The work from this chapter is directly linked to the national TABLET trial.  The 
TABLET trial is continuing recruitment until December 2015.  We intend to use all the 
data collected within the study, this is anticipated to be >10,000 cases, to give 
provide a greater sample size and examine any differences in more detail.   
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CHAPTER 7 
The effect of subclinical hypothyroidism on IVF 
outcome 
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Introduction 
 
Subclinical hypothyroidism (SCH) is defined as an elevated level of thyroid 
stimulating hormone (TSH) accompanied by a normal level of free thyroxine (FT4) in 
the circulation.  The reported incidence of SCH, in the infertility population has 
ranged between 1-43% with a mean of around 13%15,84; it is dependent upon the 
thresholds used for diagnosis and the iodine status of population.  Observational 
studies have indicated that pregnant women with subclinical hypothyroidism have an 
increased risk of adverse pregnancy outcomes such as miscarriage, perinatal loss, 
preterm birth, pre-eclampsia and low IQ in the offspring17,126.   
 
Debates regarding recommendations to screen for SCH and/or thyroid autoimmunity 
(TAI), and whether abnormal results should be treated pre-conceptually or in 
pregnancy, have been on going for the last two decades.  The work of chapters 5 
and 6 have focused on this issue.  The central challenging question has been 
whether Levothyroxine (LT4) treatment will alter fertility, obstetric or neonatal 
outcomes.  To date there are two randomised controlled trials which have looked at 
infertile women with subclinical hypothyroidism undergoing IVF treatment127,128.  Both 
studies suggested an improvement in birth rates, improvement in implantation of 
embryos and decrease in miscarriage for those women supplemented with LT4 
compared with untreated women 127,128.  The threshold for TSH treatment was 
4.0mU/L in the study by Abdel-Rahman et al and 4.5mU/L in the study by Kim et al.  
However, both studies were very small with only 70 women in Abdel-Rahman et al127 
and 64 women in Kim et al128.  A recent systematic review by Velkeniers et al18 meta-
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analysed the results of the two studies by Kim et al128 and Abdel-Rahman et al127 and 
also included data from a third study, by Negro et al129.  The study by Negro et al 
randomised women if they had TSH values above 4.2mU/L and tested positive for 
thyroid peroxidase antibodies (TPOAb); this was also a small study of only 86 
women129.  The meta-analysis showed that LT4 supplementation versus no treatment 
(or placebo) resulted in a significant increase in delivery rate and implantation rate, 
and a decrease in miscarriage.  
 
Levothyroxine, however, is not without its side effects.  If doses are too high patients 
can experience symptoms of hyperthyroidism, therefore it is imperative that should 
patients be commenced on LT4 that they have regular thyroid function test 
monitoring, pre-conception and during pregnancy.  Furthermore, a study by Browne 
et al of over 14,000 cases found that periconceptual thyroxine medication was 
significantly associated with several congenital birth defects; left ventricular outflow 
tract obstruction heart defects, hydrocephaly, hypospadias, and isolated anorectal 
atresia130.  However, because of evidence for adverse pregnancy outcomes 
associated with subclinical hypothyroidism, a subset of clinicians, particularly fertility 
specialists, prefer to routinely treat SCH.   
 
The real debate lies in defining SCH.  Given this potential benefit from LT4 treatment 
in treating SCH some clinicians are beginning to move towards treating subfertile 
women using even stricter reference ranges for “normal”; i.e. aiming to achieve a pre-
conception TSH of <2.5mU/L, however there is no conclusive evidence to support 
this.  At present the British Thyroid Association have no clear pre-conception 
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recommendations specific to subfertile women.  As discussed in chapter 5, the 
current guidance is to routinely offer treatment if non-pregnant women have a TSH 
>10mU/L.  Following this, the recommendation then jumps straight to pregnancy and 
advises that the target TSH in early pregnancy (i.e. before 12weeks gestation) for 
women who are already on Levothyroxine treatment (for overt thyroid disease) 
should be <2.5mU/L; with close monitoring of thyroid function throughout the 
pregnancy.  This is in-keeping with guidance from the American Thyroid Association 
guidelines for first trimester serum TSH concentration16.  The most commonly 
accepted upper limit of TSH, as per guidance from the United Kingdom National 
External Quality Assessment Service (UK NEQAS), for normal non-pregnant women 
is around 4.5mU/L.  However, there is no clear guidance regarding the treatment of 
subfertile women who are asymptomatic and have a TSH between 4.5-10mU/L, 
although it is stated in the “UK Guidelines for the Use of Thyroid Function Tests” 
published in July 2006 that LT4 treatment may be indicated in women who have TSH 
concentrations in this range and are trying for a pregnancy.  In contrast to the British 
Thyroid Association guidelines, the recent ATA and AACE (American Association of 
Clinical Endocrinologists) guideline advises that treatment with Levothyroxine should 
be considered in women of childbearing age with serum TSH levels between 2.5mU/l 
and the upper limit of normal (or a given laboratory’s reference range) if they are 
planning a pregnancy, including assisted reproduction in the immediate future89.  
However, the American Congress of Obstetricians and Gynaecologists have not 
supported these recommendations.  As there is no consensus in the UK over when 
or how to treat pre-conception subfertile women who have a result between 4.5-
10mU/L (or even 2.5-10mU/L), this decision on whether to treat with LT4 
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replacement or not comes down to the discretion of the clinician and patient 
preference. 
 
In the United States there is an indication from the National Association of Clinical 
Biochemistry (NACB) that it is likely in the future that the upper limit of the TSH 
euthyroid reference range will be reduced to 2.5mU/L for all adults, even without 
pregnancy.  This is based on evidence that more than 95% of rigorously screened 
normal euthyroid volunteers have serum TSH values between 0.4 and 2.5mU/L94.  
Although individuals who have a TSH between 2.5-4.5mU/L may then be classified 
as having subclinical hypothyroidism there is no clear evidence to suggest there are 
any adverse outcomes in this group84.  Studies looking at a pre-conception threshold 
of 2.5mU/L for TSH, in the subfertility population, have shown mixed findings 
regarding the use of LT4 treatment.  A study of 1055 infertility patients, by Reh et al, 
found no differences in clinical pregnancy rates, live birth or miscarriage rates for 
patients undergoing their first IVF cycle when comparing those with a TSH <2.5mU/L 
and those between 2.5 and 4.5mU/L131.  Similarly, a recent study by Chai et al, of 
627 women, also found no differences in miscarriage or live birth rates for those with 
TSH <2.5mU/L compared with those with TSH ≥2.5mU/L; furthermore the thyroid 
autoantibody level did also not affect these IVF outcomes132.  In contrast, a study by 
Fumarola in 2013, of 164 women, found that TSH >2.5mU/L was associated with 
reduced clinical pregnancy rates (22.3% in TSH ≤ 2.5mU/L group versus 8.9% in 
TSH > 2.5mU/L group; p=0.045); although there were no significant differences for 
any other IVF outcome measures133. 
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In view of the lack of clear guidance and inconsistent findings in existing evidence 
regarding when to treat subclinical hypothyroidism preconception in the infertile 
population, this led to the development of our study.  We aimed to investigate the 
effect of treated and untreated subclinical hypothyroidism, of varying thresholds of 
TSH concentration, in women undergoing treatment with assisted reproductive 
technologies.  The purpose of this study was to determine if it is safe practice to allow 
a higher threshold of TSH concentration, than is traditionally used, before 
commencing LT4 treatment pre-conceptually in infertile women with SCH, thus 
challenging the trend of moving towards stricter upper limit TSH thresholds.  
 
Aims and objectives 
1. To compare IVF outcomes for women who are euthyroid (TSH 0.44-
3.63mU/L, fT4 10-21) and women with SCH (TSH >3.63mU/L, fT4 10-21). 
2. To compare IVF outcomes for euthyroid women (TSH 0.44-3.63mU/L, fT4 10-
21) and untreated SCH (TSH 3.64-5.99mU/L, fT4 10-21) 
3. To compare IVF outcomes for women with TSH (<2.5mU/L) and women with 
untreated SCH (2.50-5.99mU/L). 
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Methods 
 
Study design 
This was a prospective cohort study conducted at the Birmingham Women’s Hospital 
Assisted Conception Unit (ACU) between June 2012 and December 2013.  The 
cohort consisted of women undergoing fresh cycle in-vitro fertilisation (IVF) or 
intracytoplasmic sperm injection (ICSI) treatment at the unit during this time period. 
Since June 2012, thyroid function testing and thyroid peroxidase antibody (TPOab) 
testing has been offered routinely to all women being seen in the ACU as part of a 
national multi-centre randomised controlled trial called TABLET.  All women who 
agreed to have their thyroid function and TPO antibody tested gave written consent 
to allow their data to be included in research studies linked to their thyroid function 
blood test, prior to their blood samples being taken.  Furthermore, the Birmingham 
Women’s Hospital research governance department granted ethical approval 
allowing access to patient notes for data extraction. 
  
Eligibility criteria 
The eligibility criteria for this study followed that of the TABLET trial (as discussed in 
chapters 5 and 6).  Women were offered the screening blood test if they were aged 
between 16-41 years, not known to be on treatment for thyroid dysfunction in the 
past or present, not known to have any cardiac disorders and not currently taking 
amiodarone or lithium.   
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Classification of SCH 
The reference range for biochemical euthyroidism was set according to Roche 
Diagnostics manufacturer’s recommended reference ranges published in 2004, 
which was derived from 269 healthy non-pregnant females of the reproductive age 
(20-39years).  This range was 0.44mU/L – 3.63mU/L with a Free T4 of 10.0 – 21.0 
pmol/L (2.5th to 97.5th centile for both).  This is the accepted reference range used for 
the TABLET trial. 
 
Selective allocation of LT4 treatment 
Prior to the commencement of this study, screening for thyroid dysfunction and/or 
thyroid antibody testing was not routine practice within the Birmingham Women’s 
Hospital fertility centre.  Consequently, a local guideline for the fertility unit was 
created regarding the management of any abnormal thyroid function results detected 
incidentally.  The decision was made to classify differing severities of SCH arbitrarily 
based on the concentrations of TSH into “mild”, “moderate” and “severe”.  In order to 
be categorised as having SCH, the free T4 level had to be within the normal range.  
Mild SCH was defined as a TSH between 3.63-5.99mU/L; moderate 6.00-9.99mU/L 
and severe >10mU/L.  It was agreed that for any patient with a TSH above the 
commonly accepted upper limit of 4.5mU/L, who presented with symptoms of 
hypothyroidism, that they should be started on LT4 treatment. TPO antibody testing 
was also performed and reported as: negative ≤59iu; indeterminate 60-99iu; positive 
≥100iu.  Treatment of LT4 was dependent on TSH concentrations alone, with or 
without the presence of TPO antibodies.  This was based on the current lack of 
evidence for whether LT4 therapy improves outcomes for women with thyroid 
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autoimmunity.  The results of the on-going large TABLET trial are eagerly awaited to 
help answer this important clinical question.  Women with “mild” SCH who would not 
be receiving supplementary LT4 treatment prior to their fertility treatment, would have 
their TFT rechecked at their routine 7 week viability scan and would be commenced 
on LT4 treatment, if necessary, to maintain the TSH at <2.5mU/L in the first trimester.  
 
Figure 35 displays the management guideline implemented into the fertility unit from 
June 2012.   
 
NB:  All women commenced on LT4 treatment pre-conception were not to undergo 
any IVF treatment until their TFTs were shown to be within the normal reference 
range.  All women taking LT4 pre-conception were advised to double their dose on 
two days of the week (Monday & Friday) following a positive pregnancy test and then 
the TFT would be checked at the routine 7 week viability scan (empirical dose 
increase).  This was in line with American Thyroid Association recommendations  
based on the findings of the THERPY” trial134.
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Figure 35.  Management Pathway for abnormal thyroid function in BWH Assisted Conception Unit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient to be informed of 
results and letter to GP. 
Advise GP to start LT4 
therapy and/or refer to 
Endocrinologist, 
recheck TFTs in 4-
6weeks and titrate dose 
accordingly. 
Once normal TFTs 
confirmed patient to call 
up ACU to book start 
date for treatment 
GP to refer patient to 
Obstetric Endocrine 
Antenatal clinic following 
positive pregnancy test. 
 
Patient to be informed of results 
and letter to GP. 
If TSH ≥10 – Needs LT4 
treatment prior to cycle, 
commence on 75mcg LT4.  GP 
to titrate dose accordingly. 
If TSH 6.0-9.99 – Needs LT4 
treatment prior to cycle.  To 
commence 50mcg LT4.  GP to 
titrate dose accordingly. 
If TSH 3.64-5.99.  No LT4 
treatment.  Patient to contact 
unit following +ve upt, to have 
TFT checked at 7/40 scan.  
Referral to Obstetric Endocrine 
Antenatal clinic for any TSH 
>2.5 in early pregnancy, LT4 
treatment to be commenced. 
Patient to be informed of 
results and letter to GP. 
Confirm diagnosis by 
checking free T3 
concentration 
If Free T3 elevated – 
advise GP to refer to 
Endocrinologist 
Once normal TFTs 
confirmed patient to call up 
ACU themselves to book 
start date for treatment. 
GP to refer patient to 
Obstetric Endocrine 
Antenatal clinic following 
positive pregnancy test. 
 
 
Patient to be informed of 
results and letter to GP. 
GP to monitor TFTs 
every 3months outside of 
pregnancy 
Patient can commence 
cycle as normal.  GP to 
refer patient to Obstetric 
Endocrine Antenatal 
clinic following positive 
pregnancy test.  
Condition not known to 
be harmful in pregnancy 
but needs regular follow 
up as risk of developing 
overt hyperthyroidism. 
 
Blood test result out of normal reference range 
  (TSH 0.44-3.63mU/L    Free T4 10-21)  
Raised TSH + Reduced T4 
= Overt Hypothyroidism 
Raised TSH + Normal T4 
= Subclinical Hypothyroidism 
Reduced TSH + Elevated T4 
= Overt Hyperthyroidism 
Reduced TSH + Normal T4 
= Subclinical Hyperthyroidism 
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Statistical analysis 
 
The baseline patient characteristics, cycle characteristics and outcome data were 
described giving frequencies with percentages (to one decimal place) for categorical 
outcomes with chi-squared test analysis to test for differences.  For continuous 
variables, means with standard deviations were calculated and differences were 
analysed using students t-test.  To estimate the contribution of thyroid function to live 
birth rate (defined as the birth of one of more living infants) and clinical pregnancy 
(defined as the presence of a gestational sac on ultrasound), univariate and multiple 
logistic regression analyses were performed to calculate odds ratios and 
corresponding 95% confidence intervals.  An enter technique was used for multiple 
logistic regression.  Covariates were preselected when they had a known effect on 
IVF outcome.  Variables added to the model were: age, body mass index, duration 
and cause of infertility, basal FSH, previous history of IVF, previous live birth and 
previous miscarriage. Subgroup analyses were performed comparing the euthyroid 
women (TSH 0.44-3.63mU/L) and untreated SCH women (TSH 3.64-5.99), as well 
as comparing a stricter euthyroid cut off (TSH 0.44-2.5mU/L) against a larger 
untreated group (TSH 2.5-5.99mU/L).   
 
Data were analysed using SPSS (ver. 21.0; SPSS Inc., Chicago).     
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Results 
 
Overall study population 
A total of 944 women seen in the infertility setting provided written consent to thyroid 
function and TPO antibody (TPOAb) testing between June 2012 and December 
2013.  Of this 944, a total of 560 underwent IVF or ICSI treatment by December 
2013.  Of this 560, 36 women were eligible for randomisation into the TABLET trial 
(euthyroid and TPOAb positive).  These 36 women were removed from the analysis 
as we could not un-blind their treatment allocation due to the trial being still in the 
recruitment phase.  A summary flow diagram outlining the patient selection in the 
study is shown in Figure 36.  Amongst women who underwent IVF treatment, 11.7% 
had subclinical hypothyroidism.  Of these, 68.3% had a TSH of 3.63-5.99mU/L and 
the remainder had a TSH equal to or greater than 6.0mU/L.  The latter group were 
those who received LT4 treatment prior to commencing their IVF treatment.   
 
SCH vs. euthyroid 
The baseline characteristics of the cohort are displayed in Table 28, and the cycle 
characteristics and outcome data are displayed in Tables 29 and 30. 
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Figure 36.  Summary of patients in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total women screened for TFT and 
TPO antibody in all fertility clinics at 
BWH between June 2012-Dec 2013 
n = 944 
Euthyroid and 
TPOAb 
negative 
 
n = 454 
Euthyroid and TPOab 
positive (+ve) 
n = 36 
 
(Randomised into 
TABLET Trial and 
removed from analysis)  
Of those screened, total women who 
underwent IVF treatment by Dec 2013 
n = 560 
Women with 
overt thyroid 
disease or 
subclinical 
hyperthyroidism 
n=10 
 
Women with subclinical hypothyroidism (SCH) 
n = 60 
TSH 3.64-5.99mU/L 
(SCH untreated)  
n = 41 
TPOab +ve 
n = 6 
TPOab -ve 
n = 35 
TSH ≥6.0mU/L 
(SCH treated)  
n = 19 
TPOab +ve 
n = 6 
TPOab -ve 
n = 13 
Women who had 
not undergone 
IVF treatment by 
Dec 2013 
n=384 
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Table 28.  Baseline characteristics of the cohort 
 
n (%) or 
Mean (±SD)  
 
  
Women 
with SCH 
 (n=60) 
 
 
Euthyroid 
women 
(n=454) 
 
 
 
P value 
Age 31.9 (4.5) 32.5 (4.2) 
 
0.3 
BMI 25.8 (4.3) 25.1 (4.2) 
 
0.2 
 
Ethnicity   
 
White 
 
27 (45.0%) 221 (48.7%) 
 
0.7 
 
Asian 
 
28 (46.7%) 
 
183 (40.3%) 
 
0.5 
 
Black 
 
2 (3.3%) 
 
24 (5.3%) 
 
0.5 
 
Chinese 
 
2 (3.3%) 
 
7 (1.5%) 
 
0.3 
 
Mixed 
 
0 (0) 
 
5 (1.1%) 
 
0.8 
 
Other 
 
1 (1.7%) 14 (3.1%) 
 
0.6 
Mean TSH concentration (mU/L) 5.83 (3.56) 1.78 (0.70) 
 
  n/a 
Mean T4 concentration (pmol/L) 14.3 (2.5) 15.5 (1.8) 
 
0.001 
Average cycle length (if regular) 25.2 (9.5) 24.8 (10.3) 
 
0.8 
Duration of infertility  
(in completed years) 3.9 (2.7) 4.3 (3.0) 
 
0.2 
Day 2 FSH 7.4 (2.2) 7.5 (2.6) 
 
0.7 
Fibroids  1 (1.7%) 20 (4.4%) 
 
0.3 
 
History of previous IVF 
treatment 14 (23.3%) 122 (26.9%) 
 
 
0.7 
Parity 0.2 (0.4) 0.2 (0.5) 
 
  -- 
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Table 28. continued 
 
 
 
n (%) or 
Mean (±SD)  
 
  
Women 
with SCH 
 (n=60) 
 
 
Euthyroid 
women 
(n=454) 
 
 
 
P value 
History of previous miscarriage 16 (26.7%) 118 (26.0%) 
 
0.9 
History of previous live birth  8 (13.3%) 86 (18.9%) 
 
0.4 
Cause of infertility    
Male factor 32 (53.3%) 213 (46.9%) 
 
0.6 
 
Tubal factor 5 (8.3%) 88 (19.4%) 
 
0.08 
 
Endometriosis  6 (10.0%) 44 (9.7%) 
 
0.9 
 
Anovulation 4 (6.7%) 25 (5.5%) 
 
0.7 
 
Diminished ovarian reserve 2 (3.3%) 27 (5.9%) 
 
0.4 
 
Unexplained 9 (15.0%) 79 (17.4%) 
 
0.7 
Other 0 (0%) 2 (0.4%) 
 
0.8 
Type of treatment    
IVF 25 (41.7%) 219 (49.2%) 
 
0.6 
ICSI 
 
33 (58.3%) 
 
226 (50.8%) 
 
0.7 
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Table 29.  Cycle characteristics of the study cohort 
 Women with 
SCH 
(n=60) 
Euthyroid 
women 
(n=454) 
 
P value 
 
Cycle data 
 
No. of oocytes retrieved  
No. of mature oocytes 
inseminated 
 
Total no. of embryos 
Fertilisation rate* 
No. of embryos transferred 
       0 
       1 
       2 
      
Day of embryo transfer 
Blastocyst transfer 
No. of embryos frozen 
 
 
 
9.0 (4.2) 
7.4 (3.5) 
 
 
1.2 (0.4) 
0.65 (0.19) 
 
1 (1.7%) 
45 (75.0%) 
14 (23.3%) 
 
3.6 (1.4) 
29 (48.3%) 
1.6 (2.1) 
 
 
 
10.4 (5.4) 
8.4 (4.5) 
 
 
1.3 (0.5) 
0.63 (0.23) 
 
17 (3.7%) 
321 (70.7%) 
116 (25.6%) 
 
3.5 (1.4) 
194 (42.7%) 
1.2 (1.8) 
 
 
 
0.02 
0.05  
 
 
0.1 
0.5 
 
0.4 
0.8 
0.8 
 
0.6 
0.6 
0.2 
 
Table 30.  Outcome data for study cohort 
Outcome data 
 
 
 
Implantation rate** 
Biochem preg. 
Clinical preg.  
Miscarriagea 
Live birthb 
       Singletonb 
       Twinsb 
Gestation 
(Mean±SD)      
SCH (n=60) 
(Treated and 
untreated) 
 
0.41 (0.5) 
29 (48.3%) 
23 (38.3%) 
4 (17.4%) 
19 (31.7%) 
17 (28.3%) 
2 (3.3%) 
38.8 (1.7) 
Euthyroid 
(n=454) 
 
 
0.38 (0.5) 
210 (46.3%) 
189 (41.6%) 
24 (12.8%) 
165 (36.3%) 
148 (32.6%) 
17 (3.7%) 
39.0 (1.3) 
 
Odds ratio 
 
 
1.08 (0.63-1.86) 
1.04 (0.65-1.68) 
0.92 (0.55-1.53) 
1.26 (0.42-3.76) 
0.87 (0.50-1.50) 
0.87 (0.49-1.53) 
0.89 (0.20-3.95) 
 
P value 
 
 
0.6 
0.9 
0.8 
0.7 
0.6 
0.6  
0.9 
0.01 
 
 
*Fertilisation rate = no. of embryos / no. of eggs inseminated 
** Implantation rate = no. of foetal hearts on scan / no. of embryos transferred 
a  Expressed as a percentage of all clinical pregnancies 
b  Expressed as a percentage of all cycles 
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The data presented in Table 30 shows that there are no significant differences in the 
outcomes for women undergoing IVF treatment who are either euthyroid or have 
subclinical hypothyroidism diagnosed preconception (regardless of treatment 
received).  The only statistically significant difference noted from the baseline 
characteristics was found in the mean T4 concentration, which showed that women 
with SCH have a lower mean T4 than women who are euthyroid; in-keeping with 
what would be expected physiologically.  The other results of statistical significance 
were for number of oocytes retrieved and number of mature oocytes inseminated, 
both appeared to be significantly lower in women with SCH than in euthyroid women 
(p=0.02 and p=0.048 respectively).  Despite this, there were no differences in 
fertilisation rate, implantation rate, or live births.  Gestation at which the baby was 
delivered was statistically significantly higher for euthyroid women compared with 
women with SCH, however there were no births below 37weeks for any women who 
delivered in the study.  When conducting a multivariate analysis adjusting for age, 
BMI, ethnicity, day2 FSH, cause of infertility, duration of infertility, previous history of 
IVF, previous miscarriage and previous live birth the results remained unchanged, 
there was no statistically significant difference noted between the two groups for the 
primary outcome of live birth (OR 0.94 (0.71-2.24) p=0.6).  
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Untreated SCH vs. euthyroid (TSH 0.44-3.64mU/L) 
To answer the question of whether untreated SCH pre-conceptually could result in 
adverse outcomes compared with euthyroid women, we compared those with a TSH 
0.44-3.64 to the untreated SCH group (TSH 3.64-5.99), the results are shown in 
Table 31.  
 
 
Table 31.  Outcome data comparing euthyroid (TSH<3.64) and untreated SCH 
(3.64-5.99) 
  Mean (±SD) Or n (%)  
 
  
 Untreated 
SCH 
TSH 3.64-
5.99 (n=41) 
Euthyroid  
TSH 0.44-
3.64 
(n=454) 
 
Odds ratio 
 
P 
value 
Outcome data 
Implantation rate 
Biochemical preg 
Clinical prega 
Miscarriageb 
Live birthb 
Gestation 
 
0.44 (0.5) 
22 (53.7%) 
18 (43.9%) 
3 (16.7%) 
15 (36.6%) 
39.0 (1.2) 
 
0.38 (0.5) 
210 (46.3%) 
189 (41.6%) 
24 (12.8%) 
165 (36.3%) 
39.0 (1.3) 
 
 
1.16 (0.67-2.00) 
1.05 (0.59-1.88) 
1.38 (0.40-4.79) 
1.01 (0.54-1.87) 
 
0.5 
0.6 
0.9 
0.6 
1.0 
-- 
 
a  Expressed as a percentage of all clinical pregnancies 
b  Expressed as a percentage of all cycles 
 
There were no statistically significant differences in fertility outcomes for those with 
untreated SCH pre-conception and the euthyroid women with TSH 0.44-3.64mU/L. 
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Untreated SCH vs. euthyroid TSH (0.44-2.5mU/L) 
To further explore the data and help answer the question of whether a stricter cut off 
TSH concentration of 2.5mU/L shows any adverse outcomes in those untreated; we 
compared the euthyroid women TSH 0.44-2.5mU/L with women with a TSH 
concentration between 2.5-5.99mU/L, the results are shown in Table 32.   
 
 
 
Table 32.  Outcome data comparing TSH <2.5 and untreated SCH (2.50-5.99) 
 Mean (SD) Or n (%) 
 
  
 Untreated SCH 
TSH 2.50-5.99 
(n=119) 
Euthyroid  
 
TSH <2.50 
(n=376) 
 
Odds ratio 
 
P 
value 
Outcome data 
Implantation rate 
Biochemical preg 
Clinical preg 
Miscarriagea 
Live birthb 
Gestation 
 
0.44 (0.5) 
57 (47.8%) 
52 (43.7%) 
8 (6.8%) 
44 (36.9%) 
38.8 (1.8) 
 
0.38 (0.5) 
175 (46.5%) 
163 (43.4%) 
18 (4.9%) 
145 (37.8%) 
39.0 (1.2) 
 
 
1.03 (0.72-1.48) 
1.01 (0.69-1.47) 
1.40 (0.60-3.31) 
0.96 (0.65-1.42) 
 
0.3 
0.9 
1.0 
0.4 
0.8 
0.3 
 
 
a Expressed as a percentage of all clinical pregnancies 
b Expressed as a percentage of all cycles 
 
 
The results show no statistically significant differences in fertility outcomes between 
the stricter threshold euthyroid group and the broader “untreated SCH” group. 
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Discussion 
Main findings 
The aim of this study was to determine if fertility outcomes, primarily live birth, were 
different for euthyroid women compared with women with subclinical hypothyroidism 
(SCH).  It is important to note that the euthyroid women were all TPOAb negative, as 
those who were TPOAb positive were randomised into the TABLET trial.  Those with 
subclinical hypothyroidism were composed of TPOAb positive and negative women.  
The group of women with subclinical hypothyroidism comprised of those who were 
treated and those who were untreated; this was dependent on the TSH 
concentration.  The purpose of this distinction was to explore the safety of allowing a 
higher threshold of TSH concentration, challenging the widely accepted upper limits, 
before treating subclinical hypothyroidism in pre-conception women.  The results of 
the study showed there were no significant differences in fertility outcomes for 
women with SCH (both treated and untreated) compared with euthyroid women; 
there were also no significant differences when using a stricter reference range for 
euthyroid (TSH 0.44-2.5mU/L). 
 
The results showed that having a raised TSH appeared to reduce the total number of 
oocytes collected as well as the number of mature oocytes inseminated, despite no 
difference in ovarian reserve (basal FSH) or rates of anovulation to potentially explain 
this.  This reduced response to ovarian stimulation and potentially reduced oocyte 
quality seen in women with SCH may suggest there is a pre-conception defect 
compared to euthyroid women.  If this were the case then only choosing to treat SCH 
in pregnancy would miss this pre-conception window, presuming there is underlying 
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thyroxine related aetiology.  Despite the reduced number of oocytes and mature 
oocytes inseminated seen in women with SCH this did not impact on any of the other 
important fertility outcomes; fertilisation rate, clinical pregnancy rate, miscarriage rate 
or live birth compared to euthyroid women. 
 
Of the 41 women who had SCH but were untreated pre-conceptually, 15 women 
went on to have successful live births, giving a live birth rate of 37%, which is just 
above the national average for women undergoing fertility treatment and similar to 
the euthyroid TPO negative women in the study.  Seven (47%) of those who had a 
successful pregnancy had a persistently raised TSH greater than 2.5mU/L when 
checked at 7weeks gestation.  A potential explanation of why more than half the 
group had a TSH fall to <2.5mU/L in early pregnancy is probably due to a 
combination of factors.  Firstly, we used a different analyser for the TFTs performed 
after the initial screening.  This was because the local trust (Birmingham Women’s 
Hospital) uses a Beckman analyser, however, for the purpose of the TABLET Trial 
(i.e. for the screening test) a Roche analyser had to be used and so these samples 
were sent to a neighbouring hospital (Queen Elizabeth Hospital).  The Beckman 
analyser has no positive bias for TSH unlike the Roche.  From our data on the same 
first trimester samples analysed on both Beckman and Roche it appears as though a 
TSH of 2.5mU/L on Beckman is about equivalent to 4.0mU/L on a Roche in the first 
trimester (personal communication from Dr Shiao Chan).  Secondly, another reason 
to help explain why 8/15 women had lower TSH levels in early pregnancy compared 
to pre-conception, could be due to the physiological fall in TSH that has been 
observed in previous studies in the first 10weeks of pregnancy (with rising levels of 
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hCG).  Cross-sectional studies by Dashe et al135 and Cotzias et al136 showed that the 
upper limit of TSH (defined as the 97.5th population centile) at the start of pregnancy 
is between 4.94-5.09mU/L and then drops to 3.0mU/L by about 10weeks with no 
intervention. 
 
All seven women who were untreated pre-conception (TSH 3.64-5.99mU/L), but 
received treatment from 7weeks onwards, went on to have successful live births and 
they all maintained euthyroidism on LT4 treatment.  The baseline characteristics (i.e. 
age, BMI, basal FSH etc.) and cycle characteristics (i.e. no. of oocytes retrieved, no. 
of mature oocytes inseminated etc.) for these seven women were compared to the 
other eight women who did not require treatment in their pregnancies, to look for any 
potential predictors of who may need treatment in early pregnancy.  No statistically 
significant differences were detected; however this was most likely due to the small 
numbers.   Of these seven women who required treatment in their pregnancy, two 
patients were also thyroid peroxidase antibody positive.  In total there were six 
women who were TPOAb positive and had TSH values between 3.64-5.99mU/L (i.e. 
untreated SCH); four of these women did not conceive.  Given that the two women 
who were TPO positive and did conceive both required LT4 treatment in pregnancy, 
this could suggest that being TPOAb positive with SCH does make it more likely for 
the TSH to go up in pregnancy, however we cannot make any strong conclusions 
due to the very small numbers.  
 
Just over half the women who became pregnant, and did not receive LT4 treatment 
prior to conception, had TSH levels <2.5mU/L in early pregnancy.  In the context of 
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the reference ranges used in this study, our findings show that there is a plausible 
argument for not routinely commencing LT4 treatment pre-conception for all women 
with a TSH 3.64-5.99mU/L and to recheck and treat in early pregnancy (if necessary) 
instead.  Furthermore there is evidence that has shown there are higher risks of 
congenital defects associated with thyroxine medication.  As mentioned in the 
introduction, a large study by Browne et al of over 14,000 cases found that 
periconceptual thyroxine medication was significantly associated with several 
congenital birth defects130.  The findings of our study, and the evidence to suggest 
thyroxine medication may cause congenital defects, supports the notion of not 
empirically treating all cases of SCH.  
 
Given that the seven women with untreated SCH who did require LT4 treatment in 
early pregnancy all went on to have successful live births, this provides some support 
for the case of not treating SCH pre-conception, but rather monitoring and managing 
from early pregnancy instead.  
 
Strengths and limitations 
One of the advantages of this study is the prospective design and rigorous data 
collection; there were no missing entries for any variables.  As thyroid function testing 
was previously not routinely performed in the Birmingham Women’s assisted 
conception unit it lead to the development of a novel guideline, allowing us to 
challenge the growing consensus on treatment of pre-conception subclinical 
hypothyroidism in subfertile women. 
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The main limitation of our cohort study is the small sample size, this may account for 
the non-significant differences found in outcomes between those with SCH and those 
without, resulting in a Type 2 error.  Due to these small numbers, reflected by the 
wide confidence intervals associated with the odds ratios seen in the analyses, we 
cannot draw strong conclusions from this study.  It may be that no differences are 
seen owing to the small numbers, and that using a larger sample size may reveal 
significant differences.   
 
One of the concerns regarding subclinical hypothyroidism is impaired neurological 
development in the foetus137.  However, the long-term impact on the child, including 
neurodevelopmental effects, was not determined by our study.  A landmark trial, 
published in the New England Journal of Medicine, studied thyroid function and IQ 
scores of children at three years of age90.  A total of 794 women with Thyrotropin 
levels above the 97.5th percentile and free T4 levels below the 2.5th percentile were 
randomised from around 12-13weeks in pregnancy90.  This study showed no benefit 
in the use of Levothyroxine in improving cognitive function in children born to 
hypothyroid women (as detected in pregnancy) compared to the children of untreated 
women90.  Consequently this leads us to question what value Levothyroxine 
treatment would have for improving childhood neurodevelopmental outcomes for 
children born from women with subclinical thyroid disease if no apparent benefit is 
seen with children born from women treated for overt disease. 
A final limitation is that women who were euthyroid pre-conception (TSH 0.44-
3.63mU/L) and those who had an optimal TSH in the 1st trimester range (i.e. 
<2.5mU/L) did not have their thyroid function repeated later in pregnancy to see if it 
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remained in euthyroid range.  The reason for this was that no clinical benefit was 
thought to be gained from re-testing known euthyroid individuals throughout their 
pregnancy and the consensus amongst the clinicians when creating the initial 
guideline was to only repeat blood test for abnormal results, as per normal practice. 
 
Comparison to existing literature 
The current NICE guidelines state that measurement of thyroid function in 
asymptomatic women with infertility, as the only isolated risk factor, should not be 
offered routinely16,138.  This is due to the lack of strong evidence regarding adverse 
IVF and pregnancy outcomes for women with subclinical thyroid disease and also the 
lack of evidence proving any benefit from treating such women pre-conception.  
 
The findings of our cohort study suggest that it may be safe to allow a higher 
threshold of subclinical hypothyroidism before considering treatment for pre-
conception subfertile women; however this conclusion must be interpreted with 
caution given the small sample size of the study.  This “higher threshold” is of course 
an arbitrary value but based on our work we can say that a TSH concentration up to 
6.0mU/L may be safe to leave untreated as long as the thyroid function test is 
checked again in early pregnancy; or if a woman does not become pregnant it should 
be re-checked in around 3months time.  This is based on what we know of the 
natural progression of SCH with studies reporting progression to overt disease in 2-
5% and reversal to normal in as many as 62% after 5 years follow up139,140.     
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Only three trials to date have looked at the effect of LT4 treatment in subfertile 
women with subclinical hypothyroidism127–129.  The upper limits of TSH used in the 
studies by Negro et al, Abdel-Rahman et al and Kim et al were 4.2mU/L, 4.2mU/L 
and 4.0mU/L respectively127–129.  When the results of these studies were meta-
analysed it showed that LT4 supplementation in women with SCH resulted in a 
significant increase in delivery rates and a decrease in miscarriage compared to 
women who did not receive treatment.  This finding is in contrast to our cohort study, 
which showed no difference in live birth or miscarriage rates between the treated and 
untreated women; furthermore we used a higher threshold for treatment (TSH 
≥6.0mU/L).  In addition, our study found that having a raised (and untreated) TSH 
appeared to reduce the total number of oocytes collected as well as the number of 
mature oocytes inseminated, however the meta-analysed data of the three trials 
showed no difference between women treated and women untreated for these 
outcomes.  One of the reasons for the discrepancies in our results compared with 
those of the meta-analysis is that our study is limited by sample size and so may be 
underpowered to show any differences; 60 women with SCH in our cohort vs. 220 
women in the meta-analysed data.  It is evident that larger numbers are required to 
accurately determine whether pre-conception LT4 treatment of subclinical 
hypothyroidism can improve outcomes for women undergoing assisted reproduction. 
 
 
Conclusions and future work 
This cohort study utilised thyroid function tests taken from patients being screened 
for the national TABLET trial.  This trial is continuing recruitment until December 
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2015.  The aim will be to collect all the outcome data for the women screened in the 
fertility setting and add to this analysis to give greater power and examine any 
differences in more detail.  Ethical approval has been obtained for this.  We 
anticipate that a further 1500 women will have been screened in the fertility setting in 
the Birmingham Womens Hospital by December 2015.  By the end of December 
2015 we would anticipate a total of 1700 euthyroid women and 240 with SCH; 
providing us with the largest cohort study of this kind.  Using live birth rate as the 
primary outcome, to see a minimally important difference of 5% between euthyroid 
women and women with SCH (37% vs. 32%) this sample size will have 57% power 
with an alpha of 0.05.  In order to reach 80% power the sample size would have to 
increase by 1.8 times to 2890 euthyroid women and 432 women with SCH to detect 
the 5% difference between 32% and 37% for an alpha of 0.05.  This will be possible 
through collaboration with the other large fertility units participating in the TABLET 
trial (i.e. Guy’s Hospital London, St Bartholomews Hospital London and St Marys 
Hospital Manchester).  These centres would have all prospectively collected thyroid 
function tests on several thousand pre-conception subfertile women, we have 
permission from the corresponding principal investigators for each site and the local 
research and development units to have access to these results and the necessary 
fertility outcome data.  Although this collaboration will provide a greater sample size, 
due to the individual units having differing management pathways for treating SCH, 
collating the results will be problematic.  What is needed is a large, appropriately 
powered multi-centre randomised controlled trial, including women from the fertility 
setting, to investigate if pre-conception Levothyroxine supplementation in women 
with subclinical hypothyroidism improves fertility and pregnancy outcomes.  
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Furthermore, the decision on whether to use the strict upper limit for TSH of 2.5mU/L 
or the currently recognised 4.5mU/L would also need to be considered carefully.   
It is important for us to continue work in this area to understand the implications of 
subclinical hypothyroidism in subfertile women so that we can make better informed 
decisions on whether to treat or not. 
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CHAPTER 8 
Discussion 
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There are many factors that can affect IVF outcome, the work of this thesis has 
focused solely on pre-treatment factors and the impact of certain important under-
investigated factors on IVF outcome.  The three key factors explored in this thesis 
were ethnicity, body-mass index (BMI) and thyroid function.  All three factors are 
common, easily available and contribute important information that can impact on 
decision making for both patients and clinicians before achieving a pregnancy.    
 
Ethnicity and IVF outcome; summary of findings and future work 
The relationship between ethnicity and assisted reproduction has been disputed for 
some time with various studies showing conflicting results.  The results of the 
systematic review, cohort study and updated meta-analysis presented in chapters 2 
and 3 provide robust evidence for the hypothesis that there is an association 
between ethnic background and IVF success.  The work of this thesis shows that 
Black and South Asian women have a statistically significant reduced chance of live 
birth following fresh IVF treatment (when compared with White women) and the 
commonly known confounders do not explain this.  For Black women, the odds of 
having a clinical pregnancy are also reduced when compared to White women.  
However, for South Asian women it appears that there are no differences in clinical 
pregnancy rates compared to White women.  This suggests that South Asian women 
are more likely to suffer miscarriage compared to White women.  Interestingly, for the 
Black population, when the frozen cycles were analysed separately from the fresh 
cycles the results showed no difference in live birth or clinical pregnancy rates 
compared with White women.  This poses the question of whether Black women 
would perform better if an “elective freeze” approach was used; i.e. all embryos to be 
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routinely frozen and implanted at a later date.  This suggestion of elective freeze for 
all women is currently proving popular amongst reproductive medicine clinicians and 
was discussed at this year’s European Society for Human Reproduction and 
Embryology (ESHRE) conference in Lisbon.  Consequently, the findings of the work 
in this thesis should certainly prompt clinicians to consider trialling this change in 
practice, certainly in the first instance with Black women.  Furthermore, the findings 
of this study should prompt investigation into the mechanisms underpinning the 
disparities seen between ethnic groups; thus allowing for modification of laboratory 
and or clinical practice to improve IVF outcome for all ethnicities.  Finally, there also 
needs to be careful consideration of whether information regarding ethnicity and its 
potential affect on IVF outcome should be routinely provided to patients as part of 
pre-treatment counselling.  Although this is not a factor that women are able to 
change, it may still have implications on their decision-making. One must be cautious 
when providing this information to patients as there is an argument to state that if 
NHS funding criteria are dictated by predictors that are associated with poorer 
chances of success (i.e. age >38, BMI >30 and smoking) then why should ethnicity 
not be included?  Given the potential controversy that may surround counselling on 
the basis of ethnicity, we would advise that this should be a decision to be made by 
individual clinicians when counselling their patients.   
 
BMI and IVF outcome; summary of findings and future work 
The relationship between raised BMI and adverse pregnancy outcomes is well 
known13, however there remains debate over the association between BMI and IVF 
outcomes.  The aim of the work in this thesis was to determine to what degree BMI 
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affects IVF outcome, and the interplay of this with other factors.  This was 
investigated by the creation of a prediction model to estimate the chances of live birth 
following IVF, incorporating BMI as a predictor.  To date, successful prediction of live 
birth after assisted reproductive technology (ART) has been limited and so far no 
model has accounted for BMI.  We developed a novel model, which encompasses 
key prognostic factors that have not previously been used; such as ovarian reserve 
and ethnicity.  The association between BMI and live birth following IVF, was strong 
when looked at in the univariate analysis; however this association became non-
significant when other important confounders were adjusted for in the final model.  
Despite this, we have demonstrated that there is still value in counseling women to 
lose weight, as shown in chapter 4 there was around a 5% reduction in chance of live 
birth (as calculated by our model) for women with a BMI >30 compared to women 
with a normal BMI.  We believe this model, once converted into a user-friendly mobile 
application and or web-page, will hold an important role in the counseling and 
decision making for women at the critical decision-making point in their journey, i.e. 
before they embark on their first treatment cycle.  Furthermore, this model provides a 
personalised approach to counselling and estimates chances of success based on 
easily measurable variables that are specific to the individual woman; rather than 
using success rates based on age-related national HFEA data.  Future work will 
involve further external validation in the form of geographical validation and then 
conversion of the model into a mobile application and/or web-page for utility by 
clinicians and patients.  Once this is undertaken, the next step would be to assess 
impact analysis; establish whether the prediction model improves decisions, in terms 
of quality or cost-effectiveness of patient care69,70.  No existing IVF prediction models 
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have reached the impact analysis stage to date.  As this model is limited to pre-
treatment variables only, there is a need for future work to be conducted to explore 
models that incorporate treatment variables; thus allowing for adjusted calculations 
as the patient progresses through their treatment. 
 
Thyroid function and autoimmunity; summary of findings and future work 
The final aspect of the PhD focused on the prevalence of thyroid dysfunction and 
thyroid autoimmunity and also the effect of subclinical thyroid disease on IVF 
outcome.  The work in these chapters also explored the relationship between thyroid 
dysfunction/autoimmunity and BMI and ethnicity, linking all three key factors within 
the thesis together.  This prevalence work looked at a broader group of women 
actively trying for a pregnancy, including women with history of one or two 
miscarriages and women with recurrent miscarriage; as well as those with infertility.    
 
At present there is debate over whether screening pre-conception women for thyroid 
disease should become universal.  This is in view of the adverse pregnancy 
outcomes seen for women with thyroid disease (including both overt and subclinical).  
The argument for the case of universal screening is that these women may be 
missed if not routinely screened, and therefore would not receive the appropriate 
treatment required to potentially avoid or reduce negative pregnancy outcomes.  This 
argument holds more strength for the cases of undiagnosed overt thyroid disease (as 
these are the group of women over whom there is no debate regarding treatment), 
however our study has shown this to be prevalent in only 0.38% of women.  Does the 
financial and practical burden of screening all women to pick up 0.38% outweigh the 
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benefits from potentially reducing adverse obstetric outcomes for these women?  The 
bigger question relates to the screening and or treatment of subclinical disease.  
Using an upper limit cut off of 2.5mU/L for subclinical hypothyroidism would result in 
around 20% of women potentially requiring monitoring and/or treatment of their 
thyroid in pregnancy, which could constitute a significant burden to the NHS.  
Subclinical hypothyroidism is linked to adverse pregnancy outcomes, as discussed in 
chapters 5 and 7; however the findings of our cohort study in chapter 7 did not show 
any differences in fertility or pregnancy outcomes between women with treated SCH 
(using Levothyroxine) and the untreated women.  The main limitation of this cohort 
study was the sample size.  The study will have a greater sample size when the 
whole dataset is analysed and will hopefully provide greater insight into the question; 
recruitment will continue until the end of December 2015. 
 
Based on the findings of the prevalence work in chapters 5 and 6 our findings 
suggest that screening for thyroid disease would be more effective as selective “case 
finding” screening rather than routine.  The “high risk” groups in particular depend on 
the thyroid disease.  In general it appears that South Asian woman and women with 
a BMI above normal have the highest prevalence’s of subclinical hypothyroidism, and 
Black women have the highest rates of hyperthyroid disease (both subclinical and 
overt); therefore these groups should be considered for TFT testing prior to 
conception.  Having said this, it may well be that South Asian women having higher 
TSH concentrations and Black women having lower TSH concentrations are in fact 
variants of normal.  Further work needs to be conducted to explore this and to look at 
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developing population-based reference ranges to account for the relevant ethnic 
groups. 
     
Finally, linked to thyroid disease is thyroid autoimmunity.  The presence of TPOAb 
have strongly been linked to increased rates of miscarriage and pre-term birth19.  
However, as seen for subclinical thyroid disease there is limited conclusive evidence 
to suggest that there is any benefit in reducing these adverse outcomes using 
Levothyroxine treatment.  Regarding pre-conception screening for TPOAb, there 
appeared to be a very subtle link between TPOAb positivity and increasing age, 
however no real cut off could be defined and the association was weak so we would 
conclude that age alone is not useful in determining which women should be 
screened.  Regarding BMI, the results of our study have shown that the prevalence 
of TPOAb was significantly higher in women with BMI ≥35 compared to women with 
normal BMI; furthermore the mean BMI for TPOAb positive women was significantly 
higher than the mean BMI for TPOAb negative women.  If evidence shows benefit in 
treating euthyroid women with TPOAb then based on the findings of our study it may 
be worth considering offering routine pre-conception TPOAb screening for women 
with BMI ≥35.  Interestingly Black and Mixed race women appear to have the lowest 
prevalence of TPO antibodies and so routine TPOAb screening for these women 
would not be advised.  There did not appear to be an association between TPOAb 
positivity and clinical originating population (i.e. whether the woman had a history of 
recurrent miscarriage or infertility) and so we would not advise specifically targeting 
these women in favour of women with a history of 1 or 2 miscarriages.  Lastly, 
increasing TSH concentration appeared to be associated with increased probability; 
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in particular the probability of being TPOAb positive seems to increase with a TSH 
level above 2.5mU/L.  Therefore, it may be worth considering TPOAb screening 
women who have TSH values >2.5mU/L; in particular it may be worth targeting South 
Asian women who are known to have higher TSH concentrations. 
 
Ultimately, large randomised controlled trials (like the awaited TABLET trial) are 
needed to help answer the question of whether pre-conception treatment of 
subclinical thyroid disease and thyroid antibodies improves pregnancy outcomes 
when compared with no treatment.  The findings of such studies will then guide 
decision-making on whether pre-conception thyroid screening should become more 
widely available. 
 
Conclusion 
Couples undergoing assisted reproductive technologies often experience great 
emotional and financial burden and the decision to undergo IVF can be challenging.  
It is therefore crucial that women are well informed about their chances of success 
and that they are appropriately stratified, investigated and managed before 
commencing their fertility treatment.  The work presented in this thesis has adopted a 
mixed methodological approach to provide new information, as well as challenge 
existing evidence, regarding the impact of ethnicity and BMI on IVF outcome.  
Furthermore, it has lead to the development of a novel IVF counselling tool for 
implementation in clinical practice.  And finally this work has provided new 
information (and disproved existing information) regarding the prevalence of thyroid 
dysfunction and autoimmunity in women of reproductive age in the UK, including 
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those undergoing assisted reproduction, to help guide screening programmes.  The 
findings of this compilation of work will hopefully further educate patients and 
clinicians and aid effective counselling and clinical decision-making prior to achieving 
a pregnancy. 
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Appendix 1. Complete case multivariate logistic regression model for live birth (n=2911) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Parameter 
Estimates 
   
 95% CI 
 
 
Standard 
Error P value Odds Ratio Lower Upper 
Age 
      
≤36 years -0.0234409 0.014 0.08 0.98 0.95 1.00 
>36 years -0.1860316 0.029 <0.001 0.83 0.78 0.88 
       
Body mass index -0.0094761 0.011 0.4 0.99 0.97 1.01 
       
Cause of infertility:       
Male factor 0.1142310 0.108 0.3 1.12 0.91 1.38 
Tubal factor -0.1280070 0.123 0.3 0.88 0.69 1.12 
Anovulation -0.0852442 0.145 0.6 0.92 0.69 1.22 
Unexplained 0.1503198 0.131 0.3 1.16 0.90 1.50 
Other (e.g. Endo, 
fibroids) 
0.0430051 0.105 0.7 1.04 0.85 1.28 
       
Ethnicity:       
White 0 
  
Reference 
  
Asian -0.0818836 0.159 0.6 0.92 0.67 1.26 
Black -0.9654467 0.418 0.02 0.38 0.17 0.86 
Chinese 0.7115788 0.569 0.2 2.04 0.67 6.22 
Other -0.7086007 0.398 0.08 0.49 0.23 1.07 
Not stated 0.1056809 0.419 0.8 1.11 0.49 2.53 
Mixed -0.0308901 0.207 0.9 0.97 0.65 1.46 
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Appendix 1 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Parameter 
Estimates 
   
 95% CI 
 
 
Standard 
Error P value Odds Ratio Lower Upper 
Previous Live Birth 
No 
Yes 
 
0 
0.3073074 
 
 
0.123 
 
 
0.01 
 
Reference 
1.36 
 
 
1.07 
 
 
1.73 
       
Previous Miscarriage 
No 
Yes 
 
0 
-0.0329350 
 
 
0.106 
 
 
0.8 
 
Reference 
0.97 
 
 
0.79 
 
 
1.19 
       
AFC 0.0366093 0.009 <0.001 1.04 1.02 1.06 
AFC (squared) -0.0004876 0.000 <0.001 1.00 1.00 1.00 
       
Duration of infertility:       
0-4 years 0   Reference   
5≤ years -0.0653509 0.031 0.04 0.94 0.88 1.00 
 
Constant 
 
-0.1601944 
 
0.547 
 
0.8 
 
0.85   
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Appendix 2.  Calibration and internal validation for complete dataset prediction 
model (n=2911)  
 
 
Predicted probability of live birth 
 
Observed probability of live birth plotted against predicted probability of Live 
Birth for each tenth of predicted probability. 
 
 
 
 
 
 
This model was internally validated using a bootstrapping technique.  The 
optimism adjusted c-statistic (AUROC curve) for this was 0.62 and the 
optimum adjusted calibration slope was 1.18. 
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Appendix 3.  Prevalence study consent form  
 
 
 
 
 
      
Blood Screening Consent Form 
 
I confirm that I have read and understand the participant screening information 
sheet dated 26/3/2012 version 4.0 for the above study. I have had the opportunity 
to consider the information, ask questions and these have been answered 
satisfactorily. 
 
I agree to provide a blood sample for thyroid antibody and thyroid function 
testing. 
 
I understand that the thyroid test results and data collected at screening will be 
anonymised, and looked at by researchers at The University of Birmingham, and 
I give my permission for these individuals to have access to my anonymised 
information. 
 
I understand that sections of any of my medical notes may be looked at by 
responsible individuals from the research team, regulatory authorities or from the 
NHS Trust where it is relevant to my taking part in research. I give permission for 
these individuals to have access to my records. 
 
I understand that my participation is voluntary and that I am not obliged to take 
part in the subsequent trial, and that my medical care or legal rights will not be 
affected. 
 
_________________________ _______________  ________________________ 
Name of Patient   Date   Signature 
 
_________________________ _______________  ________________________ 
Name of Researcher   Date   Signature 
 
3 Copies of consent Forms: 1 copy for patient, 1 copy for site file, 1 copy to be kept in 
patient’s hospital notes  
 
 
 
 
 
 
  
Please initial 
boxes 
  
  
  
Thyroid AntiBodies and 
LEvoThyroxine Study 
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Appendix 4.  Prevalence study protocol 
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  241 
  242 
  243 
 
  244 
  245 
 
  246 
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Appendix 5.  Ethical approval for prevalence study from Berkshire B REC 
 
  249 
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Appendix 6.  Prevalence of euthyroid 1 (TSH 0.44-4.50 and T4 10-21) 
   95% CI  
Subgroup Proportion % Prevalence Lower Upper 
     
Age (n=6717) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
172/181 
847/888 
1937/2016 
2402/2515 
1359/1422 
 
95.03% 
95.38% 
96.08% 
95.51% 
95.57% 
 
90.77% 
93.79% 
95.14% 
94.62% 
94.37% 
 
97.70% 
96.67% 
96.89% 
96.28% 
96.58% 
 
BMI (n=6060) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
129/132 
2996/3117 
1775/1862 
739/769 
421/445 
 
 
97.73% 
96.12% 
95.33% 
96.10% 
94.61% 
 
 
93.50% 
95.38% 
94.27% 
94.48% 
92.08% 
 
 
99.53% 
96.77% 
96.24% 
97.35% 
96.51% 
 
Ethnicity (n=6717) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
4665/4863 
478/506 
1165/1236 
93/96 
143/146 
173/175 
 
 
95.93% 
94.47% 
94.26% 
96.88% 
97.95% 
98.86% 
 
 
95.33% 
92.10% 
92.81% 
91.14% 
94.11% 
95.93% 
 
 
96.47% 
96.29% 
95.49% 
99.35% 
99.57% 
99.86% 
 
Population (n=6599) 
EPAU 
Infertility 
Recurrent misc. 
Other 
 
 
2117/2231 
3049/3171 
1357/1419 
76/77 
 
 
94.89% 
96.15% 
95.63% 
98.70% 
 
 
93.89% 
95.42% 
94.43% 
92.98% 
 
 
95.77% 
96.79% 
96.63% 
99.97% 
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Appendix 7.  Prevalence of euthyroid 1a (TSH 0.44-2.49 and T4 10-21) 
   95% CI  
Subgroup Proportion % Prevalence Lower Upper 
 
Age (n=5490) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
 
147/181 
699/888 
1575/2016 
1951/2515 
1118/1422 
 
 
81.22% 
78.72% 
78.13% 
77.57% 
78.62% 
 
 
74.75% 
75.87% 
76.26% 
75.89% 
76.40% 
 
 
86.63% 
81.37% 
79.91% 
79.19% 
80.73% 
 
BMI (n=4961) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
103/132 
2478/3117 
1469/1862 
579/769 
332/445 
 
 
78.03% 
79.50% 
78.89% 
75.29% 
74.61% 
 
 
70.00% 
78.04% 
76.97% 
72.09% 
70.29% 
 
 
84.77% 
80.90% 
80.73% 
78.30% 
78.59% 
 
Ethnicity (n=5490) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
3836/4863 
416/506 
898/1236 
75/96 
126/146 
139/175 
 
 
78.88% 
82.21% 
72.65% 
78.13% 
86.30% 
79.43% 
 
 
77.71% 
78.60% 
70.08% 
68.53% 
79.64% 
72.68% 
 
 
80.02% 
85.45% 
75.12% 
85.92% 
91.43% 
85.16% 
 
Population (n=5399) 
EPAU 
Infertility 
Recurrent misc. 
Other 
 
 
1749/2231 
2454/3171 
1133/1419 
63/77 
 
 
78.40% 
77.39% 
79.84% 
81.82% 
 
 
76.63% 
75.89% 
77.66% 
71.38% 
 
 
80.09% 
78.83% 
81.90% 
89.69% 
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Appendix 8.  Prevalence of euthyroid 1b (TSH 2.5-4.5 and T4 10-21)  
   95% CI  
Subgroup Proportion % Prevalence Lower Upper 
 
Age (n=1227) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
 
25/181 
148/888 
362/2016 
451/2515 
241/1422 
 
 
13.81% 
16.67% 
17.96% 
17.93% 
16.95% 
 
 
9.14% 
14.27% 
16.30% 
16.45% 
15.03% 
 
 
19.71% 
19.28% 
19.70% 
19.49% 
19.00% 
 
BMI (n=1099) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
26/132 
518/3117 
306/1862 
160/769 
89/445 
 
 
19.70% 
16.62% 
16.43% 
20.81% 
20.00% 
 
 
13.29% 
15.33% 
14.78% 
17.99% 
16.38% 
 
 
27.51% 
17.97% 
18.20% 
23.85% 
24.02% 
 
Ethnicity (n=1227) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
829/4863 
62/506 
267/1236 
18/96 
17/146 
34/175 
 
 
17.05% 
12.25% 
21.60% 
18.75% 
11.64% 
19.43% 
 
 
16.00% 
9.52% 
19.34% 
11.51% 
6.93% 
13.85% 
 
 
18.13% 
15.43% 
24.00% 
28.00% 
17.99% 
26.08% 
 
Population (n=1221) 
EPAU 
Infertility 
Recurrent misc. 
Other 
 
 
368/2231 
595/3171 
224/1419 
34/77 
 
 
16.49% 
18.76% 
15.79% 
44.16% 
 
 
14.98% 
17.42% 
13.93% 
32.84% 
 
 
18.10% 
20.17% 
17.79% 
55.93% 
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Appendix 9.  Prevalence of overt hypothyroidism (TSH >4.50 and T4 <10)  
   95% CI  
Subgroup Proportion % Prevalence Lower Upper 
 
Age (n=9) 
22-26 
27-31 
32-36 
37-41 
No cases in 16-21 
 
 
2/888 
2/2016 
4/2515 
1/1422 
 
 
0.23% 
0.10% 
0.16% 
0.07% 
 
 
0.03% 
0.01% 
0.04% 
0.00% 
 
 
 
0.81% 
0.36% 
0.41% 
0.39% 
 
BMI (n=7) 
18.5-24.9 
25-29.9 
≥35 
No cases in <18.5 or 
30-34.9 
 
 
2/3117 
4/1862 
1/445 
 
 
0.06% 
0.21% 
0.22% 
 
 
0.01% 
0.06% 
0.01% 
 
 
0.23% 
0.55% 
1.25% 
 
Ethnicity (n=9) 
White 
Black 
No cases in any 
other ethnic groups 
 
 
7/4863 
2/506 
 
 
0.14% 
0.40% 
 
 
0.06% 
0.05% 
 
 
 
0.30% 
1.42% 
 
 
Population (n=9) 
EPAU 
Infertility 
Recurrent misc. 
No cases in “Other” 
 
 
3/2231 
4/3171 
2/1419 
 
 
0.13% 
0.13% 
0.14% 
 
 
0.03% 
0.03% 
0.02% 
 
 
 
0.39% 
0.32% 
0.51% 
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Appendix 10.  Prevalence of overt hyperthyroidism (TSH <0.44 and T4 >21)  
   95% CI  
Subgroup Proportion % Prevalence Lower Upper 
 
Age (n=18) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
 
2/181 
3/888 
5/2016 
6/2515 
2/1422 
 
 
1.10% 
0.34% 
0.25% 
0.24% 
0.14% 
 
 
0.13% 
0.07% 
0.08% 
0.09% 
0.02% 
 
 
3.93% 
0.98% 
0.58% 
0.52% 
0.51% 
 
BMI (n=15) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
No cases in ≥35 
 
 
1/132 
11/3117 
3/1862 
1/769 
 
 
 
0.76% 
0.35% 
0.16% 
0.13% 
 
 
 
0.02% 
0.18% 
0.03% 
0.00% 
 
 
 
4.15% 
0.63% 
0.47% 
0.72% 
 
 
Ethnicity (n=18) 
White 
Black 
South Asian 
No cases in any 
other ethnic groups 
 
 
10/4863 
2/506 
6/1236 
 
 
0.21% 
0.40% 
0.49% 
 
 
 
0.10% 
0.05% 
0.18% 
 
 
0.38% 
1.42% 
1.05% 
 
Population (n=9) 
EPAU 
Infertility 
Recurrent misc. 
No cases in “Other” 
 
 
3/2231 
4/3171 
2/1419 
 
 
0.13% 
0.13% 
0.14% 
 
 
0.03% 
0.03% 
0.02% 
 
 
0.39% 
0.32% 
0.51% 
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Appendix 11.  Prevalence of moderate SCH (TSH 4.51-10 and T4 10-21)  
   95% CI  
Subgroup Proportions % Prevalence Lower Upper 
 
Age (n=147) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
 
3/181 
19/888 
33/2016 
57/2515 
35/1422 
 
 
1.66% 
2.14% 
1.64% 
2.27% 
2.46% 
 
 
0.34% 
1.29% 
1.13% 
1.72% 
1.72% 
 
 
4.77% 
3.32% 
2.29% 
2.93% 
3.41% 
 
BMI (n=134) 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
No cases in <18.5 
 
 
47/3117 
43/1862 
21/769 
13/445 
 
 
1.51% 
2.31% 
2.73% 
2.92% 
 
 
1.11% 
1.68% 
1.70% 
1.56% 
 
 
2.00% 
3.10% 
4.14% 
4.94% 
 
Ethnicity (n=147) 
White 
Black 
South Asian 
Chinese 
Mixed 
Other 
 
 
96/4863 
7/506 
40/1236 
1/96 
2/146 
2/175 
 
 
1.97% 
1.38% 
3.24% 
1.04% 
1.37% 
1.14% 
 
 
1.60% 
0.56% 
2.32% 
0.03% 
0.17% 
0.14% 
 
 
2.41% 
2.83% 
4.38% 
5.67% 
4.86% 
4.07% 
 
Population (n=144) 
EPAU 
Infertility 
Recurrent misc. 
Other 
 
 
45/2231 
67/3171 
31/1419 
1/77 
 
 
2.02% 
2.11% 
2.18% 
1.30% 
 
 
1.47% 
1.64% 
1.49% 
0.03% 
 
 
2.69% 
2.68% 
3.09% 
7.02% 
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Appendix 12.  Prevalence of severe SCH (TSH >10.0 and T4 10-21)  
   95% CI  
Subgroup Proportions % Prevalence Lower Upper 
 
Age (n=5) 
22-26 
27-31 
37-41 
No cases in 16-21 
or 32-36 
 
 
8/888 
2/2016 
3/1422 
 
 
0.90% 
0.10% 
0.21% 
 
 
0.39% 
0.01% 
0.04% 
 
 
1.77% 
0.36% 
0.62% 
 
BMI (n=5) 
18.5-24.9 
25-29.9 
≥35 
No cases in <18.5 or 
30-34.9 
 
 
1/3117 
1/1862 
3/445 
 
 
0.03% 
0.05% 
0.67% 
 
 
0.00% 
0.00% 
0.14% 
 
 
0.18% 
0.30% 
1.96% 
 
Ethnicity (n=5) 
White 
South Asian 
No cases in any 
other ethnic groups 
 
 
3/4863 
2/1236 
 
 
0.06% 
0.16% 
 
 
 
 
0.01% 
0.02% 
 
 
0.18% 
0.58% 
 
Population (n=5) 
EPAU 
Infertility 
No cases in 
“Recurrent misc.” or 
“Other” 
 
 
3/2231 
2/3171 
 
 
0.13% 
0.06% 
 
 
 
0.03% 
0.01% 
 
 
0.39% 
0.23% 
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Appendix 13.  Prevalence of subclinical hyperthyroidism (TSH <0.44 & T4 10-
21)  
   95% CI  
Subgroup Proportions % Prevalence Lower Upper 
 
Age (n=90) 
16-21 
22-26 
27-31 
32-36 
37-41 
 
 
2/181 
14/888 
21/2016 
36/2515 
17/1422 
 
 
1.10% 
1.58% 
1.04% 
1.43% 
1.20% 
 
 
0.13% 
0.86% 
0.65% 
1.00% 
0.70% 
 
 
3.93% 
2.63% 
1.59% 
1.98% 
1.91% 
 
BMI (n=79) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
≥35 
 
 
2/132 
42/3117 
28/1862 
2/769 
5/445 
 
 
1.52% 
1.35% 
1.50% 
0.26% 
1.12% 
 
 
0.18% 
0.97% 
1.00% 
0.03% 
0.37% 
 
 
5.37% 
1.82% 
2.17% 
0.94% 
2.60% 
 
Ethnicity (n=81) 
White 
Black 
South Asian 
Chinese 
Mixed 
No cases for “Other” 
 
 
55/4863 
12/506 
11/1236 
2/96 
1/146 
 
 
1.13% 
2.37% 
0.89% 
2.08% 
0.68% 
 
 
0.85% 
1.23% 
0.45% 
0.25% 
0.02% 
 
 
1.47% 
4.11% 
1.59% 
7.32% 
3.76% 
 
Population (n=80) 
EPAU 
Infertility 
Recurrent misc. 
No cases for “Other” 
 
 
39/2231 
21/3171 
20/1419 
 
 
1.75% 
0.66% 
1.41% 
 
 
 
1.25% 
0.41% 
0.86% 
 
 
2.38% 
1.01% 
2.17% 
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